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PREAMBLE
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies in the management and prevention of disease.
Rigorous and expert analysis of the available data docu-
menting relative benefits and risks of those procedures and
therapies can produce helpful guidelines that improve the
effectiveness of care, optimize patient outcomes, and favor-
ably impact the overall cost of care by focusing resources on
the most effective strategies.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged
in the preparation of such guidelines in the area of cardio-
vascular disease since 1980. This effort is directed by the
ACC/AHA Task Force on Practice Guidelines, which is
charged with developing and revising practice guidelines for
important cardiovascular diseases and procedures. Experts
in the subject under consideration are selected from involved
organizations to examine subject-specific data and write
guidelines. The process includes additional representatives
from other medical practitioner and specialty groups where
appropriate. Writing groups are specifically charged to
perform a formal literature review, weigh the strength of
evidence for or against a particular treatment or procedure,
and include estimates of expected-health outcomes in areas
where data exist. Patient-specific modifiers, comorbidities,
and issues of patient preference that might influence the
choice of particular tests or therapies are considered, along
with frequency of follow-up and cost-effectiveness.
The ACC/AHA Task Force on Practice Guidelines
makes every effort to avoid any actual or potential conflicts
of interest that might arise as a result of an outside
relationship or personal interest of a member of the writing
panel. Specifically, all members of the writing panel are
asked to provide disclosure statements of all such relation-
ships that might be perceived as real or potential conflicts of
interest. These statements are reviewed by the parent task
force, reported orally to all members of the writing panel at
the first meeting, and updated as changes occur.
These practice guidelines are intended to assist physicians
and other healthcare providers in clinical decision making
by describing a range of generally acceptable approaches for
the diagnosis, management, or prevention of specific dis-
eases or conditions. These guidelines attempt to define
practices that meet the needs of most patients in most
circumstances. The ultimate judgment regarding care of a
particular patient must be made by the physician and patient
in light of circumstances specific to that patient.
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This committee includes cardiologists with and without
involvement in interventional procedures, a cardiac surgeon,
and an official representative from the Society for Cardiac
Angiography and Interventions (SCA&I). This document
was reviewed by three official reviewers nominated by ACC,
three official reviewers nominated by AHA, the AHA
Committee on Diagnostic and Interventional Cardiac
Catheterization, the ACC Interventional Database Com-
mittee, the ACC Cath Lab Accreditation Working Group,
the ACC Cardiac Catheterization Committee, the SCA&I,
and 21 outside reviewers nominated by the Writing Com-
mittee. This document was approved for publication by the
governing bodies of ACC and AHA and officially endorsed
by the SCA&I. These guidelines will be considered current
unless the Task Force revises them or withdraws them from
distribution.
Raymond J. Gibbons, MD, FACC
Chair, ACC/AHA Task Force on Practice Guidelines
I. INTRODUCTION
The ACC/AHA Task Force on Practice Guidelines was
formed to gather information and make recommendations
about appropriate use of technology for the diagnosis and
treatment of patients with cardiovascular disease. Percuta-
neous coronary interventions (PCIs) are an important group
of technologies in this regard. Although initially limited to
balloon angioplasty and termed percutaneous transluminal
coronary angioplasty (PTCA), PCI now includes other new
techniques capable of relieving coronary narrowing. Accord-
ingly, in this document, rotational atherectomy, directional
atherectomy, extraction atherectomy, laser angioplasty, im-
plantation of intracoronary stents and other catheter devices
for treating coronary atherosclerosis are considered compo-
nents of PCI. In this context PTCA will be used to refer to
those studies using primarily balloon angioplasty while PCI
will refer to the broader group of percutaneous techniques.
These new technologies have impacted the effectiveness and
safety profile initially established for balloon angioplasty.
Moreover, important advances have occurred in the use of
adjunctive medical therapies such as glycoprotein (GP)
IIb/IIIa receptor blockers. In addition, since publication of
the previous Guidelines in 1993, greater experience in the
performance of PCI in patients with acute coronary syn-
dromes and in community hospital settings has been gained.
In view of these developments, further review and revision
of the guidelines is warranted. This document reflects the
opinion of the third ACC/AHA committee charged with
revising the guidelines for PTCA to include the broader
group of technologies now termed PCI.
Several issues relevant to the Committee’s process and the
interpretation of the Guidelines have been noted previously
and are worthy of restatement. First, PCI is a technique that
has been continually refined and modified; hence continued,
periodic Guideline revision is anticipated. Second, these
Guidelines are to be viewed as broad recommendations to
aid in the appropriate application of PCI. Under unique
circumstances, exceptions may exist. These Guidelines are
intended to complement, not replace, sound medical judg-
ment and knowledge. They are intended for operators who
possess the cognitive and technical skills for performing PCI
and assume that facilities and resources required to properly
perform PCI are available. As in the past, the indications are
categorized as Class I, II, or III, based on a multifactorial
assessment of risk as well as expected efficacy viewed in the
context of current knowledge and the relative strength of
this knowledge. Initially, this document describes the back-
ground information that forms the foundation for specific
indications. Topics fundamental to coronary intervention
are reviewed followed by separate discussions relating to
unique technical and operational issues. Formal recom-
mendations for the use of angioplasty are included in
Section V. Indications are organized according to clinical
presentation. This format is designed to enhance the use-
fulness of this document for the assessment and care of
patients with coronary artery disease (CAD).
This document employs the ACC/AHA style classifica-
tion as Class I, II, or III. These classes summarize the
indications for PCI as follows:
Class I: Conditions for which there is evidence for
and/or general agreement that the procedure
or treatment is useful and effective.
Class II: Conditions for which there is conflicting ev-
idence and/or a divergence of opinion about
the usefulness/efficacy of a procedure or treat-
ment.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well es-
tablished by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/
treatment is not useful/effective, and in some
cases may be harmful.
The weight of evidence in support of the recommenda-
tion for each listed indication is presented as follows:
Level of Evidence A: Data derived from multiple ran-
domized clinical trials.
Level of Evidence B: Data derived from a single ran-
domized trial or nonrandomized
studies.
Level of Evidence C: Consensus opinion of experts.
II. GENERAL CONSIDERATIONS AND BACKGROUND
Coronary angioplasty was first introduced by Andreas
Gruentzig in 1977 (1) as a nonsurgical method for coronary
arterial revascularization. Fundamentally, the technique in-
volved advancing a balloon tipped catheter to an area of
coronary narrowing, inflating the balloon and then remov-
ing the catheter following deflation. Early reports demon-
strated that balloon angioplasty could reduce the severity of
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coronary stenosis and diminish or eliminate objective and
subjective manifestations of ischemia (2–4). Although an-
gioplasty was clearly feasible and effective, the scope of
coronary disease to be treated was quite narrow. Also, since
angioplasty could result in sudden arterial occlusion and
subsequent myocardial infarction (MI), immediate access to
coronary bypass surgery was essential (5). With experience
and time, however, the cognitive and technical aspects as
much as the equipment used to perform angioplasty became
more refined. Observational reports of large numbers of
patients confirmed that coronary angioplasty could be ap-
plied to broad groups of coronary patients with higher rates
of success and lower rates of complications when compared
to initial experiences (6,7). More than 500,000 PCI proce-
dures are performed yearly in the U.S. (8), and it has been
estimated that more than 1,000,000 procedures are per-
formed annually worldwide.
The value of coronary angioplasty was further defined by
comparing its results to those of alternative methods of
treatment. Randomized clinical trials have assessed the
outcomes of patients treated by a strategy of initial angio-
plasty to one of medical therapy alone or to coronary artery
bypass surgery (9–14). The results of these trials have
clarified the utility of angioplasty in terms of effectiveness,
complications, and patient selection. The technique of
coronary angioplasty has also been expanded by the devel-
opment of devices that replace or serve as adjuncts to the
balloon catheter. These “new devices” have been thoroughly
evaluated and have had a critical impact in enhancing the
immediate- and long-term efficacy and safety of coronary
angioplasty. The following section of this report expands on
this background and describes the practice of PCI as it is
applied today.
New coronary devices have expanded the clinical and
anatomical indications for revascularization initially limited
by balloon catheter angioplasty. For example, stents reduce
both the acute risk of major complications and late-term
restenosis. The success of new coronary devices in meeting
these goals is in part represented by the less frequent use of
balloon angioplasty alone (,30%) and the high (.70%)
penetration of coronary stenting in the current practice of
interventional cardiology (Fig. 1). Atherectomy devices and
stenting, associated with improved acute angiographic and
clinical outcomes compared to balloon angioplasty, in spe-
cific subsets, continue to be applied to a wider patient
domain that includes multivessel disease and complex cor-
onary anatomy. However, strong evidence (level A data
from multiple randomized clinical trials) is only available for
stenting in selected patients undergoing single-vessel PCI.
The range of new, non-balloon revascularization technol-
ogy approved by the Food and Drug Administration (FDA)
for use in native or graft coronary arteries includes balloon
expandable stents, atherectomy by the Transluminal Extrac-
tion Catheter (TEC), Directional Coronary Atherectomy
(DCA), rotational atherectomy, angiojet thrombolysis cath-
eter, and Excimer Laser Coronary Atherectomy (ELCA). A
variety of devices is under investigation including new
designs of balloon or self-expanding stents, mechanical
thrombectomy devices, and local radiation devices intended
to reduce restenosis. These guidelines will focus on the
FDA-approved balloon related and non-balloon coronary
revascularization devices.
III. OUTCOMES
The outcomes of coronary interventional procedures are
measured in terms of success and complications and are
related to the mechanisms of the employed devices, as well
as the clinical and anatomic patient-related factors. Com-
plications can be divided into two categories: 1) those
common to all arterial catheterization procedures and 2)
those related to the specific technology used for the coronary
procedure. Specific definitions of success and complications
exist, and where appropriate, the definitions used herein are
consistent with the ACC-National Cardiovascular Data
RegistryTM Catheterization Laboratory Module Version 2.0
Figure 1. Frequency of device use in the SCA&I Registry.
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(15). With increased operator experience, new technology,
and adjunctive pharmacotherapy, the overall success and
complication rates of angioplasty have improved.
A. Definitions of PCI Success
The success of a PCI procedure may be defined by
angiographic, procedural, and clinical criteria.
1. Angiographic Success. A successful PCI produces sub-
stantial enlargement of the lumen at the target site. The
consensus definition prior to the widespread use of stents
was the achievement of a minimum stenosis diameter
reduction to ,50% in the presence of grade 3 TIMI flow
(assessed by angiography) (16). However, with the advent of
advanced adjunct technology, including coronary stents, a
minimum stenosis diameter reduction to ,20% has been
the clinical benchmark of an optimal angiographic result.
Frequently, there is a disparity between the visual assess-
ment and computer-aided quantitative stenosis measure-
ment (17,18), and the determination of success may be
problematic when success rates are self-reported.
2. Procedural Success. A successful PCI should achieve
angiographic success without in-hospital major clinical
complications (e.g., death, MI, emergency coronary artery
bypass surgery) during hospitalization (2,16). Although the
occurrence of emergency coronary artery bypass surgery and
death are easily identified end points, the definition of
procedure-related MI has been debated. The development
of Q-waves in addition to a threshold value of CK elevation
has been commonly used. However, the significance of
enzyme elevations in the absence of Q-waves remains a
subject of investigation and debate. Several reports have
identified non–Q-wave MIs with CK-MB elevations 3 to 5
times the upper limit of normal as having clinical signifi-
cance (19,20). Thus a significant increase in CK-MB
without Q-waves is considered by most to qualify as an
associated complication of PCI.
3. Clinical Success. In the short term, a clinically success-
ful PCI includes anatomic and procedural success with relief
of signs and/or symptoms of myocardial ischemia after the
patient recovers from the procedure. The long-term clinical
success requires that the short-term clinical success remains
durable and that the patient has persistent relief of signs and
symptoms of myocardial ischemia for more than 6 months
after the procedure. Restenosis is the principal cause of lack
of long-term clinical success when a short-term clinical
success has been achieved. Restenosis is not considered a
complication but rather an associated response to vascular
injury. The frequency of clinically important restenosis may
be judged by the frequency with which subsequent revascu-
larization procedures are performed on target vessels after
the index procedure. A very high rate of restenosis may
suggest that the operator chooses an excess of lesions which
are likely to restenose, such as long lesions or those
involving small vessels.
B. Definitions of Procedural Complications
As outlined in the 1998 coronary interventional docu-
ment (21), procedural complications are divided into six
basic categories: death, MI, emergency coronary artery
bypass graft (CABG) surgery, stroke, vascular access site
complications, and contrast agent nephropathy. Key data
elements and definitions to measure the clinical manage-
ment and outcomes of patients undergoing diagnostic cath-
eterization and/or PCI have been defined in the Clinical
Data Standards document (22) and the ACC-National
Cardiovascular Data Registry™ Catheterization Laboratory
Module version 2.0 (15). These rigorous definitions for key
adverse events are endorsed by this Writing Committee for
inclusion in the present PCI Guidelines (Table 1).
Notably, the definition of MI has evolved over the past
several years. It should be emphasized that the simple
categorization of MI into two classes based on the devel-
opment of new Q-waves alone is no longer sufficient as a
classification scheme for measuring MI following PCI.
Since the measurement of CK and CK-MB are widely
available, myocardial necrosis may be measured with a high
level of sensitivity and specificity, regardless of the clinical
presentation and associated ECG findings. The use of
CK-MB for measuring myocardial necrosis is preferable to
a less sensitive and less specific CK determination. The mass
determination of CK-MB is now commonly used at most
hospitals, and elevations of this myocardial specific enzyme
are reported in nanograms per deciliter. Cardiac troponin T
and I have now been introduced as measurements of
myocardial necrosis and have been proven to be more
sensitive and specific than CK-MB. However, prognostic
criteria after PCI based on troponin T and I have not yet
been developed.
Since normal values may vary among hospitals and
selected patient subsets, an index of the measured value is
usually reported in terms of the value of the upper limit of
normal (i.e., CK-MB index of 3 corresponds to an elevation
of CK-MB to 3 times its upper limit of normal value).
Thus, myocardial necrosis may be determined as an abnor-
mally elevated CK-MB index (.1), based upon 2 or 3 serial
determinations during the 18 to 24 h after coronary inter-
vention and the abnormality may range from a low index (1
to 3 times normal) with no or non-specific ECG findings,
to a high index (.10 to 15 times normal) with significant
ECG findings including the development of new Q-waves.
If serial determinations are performed after PCI, an
abnormally high value (CK-MB .1 times normal) can be
expected in 10 to 15% of balloon angioplasty procedures, 15
to 20% of stent procedures, 25 to 35% of atherectomy
procedures, and .25% for any device used in saphenous
vein grafts (SVGs) or long lesions with a high atheroscle-
rotic burden, even in the absence of other signs and
symptoms of MI. There is no accepted consensus on what
level of CK-MB index (with or without clinical or electro-
cardiographic [ECG] findings) is indicative of a clinically
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important MI following the interventional procedure. The
Writing Committee recommends that a CK-MB determi-
nation be performed on all patients who have signs or
symptoms of suggestive MI following the procedure or in
patients in whom there is angiographic evidence of abrupt
vessel closure, important side branch occlusion, or new and
persistent slow coronary flow. In patients in whom a
clinically driven CK-MB determination is made, a CK-MB
of .3 times the upper limit of normal would constitute a
clinically significant MI. These relationships may be con-
founded by other factors, such as atherosclerosis.
C. Acute Outcome
Despite the extension of coronary intervention to higher-
risk patients with comorbid disease and complex coronary
anatomy, angiographic and procedural success have in-
creased since the first National Heart Lung and Blood
Institute (NHLBI) registries with an associated decrease in
the major complications of Q-wave MI and emergency
CABG (Table 2) (2,6,23,24). Improvements in balloon
technology coupled with the increased use of non-balloon
devices, particularly stents (which are effective in treating
abrupt vessel closure) (25) and glycoprotein IIb/IIIa platelet
receptor antagonists (26–28) have favorably influenced
acute procedural outcome. This combined balloon/device/
pharmacologic approach to coronary intervention in elective
procedures has resulted in angiographic success rates of 96
to 99%, with Q-wave MI rates of 1 to 3%, emergency
coronary artery bypass surgery rates of 0.2 to 3%, and
unadjusted in-hospital mortality rates of 0.5 to 1.4% (29–
Table 1. Definitions of Procedural Complications (15)
Procedural Complications Definitions
Primary Cause of Death Patient died during this hospitalization.
Periprocedural MI The NEW presence of an MI as documented by at least 1 of the following criteria:
1. Evolutionary ST-segment elevations, development of new Q-waves in 2 or more contiguous ECG leads, or
new or presumably new LBBB pattern on the ECG.
2. Biochemical evidence of myocardial necrosis; this can be manifested as 1) CK-MB $3 3 the upper limit of
normal or if CK-MB not available 2) total CK $3 3 upper limit of normal. Because normal limits of certain
blood tests may vary, please check with your lab for normal limits for CK-MB and total CK.
CABG During this Admission If the patient had a CABG during this admission indicate the CABG status using the following categories:
I. Elective: The procedure could be deferred without increase risk of compromised cardiac outcome.
II. Urgent: All of the following conditions are met:
A. Not elective
B. Not emergency
C. Procedure required during same hospitalization in order to minimize chance of further clinical
deterioration.
III. Emergency: The patient’s clinical status includes any of the following:
A. Ischemic dysfunction (any of the following):
1. Ongoing ischemia including rest angina despite maximal medical therapy (medical and/or IABP)
2. Acute evolving MI within 24 h before intervention
3. Pulmonary edema requiring intubation
B. Mechanical dysfunction (either of the following):
1. Shock with circulatory support
2. Shock without circulatory support
IV. Salvage: The patient is undergoing CPR en route to the operating room.
CVA/Stroke Patient experienced a cerebrovascular accident (CVA) as documented by a loss of neurological function caused by
an ischemic event with residual symptoms at least 24 h after onset.
Vascular Complications
— Bleeding
Blood loss at the site of arterial or venous access or due to perforation of a traversed artery or vein requiring
transfusion and/or prolonging the hospital stay, and/or causing a drop in hemoglobin .3.0 gm/dl. Bleeding
attributable to the vascular site could be retroperitoneal, a local hematoma .10 cm diameter or external.
— Occlusion A total obstruction of the artery usually at the site of access requiring surgical repair. Occlusion is defined as total
obstruction of the artery by thrombus, dissection or other mechanism, usually at the site of access, requiring
surgical repair. Occlusion may be accompanied by absence of palpable pulse or Doppler signal and associated
with signs and symptoms of an ischemic limb requiring surgical intervention.
— Dissection A dissection occurred at the site of percutaneous entry. Dissection is defined as disruption of an arterial wall
resulting in splitting and separation of the intimal (or subintimal) layers.
— Pseudoaneurysm Pseudoaneurysm is defined as the occurrence of an aneurysmal dilatation of the artery at the site of catheter entry
demonstrated by arteriography or ultrasound.
— AV Fistula AV fistula is defined as a connection between the access artery (e.g., femoral) and access vein (e.g., femoral) that is
demonstrated by an imaging study (arteriography or ultrasound) and most often characterized by a continuous bruit.
Renal Failure After the lab visit—but before any subsequent lab visits only:
Indicate if the patient experienced acute renal insufficiency resulting in an increase in serum creatinine to more
than 2.0 mg/dl (or a 50% or greater increase over an abnormal baseline) measured prior to procedure, or
requiring dialysis.
CABG 5 coronary artery bypass graft; CK 5 creatine kinase; CPR 5 cardiopulmonary resuscitation; ECG 5 electrocardiographic; IABP 5 intra-aortic balloon pump; LBBB 5
left bundle-branch block, MI 5 myocardial infarction.
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34). The integrated approach utilizing adjunct pharmaco-
logic therapies and the enormous increase in the use of
stents as a primary strategy have resulted in an improved
procedural outcome of balloon angioplasty (35). Improved
balloon/pharmacologic techniques may achieve results com-
parable to those obtained with stents with the ability to
perform provisional (for suboptimal result) or bail-out (for
acute or threatened vessel closure) stent deployment.
It should be noted, however, that the incidence of
elevated creatine kinase has increased in the new device era
(36). The significance of this finding, in the absence of a
clinical event, is uncertain and the subject of ongoing
debate. This issue is discussed in more detail in Section
VI, C.1. Post-Procedure Evaluation of Ischemia.
D. Long-Term Outcome and Restenosis
Although improvements in technology, including stents
and new pharmacologic therapy, have resulted in an im-
proved acute outcome of the procedure, the impact of these
changes on long-term (5 to 10 years) outcome may be less
dramatic where factors such as advanced age, reduced left
ventricular (LV) function, and complex multivessel disease
in patients currently undergoing PCI may have a more
important influence. In addition, available data on long-
term outcome are mostly limited to patients undergoing
PTCA. Ten-year follow-up of the initial cohort of patients
treated with PTCA revealed an 89.5% survival rate (95% in
patients with single-vessel disease, 81% in patients with
multivessel disease) (45). In patients undergoing within the
1985–1986 NHLBI PTCA Registry (46), 5-year survival
was 92.9% for patients with single-vessel disease, 88.5% for
those with 2-vessel disease, and 86.5% for those with
3-vessel disease. In patients with multivessel disease under-
going PTCA in BARI (9), 5-year survival was 86.3%, and
infarct-free survival was 78.7%. Specifically, 5-year survival
was 84.7% in patients with 3-vessel disease and 87.6% in
patients with 2-vessel disease.
In addition to the presence of multivessel disease, other
clinical factors adversely impact late mortality. In random-
ized patients with treated diabetes in BARI, the 5-year
survival was 65.5%, and the cardiac mortality was 20.6% in
comparison to 5.8% cardiac mortality in patients without
treated diabetes (47), although among eligible but not
randomized diabetic patients, the 5-year cardiac mortality
was 7.5% (48). In the 1985–1986 NHLBI PTCA Registry,
4-year survival was significantly lower in women (89.2%) in
comparison to men (93.4%) (49). In addition, although LV
dysfunction was not associated with an increase in in-
hospital mortality or nonfatal MI in patients undergoing
PTCA in the same registry, it was an independent predictor
of a higher long-term mortality (50).
A major determinant of event-free survival following
coronary intervention is the incidence of restenosis which
had, until the development of stents, remained fairly con-
stant, despite multiple pharmacologic and mechanical ap-
proaches to limit this process (Table 3). Depending on the
definition, (i.e., whether clinical or angiographic restenosis
or target lesion revascularization is measured), the incidence
of restenosis following coronary intervention had been 30 to
40%, and higher in certain clinical and angiographic subsets
(51).
The pathogenesis of the response to mechanical coronary
injury is thought to relate to a combination of growth factor
stimulation, smooth muscle cell migration and proliferation,
organization of thrombus, platelet deposition, and elastic
recoil (69,70). In addition, dynamic change in vessel size (or
lack of compensatory enlargement) has been implicated
(71). It has been suggested that attempts to reduce resten-
osis have failed, in part due to lack of recognition of the
importance of this factor (72). Although numerous defini-
Table 2. Unadjusted In-Hospital Outcome Trends Following Percutaneous Interventions
Registry Years Reference N
Clinical
Success, %
In-Hospital
Mortality, %
Q-Wave
MI, %
Emergency
CABG, %
NHLBI (I)‡ 1977–1981 (37) 3,079* 61 1.2 Not reported 5.8
NHLBI (II)§ 1985–1986 (37) 2,311* 78 1.0 4.8 5.8
BARI Registry\ 1988–1991 (38) 1,189* Not reported 0.7 2.8 4.1
Northern New England¶ 1990–1993 (39) 13,014† 88.8 1.0 2.4 2.2
SCA&I# 1990–1994 (40) 4,366† 91.5 2.5 Not reported 3.4
NACI** 1990–1994 (41) 4,079* Not reported 1.6 1.6 1.9
NY State Database 1991–1994 (42,43) 62,670* Not reported 0.9 Not reported 3.4
Northern New England¶ 1994–1995 (39) 7,248† 89.2 1.1 2.1 2.3
NCN 1994–1997 (44) 76,904† Not reported 1.3 Not reported 1.7
Northern New England¶ 1995–1997 (39) 14,490† 91.5 1.2 2.0 1.3
NHLBI Dynamic Registry†† 1997–1998 (23) 1,559 92 1.9 2.8 0.4
MI 5 myocardial infarction; CABG 5 coronary artery bypass graft. The N varied among registries; several reported patients* rather than procedures†; ‡NHLBI (I), Emergency
CABG was defined as in-hospital CABG; §NHLBI (II), MI was defined as the presence of at least 2 of the 3 criteria: clinical symptoms, Q waves on ECG (Minnesota Code),
or elevated cardiac enzyme level (double the normal levels for CK or its MB fraction without Q waves). Emergency CABG was defined as in-hospital CABG; \BARI, MI was
defined as the appearance of ECG changes (new pathologic Q-waves) supported by abnormal CK-MB elevations; ¶Northern New England, A new MI is defined as a clinical
event, ECG changes and a creatine phosphokinase (CPK) rise to $2 3 normal levels with positive isoenzymes. Emergency CABG is defined as surgery performed to treat acute
closure, unstable angina, or congestive HF requiring IV nitroglycerin or ABP, or tamponade resulting from the intervention; #SCA&I, A new MI is defined as any significant
infarction (.3 3 normal) rise in MB fraction; **NACI, MI is defined as Q-wave MI; ††MI was defined as $2 of the following: 1) typical chest pain .20 min not relieved by
nitroglycerin, 2) serial ECG recordings showing changes from baseline or serially in ST-T and/or Q-waves in $2 contiguous leads, or 3) serum enzyme elevation of CK-MB
.5% of total CK (total CK .2 3 normal; LDH subtype 1 . LDH subtype 2). For expansion of study names, see the corresponding reference.
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tions of restenosis have been proposed, .50% diameter
stenosis at follow-up angiography has been most frequently
used. However, it is now recognized that the response to
arterial injury is a continuous rather than a dichotomous
process, occurring to some degree in all patients (73).
Therefore, cumulative frequency distributions of the con-
tinuous variables of minimal lumen diameter or percent
diameter stenosis are now used to evaluate restenosis in large
patient populations (74) (Fig. 2).
Although multiple clinical factors (diabetes, unstable
angina, acute MI, prior restenosis) (75,76), angiographic
factors (proximal left anterior descending artery, small vessel
diameters, total occlusion, long lesion length, SVG) (77),
and procedural factors (higher post-procedure percent di-
ameter stenosis, smaller minimal lumen diameter, and
smaller acute gain) (74) have been associated with an
increased incidence of restenosis, the ability to integrate
these factors and predict the risk of restenosis in individual
patients following the procedure remains difficult. The most
promising potential approaches to favorably impact the
restenosis process relate to: 1) the ability to decrease elastic
recoil and remodeling using intracoronary stents, and 2) to
the ability to reduce intimal hyperplasia using catheter-
based ionizing radiation. More than 6,300 patients have
been studied in 12 randomized clinical trials to assess the
efficacy of PTCA versus stents to reduce restenosis (Table 4).
The pivotal BENESTENT (32) and STRESS Trials
(31) documented that stents significantly reduce angio-
graphic restenosis in comparison to balloon angioplasty
(BENESTENT: 22% vs. 32%; STRESS: 32% vs. 42%,
respectively). These results have been corroborated in the
BENESTENT II trial in which the angiographic restenosis
rate was reduced by 45% (from 31 to 16% in patients treated
with balloon angioplasty versus heparin-coated stents, re-
spectively) (66).
In addition, randomized studies in patients with in-stent
restenosis have shown that both intracoronary gamma and
beta radiation significantly reduced the rate of subsequent
angiographic and clinical restenosis by 30 to 50% (78–81).
Late subacute thrombosis was observed in some of these
series (82), but this syndrome has resolved with judicious use of
stents and extended adjunct antiplatelet therapy with ticlopi-
dine or clopidogrel. Also, in a preliminary study of patients
undergoing successful balloon angioplasty, delivery of intra-
coronary beta radiation resulted in a restenosis rate of 15% (83).
When technically feasible, in patients who experience
restenosis, it is standard practice to perform repeat PCI. In
this setting, stents are being used with the hope of decreas-
ing the rate of subsequent restenosis. However, in-stent
restenosis, particularly when diffuse, represents a challeng-
ing problem. The efficacy of various treatment modalities
for in-stent restenosis is under active investigation.
E. Predictors of Success/Complications
1. Anatomic Factors. Target lesion anatomic factors re-
lated to adverse outcomes have been widely examined.
Lesion morphology and absolute stenosis severity were
identified as the prominent predictors of immediate out-
come during PTCA in the pre-stent era (93,94). Abrupt
vessel closure, due primarily to thrombus or dissection, was
reported in 3 to 8% of patients and was associated with
certain lesion characteristics (95–97). The risk of PTCA in
Table 3. Selected Trials Of Pharmacologic And Mechanical Approaches To Limit Restenosis
Study Year Reference N Agent
Restenosis Rate (%)
Placebo or
Control Agent
Schwartz 1988 (52) 376 Aspirin and Dipyridamole 39 38
Ellis 1989 (54) 416 Heparin 37 41
Pepine 1990 (54) 915 Methylprednislone 39 40
CARPORT 1991 (55) 649 Vapiprost 19 21
O’Keefe 1991 (56) 197 Colchicine 22 22
MERCATOR 1992 (57) 735 Cilazapril 28 28
CAVEAT* 1993 (58) 500 DCA vs. PTCA 57 50
CCAT 1993 (59) 136 DCA vs. PTCA 43 46
Serruys 1993 (60) 658 Ketanserin 32 32
BENESTENT* 1994 (32) 520 Stent vs. PTCA 32 22
ERA 1994 (61) 458 Enoxaparin 51 52
Leaf 1994 (62) 551 Fish Oil 46 52
STRESS* 1994 (31) 410 Stent vs. PTCA 42 32
Weintraub 1994 (63) 404 Lovastatin 42 39
BOAT* 1996 (34) 492 DCA vs. PTCA 40 31
Wantanabe* 1996 (64) 118 Probucol 40 20
Tardif* 1997 (65) 317 Probucol 39 21
BENESTENT II* 1998 (66) 823 Stent vs. PTCA 31 17
TREAT* 1999 (67) 255 Tranilast 39 18
PRESTO* 2000 (68) 192 DCA and Tranilast 26 11
*p , 0.05.
DCA 5 Directional Coronary Atherectomy; PTCA 5 percutaneous transluminal coronary angioplasty. For expansion of
study names, see corresponding reference.
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the pre-stent era relative to anatomic subsets has been
identified in previous NHLBI PTCA Registry data (6) and
by the ACC/AHA Task Force (16,98). The lesion classifi-
cation based on severity of characteristics proposed in the
past (98–100) has been principally altered using the present
PCI techniques which capitalize on the ability of stents to
manage initial and subsequent complications of coronary
interventions (101). As a result the Committee has revised
the previous ACC/AHA lesion classification system to
reflect low, moderate, and high risk (Table 5) in accordance
with the PCI Clinical Data Standards from the ACC-
National Cardiovascular Data Registry™ (15).
2. Clinical Factors. Coexistent clinical conditions can
increase the complication rates for any given anatomic risk
factor. For example, complications occurred in 15.4% of
diabetic patients versus 5.8% of nondiabetic patients under-
going balloon angioplasty in a multicenter experience
(94,97). Several studies have reported specific factors asso-
ciated with increased risk of adverse outcome following
balloon angioplasty. These factors include advanced age,
female gender, unstable angina, congestive heart failure
(CHF), diabetes, and multivessel CAD (9,93,94,102,103)
(Table 6). The BARI trial found that patients with diabetes
and multivessel CAD had an increased periprocedural risk
of ischemic complications and increased 5-year mortality in
comparison to patients without diabetes or in comparison to
patients with diabetes undergoing bypass surgery using
internal thoracic arterial grafts (9,38). Patients with im-
paired renal function, especially diabetics, are at increased
risk for contrast nephropathy (104) and increased 30-day
and 1-year mortality.
Increased risk for severe compromise in LV function or
fatal outcome may occur with a complication of a vessel that
also supplies collateral flow to viable myocardium. Certain
variables were used to prospectively identify patients at risk
for significant cardiovascular compromise during PTCA
(105,106). These resulted in a composite 4-variable scoring
system, prospectively validated to be both sensitive and
specific in predicting cardiovascular collapse for failed
PTCA and includes: 1) percentage of myocardium at risk
(e.g., .50% viable myocardium at risk and LV ejection
fraction of ,25%), 2) pre-angioplasty percent diameter
Figure 2. Balloon stent versus balloon angioplasty in coronary artery disease. Cumulative frequency distribution curves for the two study groups, showing
minimum lumen diameters measured before and after intervention and follow-up (B), the percentage of stenosis at follow-up, and the percentage of patients
with clinical end points. Significant differences were apparent that consistently favored the stent group over the angioplasty group with respect to the
increased minimal lumen diameter at intervention (A) and follow-up (B), the percentage of stenosis at follow-up (C), and the incidence of major clinical
events (D). The vertical dashed line in D indicated the end of the study. Reproduced with permission from Serruys PW, et al. N Engl J Med
1994;331:489–95 (32).
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stenosis, 3) multivessel CAD, and 4) diffuse disease in the
dilated segment (107) or a high myocardial jeopardy score
(108). Patients with higher pre-procedural jeopardy scores
were shown to have a greater likelihood of cardiovascular
collapse when abrupt vessel closure occurred during PTCA
(105). The clinical risk factors associated with in-hospital
adverse events have been further evaluated with additional
experience during the PCI era and summarized based on
odds ratio .2.0 or results of multivariate analysis (Table 6).
3. Risk of Death. In the majority of patients undergoing
elective PCI, death as a result of PCI is directly related to
the occurrence of coronary artery occlusion and is most
frequently associated with pronounced LV failure (105,106)
(Table 6). The clinical and angiographic variables associated
with increased mortality include advanced age, female gen-
der, diabetes, prior MI, multivessel disease, left main or
equivalent coronary disease, a large area of myocardium at
risk, pre-existing impairment of LV or renal function, and
collateral vessels supplying significant areas of myocardium
that originate distal to the segment to be dilated (Table 6)
(9,93,95,97,102–105,107–110).
4. Women. In comparison to men, women undergoing
PCI are older and have a higher incidence of hypertension,Ta
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Table 5. Lesion Classification System
Anatomic Risk Groups*
2000
PCI Stent Era
Low Risk
Discrete (length ,10 mm)
Concentric
Readily accessible
Nonangulated segment (,45°)
Smooth contour
Little or no calcification
Less than totally occlusive
Not ostial in location
No major side branch involvement
Absence of thrombus
Moderate Risk
Tubular (length 10–20 mm)
Eccentric
Moderate tortuosity of proximal segment
Moderately angulated segment (.45°, ,90°)
Irregular contour
Moderate or heavy calcification
Total occlusions ,3 months old
Ostial in location
Bifurcation lesions requiring double guidewires
Some thrombus present
High Risk
Diffuse (length .20 mm)
Excessive tortuosity of proximal segment
Extremely angulated segments .90°
Total occlusions .3 months old and/or bridging collaterals
Inability to protect major side branches
Degenerated vein grafts with friable lesions
*This classification of lesion risk is cited from the ACC-National Cardiovascular Data
Registry™ Catheterization Laboratory Module version 2.0 (15). This classification
scheme is also cited in the ACC Clinical Data Standards (22).
PCI 5 percutaneous coronary interventions.
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diabetes mellitus, hypercholesterolemia, and comorbid dis-
ease (49,111–114). Women also have more unstable angina
and a higher functional class of stable angina (Canadian
Cardiovascular Society Class III and IV) for a given extent
of disease (115). Yet, despite the higher-risk profile in
women, the extent of epicardial coronary disease is similar
(or less) in comparison to men. In addition, although
women presenting for revascularization have less multivessel
disease and better LV systolic function, the incidence of
CHF is higher in women than in men. The reason for this
gender paradox is unclear, but it has been postulated that
women have more diastolic dysfunction, perhaps based on
older age and hypertension, in comparison to men (116).
Early reports of patients undergoing PTCA revealed a
lower procedural success rate in women (112); however,
more recent studies have noted similar angiographic out-
come and incidence of MI and emergency coronary artery
bypass surgery in women and men (49). Although reports
have been inconsistent, in several large-scale registries,
in-hospital mortality is significantly higher in women, and
an independent effect of gender on acute mortality following
PTCA persists after adjustments for the baseline higher-risk
profile in women (49,117). The reason for the increase in
mortality is unknown, but small vessel size and hypertensive
heart disease in women have been thought to play a role.
Although a few studies have noted that gender is not an
independent predictor of mortality when body surface area
(a surrogate for vessel size) is accounted for (111), the
impact of body size on outcome has not been thoroughly
evaluated. The higher incidence of vascular complications,
coronary dissection, and perforation in women undergoing
coronary intervention has been attributed to the smaller
vasculature in women in comparison to men. In addition,
diagnostic intravascular ultrasound (IVUS) studies have not
Table 6. Clinical Risk Factors Associated With In-Hospital Adverse Events*
Variables Definitions
Age Date of birth as stated by the patient or family
Gender Male or female
LVEF-calculated Calculated by LV gram, echo, blood pool scan
LVEF-estimated Estimate by LV gram, echo, blood pool scan
No. of vessels .70% By angiography measured, quantified or estimated diameter stenosis; “vessel” defined as RCA and its
branches, proximal LAD (before 1st diagonal), mid/distal LAD and its branches, and Cx and its
branches
Unstable angina Progressive or new onset or occurs at rest accompanied by ECG changes, hypotension or pulmonary
congestion
CCS Class IV Highest CCS angina class leading to hospital admission and/or intervention; 0 5 no angina by Hx
CHF Hx of CHF before intervention
MI at this admission Within 24 h of AMI
Previous MI .1 day; ,7 days of AMI
Urgency of the procedure Elective: patient clinically stable; procedure routinely scheduled
Urgent: unstable patient: procedure scheduled before discharge
Emergent/ongoing ischemia: ongoing ischemia including rest angina despite maximal therapy (medical or
IABP)
Emergent/salvage: arrest with CPR immediately before entering lab
Cardiogenic shock Hypoperfusion with SBP ,80 mm Hg and central filling pressure .20 mm Hg or cardiac index ,1.8
liters/min/m2, also present if inotropes or IABP needed to maintain these values
Preprocedural IABP/CPS IABP/CPS assisted device placed before intervention
Aortic valve disease Aortic valve area ,1.0 cm2 and/or aortic regurgitation .21
Mitral regurgitation .21 Presence of mitral regurgitation .21
Diabetes (treated) Clinical diagnosis of diabetes treated either with oral agents or insulin with or without sequelae
PVD Presence of occlusive disease in the aorta, iliac, or femoral artery sufficient to cause symptoms
Stroke Hx of presence of fixed neurological deficit
Creatinine If creatinine preintervention known, list creatinine
Creatinine .2 mg/dl Creatinine .2 mg/dl known in past
Dialysis Patient on dialysis
Cholesterol .225 mg/dl (reduced risk) Measure cholesterol .225 mg/dl before intervention
Same vessel intervention (reduced risk) Any previous intervention on same vessel
Type C lesions attempted Type A: concentric noncalcified, ,10 mm in length, not bifurcated or angulated. Type C: total occlusion,
Type B: all others (ACC/AHA)
LMCA attempted-unprotected Intervention involving all or part of LMCA
LMCA attempted-protected “Protected” LMCA stenosis by patent bypass conduit
Vein graft intervention Any intervention to SVG or IMA
Thrombus Intraluminal filling defect, haziness or contrast staining in artery before intervention
*Note: More than 50% of databases that evaluated the variable showed an odds ratio .2.0 or variable chosen on multivariable analysis. The definition of variables defined herein
varies slightly from those agreed upon in the ACC Clinical Data Standards (22).
AMI 5 acute myocardial infarction; CCS 5 Canadian Cardiovascular Society; CHF 5 congestive heart failure; CPR 5 cardiopulmonary resuscitation; CPS 5 cardiopulmonary
support; Cx 5 circumflex; ECG 5 electrocardiogram; Hx 5 history; IABP 5 intra-aortic balloon pump; IMA 5 internal mammary artery; LAD 5 left anterior descending coronary
artery; LMCA 5 left main coronary artery; LV 5 left ventricle; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; PVD 5 peripheral vascular disease; RCA 5
right coronary artery; SBP 5 systolic blood pressure; SVG 5 saphenous vein graft. Adapted with permission from Block P, et al. J Am Coll Cardiol 2000;32:275–82 (106).
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detected any gender-specific differences in plaque morphol-
ogy or luminal dimensions once differences in body surface
area were corrected, suggesting that differences in vessel size
account for some of the apparent early and late outcome
differences previously noted in women (118). It has also
been postulated that the volume shifts and periods of transient
ischemia during coronary angioplasty are less well tolerated
by the hypertrophied ventricle in women, and CHF has
shown to be an independent predictor of mortality in both
women and men undergoing coronary angioplasty (119).
An improved outcome has been reported in women
undergoing both coronary balloon and new device angio-
plasty, despite the fact that the women (similar to men) are
older and with more complex disease than women treated
previously. In fact, in the 1993–1994 NHLBI PTCA
Registry (open to women only), procedural success was
higher and major complications lower in comparison to
women treated in the 1985–1986 registry (24). Addition-
ally, patients undergoing balloon angioplasty in BARI,
in-hospital mortality, MI, emergency coronary artery bypass
surgery rates, and 5-year mortality were similar in women
and men, although women had a higher incidence of
periprocedural CHF and pulmonary edema (120).
In a registry of 373 consecutive patients undergoing
directional coronary atherectomy (DCA), although early
and late outcomes were similar, the lower procedural success
observed in women (73% vs. 83%, p 5 0.011) was again
attributed to their smaller vessel caliber (121). Therefore,
although women presenting for coronary revascularization
have a higher-risk profile, currently the acute and long-term
outcomes are similar to those in men. Much of the increase
in adverse outcome seen in women can be accounted for by
comorbidities, although gender imparts a small independent
effect. Finally, it is important to note that in women
undergoing coronary intervention, the acute outcome has
improved and the long-term outcome remains excellent.
Therefore, coronary intervention should be considered for
women in need of revascularization with the anticipation of
a favorable outcome (Table 7).
5. The Elderly Patient. Age .75 years is one of the major
clinical variables associated with increased risk of complica-
tions (125). In the elderly population, the morphologic and
clinical variables are compounded by advanced years with
the very elderly having the highest risk of adverse outcomes
(126). In octogenarians, although feasibility has been estab-
lished for most interventional procedures, the risk of both
percutaneous and nonpercutaneous revascularization is in-
creased (127,128). Octogenarians undergoing percutaneous
intervention have a higher incidence of prior MI, lower LV
ejection fraction, and more frequent CHF (129). In the
stent era, procedural success rates and short-term outcomes
are comparable to those for nonoctogenarians (130). Thus,
with rare exception (primary PCI for cardiogenic shock for
patients .75 years), a separate category has not been created
in these Guidelines for the elderly. However, their higher
incidence of comorbidities should be taken into account
when considering the need for PCI.
6. Diabetes Mellitus. In the TIMI-IIB study of MI,
patients with diabetes mellitus had significantly higher
6-week (11.6% vs. 4.7%), 1-year (18.0% vs. 6.7%), and
3-year (21.6% vs. 9.6%) mortality rates compared to non-
diabetic patients (131). Patients with diabetes with a first
MI who were randomly assigned to the early invasive
strategy faired worse than those managed conservatively
(42-day mortality: death or MI, or death alone 14.8% vs.
4.2%; p , 0.001) (132). Early catheterization and interven-
tion strategy after thrombolysis was of little benefit in these
patients with diabetes. Routine catheterization and angio-
plasty in this patient subgroup should be based on clinical
need and ischemic risk stratification.
Stenting decreases the need for target revascularization
procedures in diabetic patients compared with balloon
angioplasty. The efficacy of stenting with glycoprotein
IIb/IIIa inhibitors was assessed in the diabetic population
compared to those without diabetes in a substudy of the
EPISTENT trial (133). One hundred seventy-three dia-
betic patients were randomized to stent/placebo combina-
tion, 162 patients to stent/abciximab combination, and 156
patients to balloon angioplasty/abciximab combination. For
the composite end point of death, MI, or target-vessel
revascularization, the rates were as follows: 25%, 23%, and
13% for the stent/placebo, balloon/abciximab, and stent/
abciximab groups (p 5 0.005). Irrespective of revasculariza-
tion strategy abciximab significantly reduced 6-month death
and MI rate in patients with diabetes for all strategies.
Likewise, 6-month target-vessel revascularization was re-
duced in the stent/abciximab group approach. One-year
mortality for diabetics was 4.1% for the stent/placebo group
and 1.2% for the stent/abciximab group. Although this
difference was not significant, the combination of stenting
and abciximab among diabetics resulted in a significant
reduction in 6-month rates of death and target-vessel
Table 7. Gender-Specific Late Mortality Risk
Study Year Reference Women vs. Men
Follow-Up
(yrs) Device
Mortality, Men vs.
Women (%)
p
Value
Adjusted OR
(95% CI)
NHLBI PTCA Registry 2000 (49) 2,136 (546 vs. 1,590) 4 PTCA 6.6 vs. 10.8 0.001 1.20 (0.84–1.73)
Mayo Clinic 1995 (122) 3,027 (824 vs. 2,203) 5.5 PTCA 27 vs. 22 0.06 0.94 (0.76–1.15)
Emory University 1994 (123) 10,785 (2,845 vs. 7,940) 5 PTCA 8 vs. 5 0.0002 1.08 (0.84–1.39)
BARI 1998 (120) 1,829 (489 vs. 1,340) 5 PTCA 12.8 vs. 12.0 NS 0.60 (0.43–0.84)
NACI 1997 (124) 2,855 (975 vs. 1,880) 1 PCI 5.7 vs. 5.9 NS NS
CI 5 confidence interval; NS 5 no significance; OR 5 odds ratio; PCI 5 percutaneous coronary intervention; PTCA 5 percutaneous transluminal coronary angioplasty. For
expansion of study names, see the corresponding reference.
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revascularization compared to stent/placebo or balloon an-
gioplasty/abciximab therapy (133). The BARI trial, in
which stents and abciximab were not used, showed that
survival was better for patients with treated diabetes under-
going CABG surgery with an arterial conduit than for those
undergoing angioplasty. A discussion about the selection of
diabetic patients for surgical revascularization or PCI may
be found in Section III. Outcomes, F. Comparison With
Bypass Surgery.
7. Coronary Angioplasty After CABG Surgery. Al-
though speculated to be at higher risk, patients having PCI
of native vessels after prior coronary bypass surgery have, in
recent years, nearly equivalent interventional outcomes and
complication rates compared to patients having similar
interventions without prior surgery. For PCI of SVG,
studies indicate that the rate of successful angioplasty
exceeds 90%, death ,1.2%, and Q-wave MI ,2.5% (Table
8). The incidence of non–Q-wave MI may be higher than
that associated with native coronary arteries (134–136).
In consideration of PCI for SVG, the age of the SVG and
duration and severity of myocardial ischemia should be
taken into consideration. Use of GP IIb/IIIa blockers has
not been shown to improve results of angioplasty in vein
grafts. The native vessels should be treated with PCI if
feasible. Patients with older and/or severely diseased SVGs
may benefit from elective repeat CABG surgery rather than
PCI (137,138).
In some circumstances, PCI of a protected left main
coronary artery stenosis with a patent and functional left
anterior descending or left circumflex coronary conduit can
be considered. Percutaneous coronary interventions should
be recognized as a palliative procedure with the potential to
delay the ultimate application of repeat CABG surgery.
8. Specific Technical Considerations. Certain outcomes
of PCI may be specifically related to the technology utilized
for coronary recanalization. The occurrence of periproce-
dural CPK-MB elevation 3 times the upper limit of normal
appears to occur more frequently following use of ablative
technology such as rotational or directional atherectomy
(20,34,58,140,146). Antecedent unstable angina appears to
be a clinical predictor of slow flow and periprocedural
infarction following ablative technologies (147), and direct
platelet activation has been demonstrated to occur with both
directional and rotational atherectomy (148). In support of
the premise that platelets play a pathophysiologic role in
periprocedural MI are observations that the presence and
magnitude of CK-MB elevation following ablative technol-
ogies can be reduced to levels observed following balloon
angioplasty by the administration of prophylactic platelet
GP IIb/IIIa receptor blockade (149,150).
Coronary perforation may occur more commonly follow-
ing the use of ablative technologies, including rotational,
directional or extraction atherectomy, and excimer laser
coronary angioplasty. However, the incidence of perforation
has been reported variably to be 0.10 to 1.14% with balloon
angioplasty; 0.25 to 0.70% with directional coronary
atherectomy; 0.0 to 1.3% with rotational atherectomy; 1.3 to
2.1% with extraction atherectomy; and, 1.9 to 2.0% follow-
ing excimer laser coronary angioplasty (151,152). Coronary
perforation complicates PCI more frequently in the elderly
and in women. While 20% of perforations may be secondary
to the coronary guidewire, most are related to the specific
technology used. Perforation is usually (80 to 90%) evident
at the time of the interventional procedure and should be a
primary consideration in the differential diagnosis for car-
diac tamponade manifest within 24 h of the procedure.
Perforations may be classified based on angiographic ap-
pearance as Type I—extraluminal crater without extravasa-
tion; Type II—pericardial and myocardial blush without
contrast jet extravasation; and Type III—extravasation
through a frank ($1 mm) perforation (151). In the absence
of extravasation (Type III), the majority of perforations may
be effectively managed without urgent surgical intervention.
Type III perforations have been successfully managed non-
operatively with pericardiocentesis, reversal of anticoagula-
tion, and either prolonged perfusion balloon inflation at the
site of perforation or deployment of a covered stent. If these
approaches are not successful, perforations caused by direc-
tional atherectomy catheters usually require surgical repair
(Table 9).
9. Issues of Hemodynamic Support in High-Risk Angio-
plasty. Controversy exists about the ability to predict he-
modynamic compromise during coronary angioplasty. He-
modynamic compromise, defined as a decrease in systolic
blood pressure to an absolute level ,90 mm Hg during
balloon inflation, was often associated with LV ejection
fraction ,35%, .50% of myocardium at risk, and PTCA
performed on the last remaining vessel (95,107).
Early feasibility studies of high-risk PTCA using percu-
taneous cardiopulmonary support (CPS) indicated that
although initial likelihood of success was high, vascular
morbidity was also high with an incidence of 43%
Table 8. Probability of Success, Complications, and Restenosis
After Balloon Angioplasty or Stenting in Patients Following
Coronary Bypass Surgery
Conduit Site
Success
Rate
Death
Rate
MI
Rate*
Restenosis
Rate†
Saphenous vein graft (140–144) .92% ,2% 15% 20–35%
Internal mammary (145) 75% ,2% 15% 25%
Left main (146) 95% ,2% 10% 25%
*.3 times normal CK-MB on serial determinations following intervention; †resten-
osis measured as target-vessel revascularization.
Table 9. Procedural Outcomes Associated With
Specific Technologies
Technologies
Increased Complication Rates
Periprocedural
MI
Coronary
Perforation
Directional atherectomy X X
Rotational atherectomy X X
Extraction atherectomy X
Excimer laser coronary angioplasty X
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(153,154). However, no study has published data to validate
commonly employed high-risk categorization.
Elective high-risk PCI can be performed safely without
intra-aortic balloon pump (IABP) or CPS in most circum-
stances. Emergency high-risk PCI such as direct PCI for
acute MI can usually be performed without IABP or CPS.
CPS for high-risk PCI should be reserved only for patients
at the extreme end of the spectrum of hemodynamic
compromise, such as those patients with extremely de-
pressed LV function and patients in cardiogenic shock.
However, it should be noted that in patients with borderline
hemodynamics, ongoing ischemia, or cardiogenic shock,
insertion of an intra-aortic balloon just prior to coronary
instrumentation has been associated with improved out-
comes (155,156). Furthermore, it is reasonable to obtain
vascular access in the contralateral femoral artery prior to the
procedure in patients in whom the risk of hemodynamic
compromise is high, thereby facilitating intra-aortic balloon
insertion, if necessary.
For high-risk patients, clinical and anatomic variables
influencing complications and outcome should be assessed
before the performance of PCI to determine procedural risk,
the risk of abrupt vessel closure, and potential for cardio-
vascular collapse. In patients having a higher-risk profile,
consideration of alternative therapies, particularly coronary
bypass surgery, formalized surgical standby, or periproce-
dural hemodynamic support should be addressed before
proceeding with PCI.
F. Comparison With Bypass Surgery
The major advantage of PCI is its relative ease of use,
avoiding general anesthesia, thoracotomy, extracorporeal
circulation, CNS complications, and prolonged convales-
cence. Repeat PCI can be performed more easily than repeat
bypass surgery, and revascularization can be achieved more
quickly in emergency situations. The disadvantages of PCI
are early restenosis and the inability to relieve many totally
occluded arteries and/or those vessels with extensive athero-
sclerotic disease.
Coronary artery bypass surgery has the advantages of
greater durability (graft patency rates exceeding 90% at 10
years with arterial conduits) (157) and more complete
revascularization irrespective of the morphology of the
obstructing atherosclerotic lesion. Generally speaking, the
greater the extent of coronary atherosclerosis and its dif-
fuseness, the more compelling the choice of coronary artery
bypass surgery, particularly if LV function is depressed.
Patients with lesser extent of disease and localized lesions
are good candidates for endovascular approaches.
PTCA and coronary artery bypass surgery have been
compared in many nonrandomized and randomized studies.
The most accurate comparisons of outcomes are best made
from prospective randomized trials of patients suitable for
either treatment. Although results of these trials provide
useful information for selection of therapy in several patient
subgroups, prior studies of PTCA may not reflect outcome
of current PCI practice, which includes frequent use of
stents and antiplatelet drugs. Similarly, many previous
studies of CABG may not reflect outcome of current
surgical practice in which arterial conduits are used when-
ever practicable. Beating heart bypass operations are also
employed for selected patients with single-vessel disease
with reduced morbidity (158). In addition, patients are
selected for PCI (with or without stenting) because of
certain lesion characteristics, and these anatomical criteria
are not required for CABG.
Randomized trials also must be interpreted carefully. It is
unethical to withhold subsequent PCI or CABG from
patients solely because they fail an earlier treatment; thus,
comparative prospective studies can only compare initial
strategies of revascularization. This critically important
point is frequently overlooked by those who claim that a
randomized study proves equally good outcome of one
method of revascularization over the other. Indeed, it would
seem highly unlikely that any randomized trial of PCI and
CABG could demonstrate a survival advantage of an initial
revascularization method as long as frequent crossover to
alternate and/or new therapies is allowed.
Despite these limitations, some generalizations can be
made from comparative trials of PTCA and CABG. First,
for most patients with single-vessel disease, late survival is
similar with either revascularization strategy, and this might
be expected given the generally good prognosis of most
patients with single-vessel disease managed medically (159–
161).
Two prospective clinical trials have evaluated PTCA and
CABG for revascularization of isolated disease of the left
anterior descending coronary artery. Investigators in the
Medicine, Angioplasty or Surgery Study (MASS) used a
combined end point of cardiac death, MI, or refractory
angina requiring repeat revascularization by surgery; at 3
years of follow-up, this combined end point occurred in
24% of PTCA patients, in 17% of medical patients, and in
3% of surgical patients (162). Importantly, there was no
difference in overall survival in the three groups. In the
Lausanne trial of 134 patients with isolated left anterior
descending artery disease treated by either PTCA (68
patients) or bypass with an internal mammary artery, sur-
vival was similar in the two groups, and 94% of PTCA
patients and 95% of CABG patients were free of limiting
symptoms (163). However, patients in the PTCA group
took more antianginal drugs than surgical patients, and at
median follow-up of 2.5 years, 86% of CABG-treated
versus 43% of PTCA-treated patients were free from late
events (p , 0.01); this difference was primarily due to
restenosis (32%) requiring subsequent CABG (16%) or
PTCA (15%). It should be emphasized that neither of the
two aforementioned trials included stenting, a technique
which would be expected to reduce rates of early restenosis
by as much as 50% in appropriately selected lesions
(86,164,165).
In a similar manner, the 3-year follow-up of the Argen-
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tine randomized trial of PTCA versus CABG multivessel
disease (ERACI study) (164) demonstrated that in patients
randomized to angioplasty or bypass surgery, the 1-, 3-, and
5-year follow-up results indicated that freedom from com-
bined cardiac events was significantly greater for bypass
surgery than for angioplasty group (77% vs. 47%; p ,
0.001). However, there were no differences in overall and
cardiac mortality or in the frequency of MI between the two
groups. Patients who had bypass surgery were more fre-
quently free of angina (79% vs. 57%) and had fewer
additional reinterventions (6.3% vs. 37%) than in patients
who had angioplasty. This study indicated that freedom
from combined cardiac events at 3-year follow-up was
greater in bypass patients than those who had angioplasty
and that the angioplasty group had a higher incidence of
recurrence of angina and need for repeat procedures. Cu-
mulative cost at 3 years was greater for surgery than for the
angioplasty group.
In the ARTS trial, the first trial to compare stenting with
surgery, there was no significant difference in mortality
between PCI and surgical groups at one year. The main
difference compared to previous PTCA and CABG trials
was an approximate 50% reduction in the need for repeat
revascularization in a group randomized to PCI with stent
placement (166).
Direct comparison of initial strategies of PCI or CABG
in patients with multivessel coronary disease is possible only
by randomized trials because of selection criteria of patients
for PCI. There have been 5 large (.300 patients) random-
ized trials of PTCA versus CABG and 2 smaller studies;
characteristics of the studies are summarized in Table 10
(9–12,164,167,168). These trials demonstrate that in ap-
propriately selected patients with multivessel coronary dis-
ease, an initial strategy of standard PTCA yields similar
overall outcomes (e.g., death, MI) compared to initial
revascularization with coronary artery bypass. In BARI, the
only trial with the largest patient enrollment to look at
survival alone, 5-year survival was 86.3% for those assigned
to PTCA versus 89.3% for those assigned to CABG (p 5
0.19), and 5-year survivals free from Q-wave MI were
78.7% and 80.4%, respectively. However, after 5 years of
follow-up, 54% of those assigned to PTCA had undergone
additional revascularization procedures compared to 8% of
the patients assigned to CABG (9). Indications for PCI for
various patient subsets are presented in Section V. Indica-
tions.
An important exception to the conclusion of the relative
safety of PCI in multivessel disease is the subgroup of
patients with treated diabetes mellitus. Among treated
diabetic patients in BARI assigned to PTCA, 5-year sur-
vival was 65.5% compared to 80.6% for patients having
CABG (p 5 0.003); the improved outcome with CABG
was due to reduced cardiac mortality (5.8% vs. 20.6%, p 5
0.0003), which was confined to those receiving at least 1
internal mammary artery graft (9). Better survival of diabetic
patients with multivessel disease treated initially with
CABG has been observed in a large retrospective study from
Emory (169) and may be due to the apparent additive effects
of diabetes mellitus and instrumentation of an artery on
development of new stenotic lesions (170). As compelling as
these reports may be, it is of interest that treated diabetic
patients enrolled in the BARI Registry did not show a
similar advantage for CABG over PCI, suggesting that
physician judgment in the selection of diabetic patients for
PCI may be an important factor (38,48).
Moreover, direct comparison between outcomes of PCI
and CABG among the diabetic population has not been
made using platelet receptor antagonists with PCI. In this
setting, PCI may be more competitive with CABG. The
EPISTENT trial demonstrated significant reductions of
Table 10. Summary of Randomized Trials of PTCA and CABG for Multivessel Disease
Trial Year Reference Location N
Follow-Up
(yrs) Endpoint Comment
BARI 1997 (9) North America
multicenter
1,829 5 Primary endpoint death Overall survival similar with PTCA and CABG,
but late survival of diabetic patients better with
CABG when internal mammary grafts used
CABRI 1995 (167) Europe
multicenter
1,054 1 Mortality, symptom status Complete revascularization with PTCA was not
required
RITA 1993 (10) U.K.
multicenter
1,011 2.5 Death or MI 45% of patients had SVD
EAST 1994 (11) Emory
University
392 3 Death, Q-wave, MI, or
large ischemic defect on
thallium
Repeat revascularization in 54% of PTCA group
compared to 13% of patients having CABG
GABI 1994 (12) Germany
multicenter
359 1 Freedom from angina IMA used in only 37% of CABG patients; over
80% of patients had 2-vessel disease
Toulouse 1997 (168) France 152 2.8 Freedom from angina 1 year
after revascularization
Similar survival with PTCA and CABG at 5
years, but better event-free survival with
CABG
ERACI 1996 (164) Argentina 127 3.8 Event-free survival (MI,
angina, and repeat
revascularization)
Similar in-hospital and 1-yr survival and freedom
from MI; less angina and fewer repeat
procedures after CABG
CABG 5 coronary artery bypass graft; IMA 5 internal mammary artery; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty; SVD 5
single-vessel disease. For expansion of study names, see the corresponding reference.
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major cardiac events at 30 days and at 6 months in the
abciximab groups undergoing stenting compared to those
with stenting and placebo (133).
Randomized trials of PTCA and CABG provide addi-
tional information on symptom relief, quality of life, and
costs of the two revascularization methods. Both revascu-
larization techniques relieve angina. However, to achieve
similar clinical outcomes, patients treated with PTCA are
more likely to require further interventions than patients
having surgery. Analysis of quality-of-life data from BARI
suggests that functional status including activities of daily
living improved less in patients assigned to PTCA than in
those assigned to CABG (p , 0.05), although patients with
initial PTCA returned to work five weeks sooner than did
patients undergoing operation (p , 0.001) (171).
G. Comparison With Medicine
There has been a considerable effort made to evaluate the
relative effectiveness of bypass surgery as compared to PCI
for coronary artery revascularization. In contrast to this, very
little effort has been directed toward comparing medical
therapy with PCI for the management of stable and
unstable angina. 3 Randomized trials are currently available
comparing PCI with the medical management of angina
(172–174). The ACME investigators randomized 212 pa-
tients with single-vessel disease, stable angina pectoris, and
ischemia on treadmill testing to PTCA or medical therapy.
This trial demonstrated superior control of symptoms and
better exercise capacity in patients managed with PTCA as
compared to medical therapy. Death and MI were infre-
quent and similar in both groups. The Veterans Adminis-
tration ACME trial investigators long-term results in an
additional 101 randomized patients with double-vessel dis-
ease not previously reported (175) indicated that patients
randomized to medical therapy or PTCA had similar
improvement in exercise duration, freedom from angina,
and improvement in quality of life at the time of 6-month
follow-up. Thus, these patients with double-vessel angio-
plasty did not demonstrate superior control of their symp-
toms as compared to medical therapy as was experienced by
the ACME patients with single-vessel disease. This small
study suggests that PTCA is less effective in controlling
symptoms in patients with double-vessel and stable angina
as compared to single-vessel disease.
The RITA-2 investigators randomized 1,018 stable pa-
tients with stable angina to PTCA or conservative (medical)
therapy (173). Patients who had inadequate control of their
symptoms with optimal medical therapy were allowed to
cross-over to myocardial revascularization. The combined
end point of the trial was all cause mortality and nonfatal
MI. The 504 PTCA and 514 medical patients were fol-
lowed for a mean of 2.7 years. Death and definite MI
occurred in 32 of the PTCA patients (6.3%) and in 17 of the
medical patients (3.3%), p 5 0.02. Of the 18 deaths (11
PTCA and 7 medical) only 8 were due to heart disease.
Twenty-three percent of the medical patients required a
revascularization procedure during follow-up. Angina im-
proved in both groups, but there was a 16.5% absolute
excess of grade 2 or worse angina in the medical group at 3
months following randomization (p , 0.001). The PTCA
patients also had greater improvement in their exercise
duration as compared to the medical patients (p , 0.001).
During follow-up 40 patients randomized to PTCA re-
quired CABG surgery (7.9%) as compared to 30 of the
medical patients (5.8%). Thus, RITA-2 demonstrated that
PTCA results in better control of symptoms of ischemia
and improves exercise capacity as compared to medical
therapy, but is associated with a higher combined end point
of death and periprocedural MI. It is important to remem-
ber that although the patients in this trial were asymptom-
atic or had only mild angina, 62% of them had multivessel
CAD and 34% had significant disease in the proximal
segment of the left anterior descending coronary artery (176).
Thus, most of these patients had severe anatomic CAD.
The Asymptomatic Cardiac Ischemia Pilot (ACIP) study
provides additional information comparing medical therapy
with PTCA or CABG revascularization in patients with
documented CAD and asymptomatic ischemia by both
stress testing and ambulatory ECG monitoring (176). This
trial randomized 558 patients suitable for revascularization
by PTCA or CABG to 3 treatment strategies: angina-
guided drug therapy (n 5 183), angina plus ischemia-
guided drug therapy (n 5 183), and revascularization by
PTCA or CABG surgery (n 5 192). Of the 192 patients
that were randomized to revascularization, 102 were se-
lected for PTCA and 90 for CABG. At 2 years of
follow-up, death or MI had occurred in 4.7% of the
revascularization patients as compared to 8.8% of the
ischemia-guided group and 12.1% of the angina-guided
group (p , 0.01). Because a large portion of the patients
underwent CABG surgery instead of PTCA in order to
achieve complete revascularization, it is not appropriate to
directly compare these results with RITA-2. Nonetheless,
the ACIP study suggests that outcomes of revascularization
with CABG surgery and PTCA are very favorable com-
pared to medical therapy in patients with asymptomatic
ischemia with or without mild angina. It should be empha-
sized that aggressive lipid-lowering therapy was not widely
employed in the medical treatment arm of ACIP.
AVERT (174) randomly assigned 341 patients with
stable CAD, normal LV function, and Class I and/or II
angina to PTCA or medical therapy with 80 mg daily
atorvastatin (mean LDL 5 77 mg/dl). At 18 months
follow-up, 13% of the medically treated group had ischemic
events as compared to 21% of the PTCA group (p 5 0.048).
Angina relief was greater in those treated with PTCA.
Although not statistically different when adjusted for in-
terim analysis, these data suggest that in low-risk patients
with stable CAD, aggressive lipid-lowering therapy can be
as effective as PTCA in reducing ischemic events.
Based on the limited data available from randomized
trials comparing medical therapy with PTCA, it seems
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prudent to consider medical therapy for the initial manage-
ment of most patients with Canadian Cardiovascular Soci-
ety Classification Class I and II and reserve PTCA and
CABG for those patients with more severe symptoms and
ischemia. The symptomatic individual patient who wishes
to remain physically active, regardless of age, will more often
require PCI although one trial (RITA-2) (94,173) suggests
that this option may be associated with an increased initial
risk. The results of the ACIP trial indicate that higher-risk
patients with asymptomatic ischemia and significant CAD
who undergo complete revascularization with CABG or
PTCA may have a better outcome as compared to those
with medical management. This finding had not been
previously demonstrated by trials comparing medical man-
agement with surgical revascularization (16,98) (Table 11).
In contrast, the results of AVERT indicate revascularization
provides no benefit when compared to aggressive lipid-
lowering therapy in low-risk patients. Clinical Outcomes
Utilization Revascularization and Aggressive Drug Evalua-
tion (COURAGE) trial, a 3,250 patient-based trial, will
compare intensive medical therapy with revascularization
over 5 to 7 years. It is anticipated that this trial will answer
many questions, in addition to quality-of-life assessment
and economic cost analysis (177–179) Patients with unsta-
ble angina and non–ST-segment elevation MI have been
randomized to medical therapy or PCI in the FRISC II and
TACTICS TIMI 18 trials. These trials utilizing stenting as
the primary therapy have favored the invasive approach.
They are discussed under Section V. B.
IV. INSTITUTIONAL AND OPERATOR COMPETENCY
A. Quality Assurance
A mechanism for valid peer review must be established
and ongoing at each institution performing PCI. Interven-
tional cardiology procedures are associated with complica-
tions that in general are inversely related to operator and
institutional volume (43,180–183). The mechanism for
institutional review should provide an opportunity for in-
terventionalists as well as physicians who do not perform
angioplasty, but are knowledgeable about it, to review
overall results of the program on a regular basis. The
responsible supervising authority should monitor the fol-
lowing issues as outlined in Table 12.
The institutional credentialing committee should docu-
ment that an interventionalist wishing to start practice
meets the established training criteria, including those of the
ACC Task Force on Training in Cardiac Catheterization
and Interventional Cardiology (21,185,186). The ACC
Training Statement (186) for coronary invasive training
requires a 3-year comprehensive cardiac program with 12
months of training in diagnostic catheterization during
which the trainee performs 300 diagnostic catheterizations
with 200 of those being the primary operator. The inter-
ventional training requires a fourth year of fellowship during
which the trainee should perform more than 250 interven-
tional procedures, but not more than 600/year (186). To be
eligible for the American Board of Internal Medicine
(ABIM) certifying examination in interventional cardiol-
ogy, a trainee must be actively involved in at least 250
interventional procedures during a 4th year of interventional
cardiology fellowship. Only one trainee may receive credit
for the intervention on a given patient. Until 2003, the
practicing interventionalist can qualify for the examination
by active involvement in interventional cardiology, includ-
ing the performance of at least 150 interventions over the
prior 2 year period (187). Credentials committees should
evaluate the physicians’ outcomes to be certain that volume
and results meet the current standards or benchmarks for
successful management (21). These benchmarks refer to
procedural rates of unadjusted mortality (0.9%) and emer-
gency coronary artery bypass surgery (#3.0%). It should be
noted that these benchmarks are derived from PTCA
performed in New York State on all procedures including
those for complicated acute MI and that they were gathered
before the use of stents and platelet GP IIb/IIIa inhibitors.
Thus, the standard for benchmark complication rates will be
subject to future revision as newer data emerge. It is
important that institutions assist with these efforts by
participating in active database efforts to track clinical and
procedural information for individual operators and their
institutions. In the future, certification by the ABIM in
Interventional Cardiology should be required.
This Writing Committee agrees with the ACC Task
Force recommendations for the Assessment and Mainte-
nance of Proficiency in Coronary Interventional Procedures
(21). Institutions performing PCI should meet the follow-
ing standards as outlined in Tables 13 and 14 (21,184,186).
B. Operator and Institutional Volume
The proliferation of small angioplasty or small surgical
programs to support such angioplasty programs is strongly
discouraged. Several studies have identified procedural vol-
ume as a determining factor for frequency of complications
with PCI (43,182,183,188–191). Kimmel, using data from
the Society of Cardiac Angiography and Interventions
(SCA&I), found that an inverse relationship existed be-
tween the number of angioplasty procedures performed at a
hospital and the rate of major complications (181). These
results were risk-stratified and independent of the patient-
risk profile. Significantly fewer complications occurred in
laboratories performing $400 angioplasty procedures per
year. Conversely, low-volume hospitals were associated with
higher rates of emergency coronary artery bypass surgery
and death (182). Improved outcomes were identified with a
threshold volume of 75 Medicare angioplasties per physi-
cian and 200 Medicare angioplasty procedures per hospital.
Using a 35 to 50% ratio of Medicare patients, the threshold
value was 150 to 200 angioplasty procedures/cardiologist
and 400 to 600 angioplasty procedures/institution (40).
Other studies have also supported the relationship of com-
plications to procedural volume (43,180,183). Although
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Table 11. PCI Comparison With Medical Therapy
Study Year Reference N Patient Population Treatment
Follow-
Up
Results
CommentsPCI Medical Therapy Significance
ACME 1992 (172) 212 Patients with single-vessel
disease
Medical therapy vs.
balloon angioplasty
64% less angina 46% less angina p , 0.01 The PTCA group had less angina,
better exercise performance and
more improvement in quality of
life scores, but had more
complications (emergency bypass 2
patients, MI in 5, and repeat
PTCA in 16).
VA ACME 1997 (175) 328 Patients with documented
chronic stable angina
227 single-vessel disease
101 double-vessel disease
Medical therapy vs.
balloon angioplasty
3 yrs 63% less angina 48% less angina p 5 0.02 Among patients with single-vessel
disease, the PTCA group had less
angina, better exercise performance,
and more improvement in quality
of life scores.
RITA-2 1997 (10) 1,018 53% with Class II angina
47% with prior angina
7% triple-vessel disease
Medical therapy vs.
balloon angioplasty
2.7 yrs 6.3% death or MI 3.3% death or MI p 5 0.02 The PTCA group had increased rates
of death and MI, but had 7% less
Class II angina at 2 years and
longer exercise treadmill test time
at 3 months.
ACIP 1997 (176) 558 Patients with documented
CAD and
asymptomatic ischemia
183 angina-guided drug
therapy
183 angina plus ischemia-
guided drug therapy
192 revascularization by
PTCA or CABG
Angina-guided drug
therapy vs. angina
plus ischemia-
guided drug
therapy vs.
revascularization
2 yrs 4.7% death or MI 8.8% death or MI for
ischemia-guided
drug therapy
12.1% death or MI for
angina-guided drug
therapy
p , 0.01 40% of patients had previous MI,
23% had prior PTCA or CABG
and 38% had triple-vessel disease.
AVERT 1999 (174) 341 Patients with stable
CAD, normal LV
function and angina
Class I/II
Medical therapy with
atorvastatin vs.
PTCA
18 mo 21% ischemic events 13% ischemic events p 5 0.048 p 5 0.045 needed for significance due
to interim analysis. Patients
required to complete 4 min on
Bruce protocol. Only 2 deaths
among 341 patients in 18 months.
Significant improvement in angina
in patients treated with PTCA
compared with medical therapy.
CABG 5 coronary artery bypass graft; CAD 5 coronary artery disease; LV 5 left ventricular; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention; PTCA 5 percutaneous transluminal coronary angioplasty. For
expansion of study names, see corresponding reference.
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some investigators have suggested that low procedure vol-
ume does not contribute to poor outcomes (188,192), these
studies are small in number and underpowered for analysis
(189). Development of small cardiovascular surgical pro-
grams to support angioplasty is a poor use of resources that
will likely lead to suboptimal results (190).
Given the concerns regarding operator volume and sur-
gical standby, it is recommended that PCI be performed by
higher volume operators ($75 cases/year) with advanced
technical skills (e.g., subspecialty certification) at institu-
tions with fully equipped interventional laboratories and
experienced support staff. This setting will most often be in
a high-volume center (.400 cases/year) associated with an
on-site cardiovascular surgical program (193). Similar con-
cerns have been identified and supported by the Task Force
for Practice Guidelines for Coronary Angiography (194).
Intuitively, it is clear that it would be best for the rare
patient requiring surgery after elective PCI to remain in the
same hospital rather than have the patient and family
undergo the confusion, stress, and anxiety of emergency
transfer. Given the widespread availability of sophisticated
interventional/surgical programs in the U.S., it is difficult to
demonstrate a need for additional low-volume programs to
do elective angioplasty except in underserved areas that are
geographically far removed from major centers. This Com-
mittee acknowledges that not every cardiologist desiring to
do PCI should perform these procedures and not every
hospital anxious to have an interventional program should
start one (191). This caveat is particularly true where there
are high-volume programs and operators nearby. In these
situations, operators should be subspecialty board certified.
The Committee, therefore, recommends that angioplasty
is best done by high-volume operators in high-volume
institutions. Any change in this recommendation awaits
further data confirming the comparable safety and outcomes
for patients treated in an alternative manner. The Commit-
tee cannot recommend angioplasty by low-volume operators
(,75 cases/year) working in low-volume institutions (,200
cases/year) with or without on-site surgical coverage. As
noted earlier, ongoing investigational experience and clinical
data are mandatory if these recommendations are to be
modified.
Recommendations for PCI Institutional and Operator
Volumes at Centers With Onsite Cardiac Surgery
(21,186) (Table 14)
Class I
1. PCI done by operators with acceptable volume
(>75) at high-volume centers (>400). (Level of
Evidence: B)
Class IIa
1. PCI done by operators with acceptable volume
(>75) at low-volume centers (200 to 400). (Level of
Evidence: C)
2. PCI done by low-volume operators (<75) at high-
volume centers (>400). Note: Ideally operators
with an annual procedure volume <75 should only
Table 12. Key Components of a Quality Assurance Program
Clinical Proficiency c General indications/contraindications
c Institutional and individual operator complication rates, mortality and
emergency bypass surgery
c Institutional and individual operator procedure volumes
c Training and qualifications of support staff
Equipment Maintenance
and Management
c Quality of laboratory facility (See ACC/SCA&I Expert Consensus Document
on Cardiac Catheterization Laboratory Standards (184))
Quality Improvement
Process
c Establishment of an active concurrent database to track clinical and procedural
information as well as patient outcomes for individual operators and the
institution. The ACC-National Cardiovascular Data Registry™ is strongly
recommended for this purpose
Radiation Safety c Educational program in the diagnostic use of X-ray
c Patient and operator radiation exposure
Table 13. Considerations for the Assessment and
Maintenance of Proficiency in Coronary Interventional
Procedures (21,184,186)
Institutions
c Quality assessment monitoring of privileges and risk/stratified
outcomes
c Provide support for a quality assurance staff person (eg, nurse) to
monitor complications
c Minimal institutional performance activity of 200 interventions per
year with the ideal minimum of 400 interventions per year
c Interventional program director who has a career experience of
.500 PCI procedures and is board certified by ABIM in
interventional cardiology
c Facility and equipment requirements to provide high resolution
fluoroscopy and digital video processing
c Experienced support staff to respond to emergencies. (See Section
IV, C. Need for Surgical Backup for discussion.)
c Establishment of a mentoring program for operators who perform
,75 procedures per year by the individuals who perform $150
procedures per year
Physicians
c Procedural volume of $75 per year
c Continuation of privileges based on outcome benchmark rates with
consideration of not granting privileges to operators who exceed
adjusted case mix benchmark complication rates for a 2-year period
c Ongoing quality assessment comparing results with current
benchmarks with risk stratification of complication rates
c Board certification by ABIM in interventional cardiology
ABIM 5 American Board of Internal Medicine; PCI 5 percutaneous coronary
intervention.
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work at institutions with an activity level of >600
procedures/year.* (Level of Evidence: C)
Class III
1. PCI done by low-volume operators (<75) at low-
volume centers (200 to 400). Note: An institution
with a volume <200 procedures/year, unless in a
region that is underserved because of geography,
should carefully consider whether it should con-
tinue to offer service.* (Level of Evidence: C)
C. On-Site Cardiac Surgical Backup
Cardiac surgical backup for PCI has evolved from the
formal surgical standby in the 1980s to an informal arrange-
ment of first available operating room and, in some cases,
off-site surgical backup (40,195–199). With the advent of
intracoronary stenting, there has been a decrease in the need
for emergency coronary artery bypass, ranging between 0.4
and 2% (200–202). Not surprisingly, emergency coronary
artery bypass for a patient with an occluded or dissected
coronary artery is associated with a higher mortality than
elective surgery (203–208). Emergency procedures are also
associated with high rates of perioperative infarction and
less frequent use of arterial conduits. Complex CAD inter-
vention, hemodynamic instability, and prolonged time to
reperfusion are contributing factors to the increased risk of
emergency bypass surgery.
1. Primary PCI Without On-Site Cardiac Surgery. Al-
though thrombolytic trials demonstrated that early reperfu-
sion saves myocardium and reduces mortality (209–212),
the superiority and greater applicability of primary PCI for
the treatment of acute MI has raised the question of
whether primary PCI should be performed at institutions
with diagnostic cardiac catheterization laboratories that do
not perform elective PCI or have on-site cardiac surgery.
For this reason, the establishment of PCI programs at
institutions without on-site cardiovascular surgery has been
promoted as necessary to maintain quality of care (195–
197,213–220). In those patients where there is a contrain-
dication to thrombolytic therapy, or when there are com-
plications such as cardiogenic shock, catheter-based therapy
may limit infarct size (221,222). It must be realized that
PCI in the early phase of an acute MI can be difficult and
requires even more skill and experience than routine PCI in
the stable patient. The need for an experienced operator and
experienced laboratory technical support (223) with avail-
ability of a broad range of catheters, guidewires, stents, and
other devices (e.g., IABP) that are required for optimum
results in an acutely ill patient is of major importance (Table
15). If these complex patients are treated by intervention-
alists with limited experience at institutions with low
volume, then the gains of early intervention may be lost
because of increased complications. In such circumstances,
transfer to a center that routinely performs complex PCI
will often be a more effective and efficient course of action
(16). Thrombolysis is still an acceptable form of therapy
(224) and is preferable to acute PCI by an inexperienced
team (224,225).
Reports of emergency primary angioplasty programs from
hospitals without established open-heart surgery or elective
angioplasty, similar to those of most tertiary centers, have
demonstrated generally favorable results. Such acceptable
clinical results have been reported with intensive training,
continuous oversight, and the combination of nearby,
readily available bypass surgery support, a team of highly
experienced interventionalists and support staff, and careful
patient selection (214). However, poor results of similar
endeavors are rarely reported. Before the use of stenting and
glycoprotein receptor blockers, primary angioplasty in cer-
tain hospitals has been associated with acute mortality rates
greater than those reported from centers with established
primary angioplasty programs. Overall, in-hospital mortal-
ity rates have ranged from 1.4 to 13% (196,197,216).
Criteria have been suggested for the performance of
*Operators who perform ,75 procedures/year should develop a defined mentoring
relationship with a highly experienced operator who has an annual procedural volume
.150 procedures/year.
Table 14. Recommendations for PCI Institutional and Operator Volumes at Centers With On-Site Cardiac Surgery (21,186)
Operator Volume
Minimum Institutional Volume Optimal Institutional Volume
Institutions performing 200–400 procedures annually Institutions performing >400 procedures annually
Low (,75 procedures
annually)
Class IIb Class IIa
PCI done by low-volume operators (,75) at low-volume
centers (200–400).*
PCI done by low-volume operators (,75) at high-volume
centers (.400).*
(Level of Evidence: C) (Level of Evidence: C)
Note: An institution with a volume ,200 procedures/year,
unless in a region that is underserved because of
geography, should carefully consider whether it should
continue to offer the service.
Note: Ideally, operators with annual procedure volume ,75
should only work at institutions with an activity level of
.600 procedures/year.
Acceptable ($75
procedures annually)
Class IIa Class I
PCI done by operators with acceptable volume ($75) at
low-volume centers (200–400).
PCI done by operators with acceptable volume ($75) at
high-volume centers (.400).
(Level of Evidence: C) (Level of Evidence: B)
*Note: Operators who perform ,75 procedures/year should develop a defined mentoring relationship with a highly experienced operator who has an annual procedural volume
$150 procedures/year.
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primary PCI at hospitals without on-site cardiac surgery
(Tables 15 and 16). Of note, large-scale registries have
shown an inverse relationship between the number of
primary angioplasty procedures performed and in-hospital
mortality (226–228). The data suggest that both door-to-
balloon time and in-hospital mortality are significantly
lower in institutions performing a minimum of 36 primary
angioplasty procedures per year (229). Communities may
identify a unique qualified and experienced center wherein
the on-site intervention for acute MI could be performed.
Suboptimal results may relate to operator/staff inexperience
and capabilities and delays in performing angioplasty for
logistical reasons (230). From clinical data and expert
consensus, the Committee recommends that primary PCI
for acute MI performed at hospitals without established
elective PCI programs should be restricted to those institu-
tions capable of performing a requisite minimum number of
primary angioplasty procedures (36/year) with a proven plan
for rapid and effective PCI as well as rapid access to cardiac
surgery in a nearby facility (193) (Table 17).
2. Elective PCI Without On-Site Surgery. Technical
improvements in interventional cardiology have led to the
development of elective angioplasty programs without on-
site surgical coverage. Several centers have reported satis-
factory results based on careful case selection with well-
defined arrangements for immediate transfer to a surgical
program (195–199,231–235). The studies of angioplasty
without on-site surgical coverage have not identified signif-
icant differences in the outcomes, recalling the infrequent
rate of complications (236). Despite many reported success-
ful angioplasty series without on-site surgical backup and a
very low percentage need for off-site surgery in failed
angioplasty, some clinicians have expressed concern
(237,238) about the appropriateness of elective angioplasty
in centers without on-site surgical coverage. Caution is
warranted before endorsing an unrestricted policy for PCI
in hospitals without appropriate facilities. Several outstand-
ing and critically important clinical issues, such as timely
management of ischemic complications, adequacy of spe-
cialized post-interventional care, logistics for managing
cardiac surgical or vascular complications and operator/
laboratory volumes, and accreditation must be addressed.
Mere convenience should not replace safety and efficacy in
establishing an elective PCI program without on-site sur-
gery.
At this time, the Committee, therefore, continues to
support the recommendation that elective PCI should not
be performed in facilities without on-site cardiac surgery
(Table 17). As with many dynamic areas in interventional
cardiology, these recommendations may be subject to revi-
sion as clinical data and experience increase.
Table 15. Criteria for the Performance of Primary Angioplasty
at Hospitals Without On-Site Cardiac Surgery
1. The operators must be experienced interventionalists who regularly
perform elective intervention at a surgical center ($75 cases/year).
The institution must perform a minimum of 36 primary PCI
procedures per year.
2. The nursing and technical catheterization laboratory staff must be
experienced in handling acutely ill patients and comfortable with
interventional equipment. They must have acquired experience in
dedicated interventional laboratories at a surgical center. They
participate in a 24-h, 365-day call schedule.
3. The catheterization laboratory itself must be well-equipped, with
optimal imaging systems, resuscitative equipment, IABP support,
and must be well-stocked with a broad array of interventional
equipment.
4. The cardiac care unit nurses must be adept in hemodynamic
monitoring and IABP management.
5. The hospital administration must fully support the program and
enable the fulfillment of the above institutional requirements.
6. There must be formalized written protocols in place for immediate
(within 1 h) and efficient transfer of patients to the nearest cardiac
surgical facility which are reviewed/tested on a regular (quarterly) basis.
7. Primary intervention must be performed routinely as the treatment
of choice around the clock for a large proportion of patients with
AMI, to ensure streamlined care paths and increased case volumes.
8. Case selection for the performance of primary angioplasty must be
rigorous. Criteria for the types of lesions appropriate for primary
angioplasty and for the selection for transfer for emergent
aortocoronary bypass surgery are shown in Table 16.
9. There must be an ongoing program of outcomes analysis and
formalized periodic case review.
10. Institutions should participate in a 3- to 6-month-period of
implementation during which time development of a formalized
primary PCI program is instituted that includes establishing
standards, training staff, detailed logistic development, and creation
of a quality assessment and error management system.
AMI 5 acute myocardial infarction; IABP 5 intra-aortic balloon pump; PCI 5
percutaneous coronary intervention.
Adapted with permission from Wharton TP Jr, McNamara NS, Fedele FA, Jacobs
MI, Gladstone AR, Funk EJ. Primary angioplasty for the treatment of acute
myocardial infarction: experience at two community hospitals without cardiac surgery.
J Am Coll Cardiol 1999;33:1257–65.
Table 16. Patient Selection for Angioplasty and Emergency
Aortocoronary Bypass at Hospitals Without On-Site
Cardiac Surgery
Avoid intervention in hemodynamically stable patients with:
c Significant ($60%) stenosis of an unprotected left main (LM)
coronary artery upstream from an acute occlusion in the left coronary
system that might be disrupted by the angioplasty catheter
c Extremely long or angulated infarct-related lesions with TIMI grade 3
flow
c Infarct-related lesions with TIMI grade 3 flow in stable patients with
3-vessel disease (257,266)
c Infarct-related lesions of small or secondary vessels
c Lesions in other than the infarct artery
Transfer for emergent aortocoronary bypass surgery patients with:
c High-grade residual left main or multivessel coronary disease and
clinical or hemodynamic instability
—After angioplasty or occluded vessels
—Preferably with intraaortic balloon pump support
Adapted with permission from Wharton TP Jr, McNamara NS, Fedele FA,
Jacobs MI, Gladstone AR, Funk EJ. Primary angioplasty for the treatment of acute
myocardial infarction: experience at two community hospitals without cardiac
surgery.J Am Coll Cardiol 1999;33:1257–65.
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Recommendations for PCI With and Without On-Site
Cardiac Surgery (Table 17)
Class I
1. Patients undergoing elective PCI in facilities with
on-site cardiac surgery. (Level of Evidence: B)
2. Patients undergoing primary PCI in facilities with
on-site cardiac surgery. (Level of Evidence: B)
Class IIb
1. Patients undergoing primary PCI in facilities with-
out on-site cardiac surgery, but with a proven plan
for rapid access (within 1 h) to a cardiac surgery
operating room in a nearby facility with appropriate
hemodynamic support capability for transfer. The
procedure should be limited to patients with ST-
segment elevation MI or new LBBB on ECG, and
done in a timely fashion (balloon inflation within
90 6 30 min of admission) by persons skilled in the
procedure (>75 PCIs/year) (193) and only at facil-
ities performing a minimum of 36 primary PCI
procedures per year (229). (Level of Evidence: B)
Class III
1. Patients undergoing elective PCI in facilities with-
out on-site cardiac surgery. (Level of Evidence: C)
2. Patients undergoing primary PCI in facilities with-
out on-site cardiac surgery and without a proven
plan for rapid access (within 1 h) to a cardiac
surgery operating room in a nearby facility with
appropriate hemodynamic support capability for
transfer or when performed by lower skilled opera-
tors (<75 PCIs/year) in a facility performing <36
primary PCI procedures/year. (Level of Evidence: C)
V. INDICATIONS
A broad spectrum of clinical presentations exists wherein
patients may be considered candidates for PCI, ranging
from asymptomatic to severely symptomatic or unstable,
with variable degrees of jeopardized myocardium. Selection
of appropriate candidates for PCI in a variety of clinical
presentations is reviewed in this section.
Each time that a patient is considered for revasculariza-
tion, the potential risk and benefits of the particular proce-
dure under consideration must be weighed against alterna-
tive therapies (Table 18).
When PCI is considered, the benefits and risks of surgical
revascularization and medical therapy always deserve
thoughtful discussion with the patient and family. The
initial simplicity and associated low morbidity of PCI as
compared to surgical therapy is always attractive, but the
patient and family must understand the limitations inherent
in current PCI procedures, including a realistic presentation
of the likelihood of restenosis and the potential for incom-
plete revascularization as compared with CABG surgery. In
patients with CAD who are asymptomatic or have only mild
Table 17. Recommendations for PCI With and Without On-Site Cardiac Surgery
With On-Site Cardiac Surgery Without On-Site Cardiac Surgery
Elective PCI Class I Class III
Patients undergoing elective PCI in facilities with
on-site cardiac surgery.
Patients undergoing elective PCI in facilities without on-site cardiac surgery.
(Level of Evidence: C)
(Level of Evidence: B)
Primary PCI Class I Class IIb
Patients undergoing primary PCI in facilities
with on-site cardiac surgery.
(Level of Evidence: B)
Patients undergoing primary PCI in facilities without on-site cardiac
surgery, but with a proven plan for rapid access (within 1 h) to a cardiac
surgery operating room in a nearby facility with appropriate hemodynamic
support capability for transfer. The procedure should be limited to
patients with ST-segment elevation MI or new LBBB on ECG, and
done in a timely fashion (balloon inflation within 90 6 30 min of
admission) by persons skilled in the procedure ($75 PCIs/year) (193) and
only at facilities performing a minimum of 36 primary PCI procedures
per year (229).
(Level of Evidence: B)
Class III
Patients undergoing primary PCI in facilities without on-site cardiac surgery
and without a proven plan for rapid access (within 1 h) to a cardiac
surgery operating room in a nearby facility with appropriate hemodynamic
support capability for transfer.
(Level of Evidence: C)
ECG 5 electrocardiography; LBBB 5 left bundle-branch block; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention.
Table 18. Provider Checklist: Key Areas for Consideration
Patients at High Risk
N Assess key clinical and anatomical variables
N Consider alternative therapies such as CABG in consultation with the
patient
N Ensure that formalized surgical standby is available
N Ensure periprocedural hemodynamic support is available
Patients at Low Risk
N Assess key clinical and anatomical variables
N Consider alternative therapies such as medical therapy in consultation
with the patient
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symptoms, the potential benefit of antianginal drug therapy
along with an aggressive program of risk reduction must also
be understood by the patient before a revascularization
procedure is performed.
A. Asymptomatic or Mild Angina
In the previous ACC/AHA Guidelines for PTCA, spe-
cific recommendations were made separately for patients
with single- or multivessel disease (16,98). The current
techniques of PCI have matured to the point where, in
patients with favorable anatomy, the competent practitioner
can perform either single- or multivessel PCI at low risk and
with a high likelihood of initial success. For this reason, in
this revision of the Guidelines, recommendations will be
made largely based upon the patients’ clinical condition,
specific coronary lesion morphology and anatomy, LV func-
tion, and associated medical conditions, and less emphasis will
be placed on the number of lesions or vessels requiring PCI.
The CCS Class of angina (I to IV) is used to define the severity
of symptoms. The categories described in this section refer to
an initial PCI procedure in a patient without prior CABG
surgery. The randomized trials comparing PTCA and medical
therapy have been discussed (Table 11).
The Committee recognizes that the majority of patients
with asymptomatic ischemia or mild angina should be
treated medically. The published ACIP study (176) casts
some doubt on the wisdom of medical management for
those higher-risk patients who are asymptomatic or have
mild angina, but have objective evidence by both treadmill
testing and ambulatory monitoring of significant myocardial
ischemia and CAD. In addition, there is a substantial
portion of the middle and older age populations in this
country that remains physically active, participating in
sports, such as tennis and skiing, or performing regular and
vigorous physical exercise, such as jogging, who have CAD.
For such individuals with moderate or severe ischemia and
few symptoms, revascularization with PCI or CABG sur-
gery may reduce their risk of serious or fatal cardiac events.
For this reason, patients in this category of higher-risk
asymptomatic ischemia or mild symptoms and severe ana-
tomic CAD are placed in Class I or II. Percutaneous
coronary intervention may be considered if there is a high
likelihood of success and a low risk of morbidity or mortal-
ity. The judgment of the experienced physician is deemed
valuable in assessing the extent of ischemia.
Recommendations for PCI in Asymptomatic or Class I
Angina Patients (Table 19)
Class I
1. Patients who do not have treated diabetes with
asymptomatic ischemia or mild angina with 1 or
more significant lesions in 1 or 2 coronary arteries
suitable for PCI with a high likelihood of success
and a low risk of morbidity and mortality. The
vessels to be dilated must subtend a large area of
viable myocardium (108) (Table 20). (Level of Evi-
dence: B)
Table 19. Recommendations for PCI in Asymptomatic or Class I Angina Patients
Class I Class IIa Class IIb Class III
Patients who do not have treated
diabetes with asymptomatic
ischemia or mild angina with
1 or more significant lesions in
1 or 2 coronary arteries
suitable for PCI with a high
likelihood of success and a low
risk of morbidity and
mortality.
The vessels to be dilated must
subtend a large area of viable
myocardium (Table 20).
(Level of Evidence: B)
The same clinical and anatomic
requirements for Class I,
except the myocardial area at
risk is of moderate size or
the patient has treated
diabetes.
(Level of Evidence: B)
Patients with asymptomatic ischemia
or mild angina with $3 coronary
arteries suitable for PCI with a
high likelihood of success and a
low risk of morbidity and
mortality.
The vessels to be dilated must
subtend at least a moderate area
of viable myocardium.
In the physician’s judgment, there
should be evidence of myocardial
ischemia such as ECG exercise
testing, stress nuclear imaging,
stress echocardiography,
ambulatory ECG monitoring, or
intracoronary physiologic
measurements.
(Level of Evidence: B)
Patients with asymptomatic ischemia
or mild angina who do not meet
the criteria as listed under Class I
or Class II and who have:
a. Only a small area of viable
myocardium at risk.
b. No objective evidence of
ischemia.
c. Lesions that have a low
likelihood of successful dilation.
d. Mild symptoms that are
unlikely to be due to
myocardial ischemia.
e. Factors associated with
increased risk of morbidity or
mortality.
f. Left main disease.
g. Insignificant disease ,50%.
(Level of Evidence: C)
PCI 5 percutaneous coronary intervention.
Table 20. Noninvasive Risk Stratification: High Risk
(.3% Annual Mortality Rate)
c High-risk treadmill score (score #211)
c Stress-induced large perfusion defect (particularly if anterior)
c Stress-induced perfusion defects of moderate size
c Stress-induced multiple perfusion defect with LV dilation or increased
lung uptake (thallium-201)
c Echocardiographic wall motion abnormality (involving .2 segments)
developing at a low dose of dobutamine (#10 mgzkg21zmin21) or at a
low heart rate (120 bpm)
c Stress echocardiographic evidence of extensive ischemia
Adapted with permission from Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/
ACP-ASIM guidelines for the management of patients with chronic stable angina.
J Am Coll Cardiol 1999;33:2092–197.
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Class IIa
1. The same clinical and anatomic requirements for
Class I, except the myocardial area at risk is of
moderate size or the patient has treated diabetes.
(Level of Evidence: B)
Class IIb
1. Patients with asymptomatic ischemia or mild an-
gina with >3 coronary arteries suitable for PCI
with a high likelihood of success and a low risk of
morbidity and mortality. The vessels to be dilated
must subtend at least a moderate area of viable
myocardium. In the physician’s judgment, there
should be evidence of myocardial ischemia by
ECG exercise testing, stress nuclear imaging,
stress echocardiography or ambulatory ECG mon-
itoring, or intracoronary physiologic measure-
ments. (Level of Evidence: B)
Class III
1. Patients with asymptomatic ischemia or mild an-
gina who do not meet the criteria as listed under
Class I or Class II and who have:
a. Only a small area of viable myocardium at
risk.
b. No objective evidence of ischemia.
c. Lesions that have a low likelihood of
successful dilation.
d. Mild symptoms that are unlikely to be due
to myocardial ischemia.
e. Factors associated with increased risk of
morbidity or mortality.
f. Left main disease.
g. Insignificant disease <50%. (Level of Ev-
idence: C)
B. Angina Class II to IV or Unstable Angina
Many patients with moderate or severe stable angina or
unstable angina do not respond adequately to medical
therapy and often have significant coronary artery stenoses
that are suitable for revascularization with CABG surgery or
PCI. In addition, a proportion of these patients have
reduced LV systolic function, which places them in a group
that is known to have improved survival with CABG
surgery and possibly with revascularization by PCI
(178,179,240,241). In nondiabetic patients with 1- or
2-vessel disease in whom angioplasty of 1 or more lesions
has a high likelihood of initial success, PCI is the preferred
approach. In a minority of such patients, CABG surgery
may be preferred, particularly for those in whom the left
anterior descending coronary artery can be revascularized
with the internal mammary artery or in those with left main
coronary disease. In patients with unstable angina or non–
Q-wave MI, intensive medical therapy should be initiated
prior to revascularization with PCI or CABG surgery
(242–244).
Clinical investigations evaluating the use of routine cath-
eterization and PCI for patients with unstable angina and
NSTEMI (non–ST-segment elevation MI) have yielded
inconsistent results. TIMI-IIIB was the first to compare
strategies of routine catheterization and revascularization in
addition to medical therapy and selective use of aggressive
treatment. In TIMI-IIIB, there was no difference in the
incidence of death or recurrent MI at 1 year between the 2
strategies, but patients treated by the aggressive strategy
experienced less angina and repeat hospitalizations for
ischemia and required fewer medications (245). In the
VANQWISH trial performed by the Veterans Administra-
tion, no difference in death or death and MI was observed
between the two strategies at late follow-up, but the
minority of patients in the aggressive strategy received
revascularization, and the mortality rate for those having
CABG was high (246). The FRISC II trial compared
medical and revascularization approaches among patients
after 6 days of low molecular weight heparin therapy before
a decision regarding PCI (247). Those randomized to the
conservative therapy only underwent PCI if they had
$3 mm ST depression on stress testing. Compared with
prior studies, patients assigned to the aggressive strategy in
FRISC II experienced a 22% reduction (p 5 0.031) in the
incidence of death or MI at 6 months (9.4%) compared to
conservatively treated patients (12.1%). In addition, there
was a significant decrease in MI rate alone and a non-
significantly lower mortality rate in the treated group (1.9%
vs. 2.9%; p 5 0.10). Symptoms of angina and hospital
readmission were decreased 50% by the invasive strategy.
These findings were supported by long-term follow-up from
the FRISC II study indicating that low-molecular-weight
heparin and early intervention lowered the risk of death,
MI, and revascularization in unstable coronary syndromes,
at least during the first 1 month of therapy. Early protective
therapy could be used to lower the risk of late events in
patients waiting for definitive PCI (248). This treatment
benefit was most pronounced for high-risk patients. The
FRISC II trial (247) results support the use of catheteriza-
tion and revascularization for selected patients with an acute
coronary syndrome. The Treat Angina with Aggrastat and
determine the Cost of Therapy with an Invasive or Con-
servative Strategy (TACTICS) Trial randomized 2,220
patients to an early invasive strategy in which cardiac
catheterization and revascularization were performed 4 to
48 h after randomization or to a conservative strategy in
which revascularization was reserved for those patients who
developed recurrent ischemia after medical stabilization. All
patients were treated with aspirin, heparin, beta-blockers,
cholesterol-lowering therapy, and tirofiban. The primary
end point, a composite of death, MI, and rehospitalization
for worsening chest pain by 6 months, was lower in patients
assigned to the invasive strategy (15.9% vs. 19.4% in
patients assigned to conservative therapy; p 5 0.0025). The
rate of death or MI was also significantly reduced at 6
months in the invasive strategy arm (7.3% vs. 9.5% in
patients assigned to conservative therapy; p , 0.05) (249).
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These promising results have not yet undergone peer review
and have not been published.
The indications for coronary angiography are summa-
rized in the ACC/AHA Coronary Angiography Guidelines
(194), and recommendations for PCI are summarized in the
ACC/AHA Unstable Angina Guidelines (250). Indications
for PCI for patients with angina Class II to IV, unstable
angina, or non–Q-wave infarction follow.
Recommendations for Patients with Moderate or
Severe Symptoms (Angina Class II to IV, Unstable
Angina or Non–ST-Elevation MI) With Single- or
Multivessel Coronary Disease on Medical Therapy
(Table 21)
Class I
1. Patients with 1 or more significant lesions in 1 or
more coronary arteries suitable for PCI with a high
likelihood of success and low risk of morbidity or
mortality (Tables 6 and 8). The vessel(s) to be
dilated must subtend a moderate or large area of
viable myocardium and have high risk (Table 20).
(Level of Evidence: B)
Class IIa
1. Patients with focal saphenous vein graft lesions or
multiple stenoses who are poor candidates for re-
operative surgery. (Level of Evidence: C)
Class IIb
1. Patient has 1 or more lesions to be dilated with
reduced likelihood of success (Table 6) or the
vessel(s) subtend a less than moderate area of viable
myocardium. Patients with 2- or 3-vessel disease,
with significant proximal LAD CAD and treated
diabetes or abnormal LV function. (Level of Evi-
dence: B)
Class III
1. Patient has no evidence of myocardial injury or
ischemia on objective testing and has not had a trial
of medical therapy, or has
a. Only a small area of myocardium at risk.
b. All lesions or the culprit lesion to be
dilated with morphology with a low like-
lihood of success.
c. A high risk of procedure-related morbidity
or mortality. (Level of Evidence: C)
2. Patients with insignificant coronary stenosis (e.g.,
<50% diameter). (Level of Evidence: C)
3. Patients with significant left main CAD who are
candidates for CABG. (Level of Evidence: B)
It is recognized by the Committee that the assessment of
risk of unsuccessful PCI or serious morbidity or mortality
must always be made with consideration of the alternative
therapies available for the patient, including more intensive
or prolonged medical therapy or surgical revascularization
(Table 22), especially in patients with unstable angina
pectoris.
When CABG surgery is a poor option because of high
risk due to special considerations or other organ system
disease, patients otherwise in Class IIb may be appropriately
managed with PCI. Under these special circumstances
formal surgical consultation is recommended.
Table 21. Recommendations for PCI in Moderate or Severe Symptomatic, Class II–IV Angina, Unstable Angina, or Non–ST-
Elevation MI Patients
Class I Class IIa Class IIb Class III
Patients with 1 or more significant
lesions in 1 or more coronary
arteries suitable for PCI with a
high likelihood of success and low
risk of morbidity or mortality
(Tables 6 and 8).
The vessel(s) to be dilated should
subtend a moderate or large area
of viable myocardium and have
high risk (Table 20).
(Level of Evidence: B)
Patients with focal saphenous vein
graft lesions or multiple
stenoses who are poor
candidates for reoperative
surgery.
(Level of Evidence: C)
Patient has 1 or more lesions
to be dilated with reduced
likelihood of success (Table
5) or the vessel(s) subtend a
less than moderate area of
viable myocardium.
Patients with 2- or 3-vessel
disease, with significant
proximal LAD CAD and
treated diabetes or abnormal
LV function.
(Level of Evidence: B)
Patient has no evidence of myocardial
injury or ischemia on objective
testing and has not had a trial of
medical therapy, or has:
a. Only a small area of myocardium
at risk.
b. All lesions or the culprit lesion to
be dilated with morphology with
a low likelihood of success.
c. A high-risk of procedure-related
morbidity or mortality.
(Level of Evidence: C)
Patients with insignificant coronary
stenosis (e.g., ,50% diameter).
(Level of Evidence: C)
Patients with significant left main
CAD who are candidates for
CABG.
(Level of Evidence: B)
CABG 5 coronary artery bypass graft; CAD 5 coronary artery disease; LAD 5 left anterior descending coronary artery; MI 5 myocardial infarction; PCI 5 percutaneous
coronary intervention.
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Table 22. Invasive vs. Conservative Strategies in Unstable Angina Patients
Study Year Reference N Patient Population Treatment Follow-Up
Results
CommentsPCI Medical Therapy Significance
TIMI-IIIB 1995 (245) 1,473 Patients 21–76 years
of age presenting
within 24 h of
ischemic
discomfort at rest
consistent with
unstable angina or
non-Q-wave MI.
Medical therapy (tPA
vs placebo) and
early invasive or
conservative
strategy
6 weeks 16.2% combined
primary endpoints
18.1% combined
primary endpoints
NS While no difference was found
in combined primary
endpoints (death, MI,
positive ETT), the early
invasive strategy was
associated with shorter
hospital stay and lower
incidence of
rehospitalization.
1 year 12.4% 10.6% NS
VANQWISH 1998 (246) 920 Patients with an
evolving MI
Invasive vs
conservative
Avg. 23
months
32.9% death and
MI
30.3% death and
MI
p 5 0.35 Fewer patients treated
conservatively had death
plus MI or death at hospital
discharge at 1 month and at
1 year. The invasive group
had a higher CABG
mortality rate (11.6% vs.
3.4%).
FRISC II 1999 (247) 2,457 Patient’s ischemic
symptoms in
previous 48 h
accompanied by
ECG changes or
elevated markers.
Early invasive therapy
or noninvasive
treatment strategy.
Patients also
received dalteparin
or placebo for 3
months.
6 months 9.4% death or MI 12.1% death or MI p 5 0.031 Invasive strategy was
associated with 50% lower
recurrent angina and
hospital readmission rates.
CABG 5 coronary artery bypass; ECG 5 electrocardiography; ETT 5 exercise treadmill test; MI 5 myocardial infarction; NS 5 no significance; PCI 5 percutaneous coronary intervention. For expansion of study names, see
corresponding references.
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C. Myocardial Infarction
The results of randomized clinical trials of intravenous
thrombolysis and subsequent management strategies of
immediate, delayed, and deferred PCI have established the
benefits of early pharmacologic and mechanical reperfusion
therapies for patients with acute MI (209,210,251–256).
Acute MI results from a severe and sudden cessation of
myocardial blood flow, most commonly due to
atherosclerotic-thrombotic occlusion of a major epicardial
coronary artery. Percutaneous coronary intervention is a very
effective method for re-establishing coronary perfusion and
is suitable for $90% of patients. Considerable data support
the use of PCI for patients with acute MI (257,258).
Reported rates of achieving TIMI 3 flow, the goal of
reperfusion therapy, range from 70 to 90% (259). Late
follow-up angiography demonstrates that 87% of infarct
arteries remain patent (260). Although most evaluations of
PCI have been in patients who are eligible to receive
thrombolytic therapy, considerable experience supports the
value of PCI for patients who may not be suitable for
thrombolytic therapy due to an increased risk of bleeding
(261).
Intracoronary stents appear to augment the results of PCI
for MI (Table 23). Preliminary results suggest that stenting
achieves a better immediate angiographic result with a larger
arterial lumen, less reclosure of the infarct-related artery,
and fewer subsequent ischemic events than PTCA alone
(262–264). Results from a randomized clinical trial suggest
that stenting enhances late clinical outcomes (reduction in
composite end point attributable to a decrease in target-
vessel revascularization) when compared to PTCA alone
(264). However, an increase in mortality at 1 year among
the stent group has been reported in the Stent-PAMI trial
(265).
Primary PTCA performed without routine stenting has
been compared to thrombolytic therapy in several random-
ized clinical trials. These investigations consistently dem-
onstrate that PTCA-treated patients experience less recur-
rent ischemia or infarction than those treated by
thrombolysis (266–269). Trends favoring a survival benefit
with PTCA are noted. The most recent and largest single
trial (1,138 patients) demonstrated significant benefit in the
composite end point death, recurrent MI, or disabling
stroke at 30 days favoring angioplasty, although this benefit
was not sustained at 6 months (260,270). Two meta-
analyses showed superiority of PCI over thrombolysis for
mortality with risk reductions of 0.34 and 0.56 (271,272). It
is important to note that these results of PCI have been
achieved in medical centers with experienced providers and
under circumstances where angioplasty can be performed
immediately following patient presentation (Fig. 3).
1. PCI in Thrombolytic-Ineligible Patients. Random-
ized, controlled clinical trials evaluating the outcome of PCI
for patients who present with ST-segment elevation but
who are ineligible for thrombolytic therapy and for patients Ta
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who experience infarction without ST-segment elevation
have not been performed. Nevertheless, there is a general
consensus that PCI is an appropriate means for achieving
reperfusion in patients who cannot receive thrombolytics
because of increased risk of hemorrhage. Other reasons also
exclude acute MI patients from thrombolytic therapy, and
the outcome of PCI in these patients may differ from those
eligible for lytic therapy. For example, patients who present
without ST-elevation are more often older and female and
have higher in-hospital mortality than those with ST-
segment elevation. Little data are available to characterize
the value of primary PCI for this subset of acute MI patients
(261) (Table 24).
2. Post-Thrombolysis PCI. In asymptomatic patients, the
strategies of routine PCI of the stenotic infarct-related
artery immediately after successful thrombolysis show no
benefit with regard to salvage of jeopardized myocardium or
prevention of reinfarction or death. In some studies this
approach was associated with increased incidence of adverse
events, which include bleeding, recurrent ischemia, emer-
gency coronary artery surgery, and death (279–282). Rou-
tine PCI immediately after thrombolysis may increase the
chance for vascular complications at the catheterization
access site and hemorrhage into the infarct-related vessel
wall (282).
Spontaneous recurrent ischemia and reinfarction have
been observed to occur in approximately 15 to 25% of
thrombolytic-treated patients (131,254,283). The majority
of spontaneous cardiac ischemic events occur within the first
24 to 48 h following treatment with thrombolytic therapy
and are associated with an increase in-hospital morbidity
and mortality (284–286). Patients at risk for recurrent
ischemia tend to be older and have more anterior infarcts.
Some thrombolytic-treated patients initially managed con-
servatively will require urgent cardiac catheterization and
revascularization because of recurrent MI (287,288).
To assess whether low-dose alteplase with standard dose
abciximab enhanced 90-min reperfusion after acute MI, the
strategies for patency enhancement in the emergency de-
partment (SPEED study group) examined the outcomes of
484 patients divided into five groups receiving combinations
of abciximab, with and without low-dose reteplase, reteplase
alone, and standard reteplase. The results of this trial
indicated that adding reteplase to abciximab treatment for
acute MI versus reteplase alone enhanced the incidence of
early complete reperfusion after initiation of therapy in the
emergency department (287). Similar data have been sup-
portive from the GUSTO-IV trial and GUSTO-I investi-
gators (288,289).
3. Rescue PCI. Rescue (also known as salvage) PCI is
defined as PCI after failed thrombolysis for patients with
continuing or recurrent myocardial ischemia. Rescue PCI
has resulted in higher rates of early infarct-artery patency,
improved regional infarct zone wall motion, and greater
freedom from adverse in-hospital clinical events compared
to a deferred PCI strategy (290). The randomized evalua-
tion of rescue PCI with combined utilization end points
trial (RESCUE) demonstrated a reduction in rates of
Figure 3. Mortality at the end of study in all the trials comparing primary percutaneous transluminal coronary angioplasty (PTCA) with thrombolytic drug
treatment. The rates for each study are grouped by thrombolytic drug regimen. The odds ratio with 95% confidence intervals (CIs) are plotted on the right.
Tests for homogenity: streptokinase trials, p 5 0.08; tissue-type plasminogen activator (t-PA) trials, p 5 0.33; accelerated t-PA trials, p 5 0.21;
thrombolytic regiment, p 5 0.96; and overall; p 5 0.24. Percentages are pooled results and odds ratios calculated by exact method using all trials. CI 5
confidence interval; PTCA 5 percutaneous transluminal coronary angioplasty. Reproduced with permission from Weaver WD, et al. JAMA
1997;278:2093–8 (272). Reference numbers within the figure correspond to the original article.
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in-hospital death and combined death and CHF main-
tained up to 1 year after study entry for patients presenting
with anterior wall MI who failed thrombolytic therapy
(291,292). Improvement in TIMI grade flow from #2 to 3
may offer additional clinical benefit.
4. PCI for Cardiogenic Shock. Observational studies
support the value of PCI for patients who develop cardio-
genic shock in the early hours of MI. For patients who do
not have mechanical causes of shock, such as acute mitral
regurgitation or septal or free wall rupture, mortality among
those having PCI is lower than those treated by medical
means (222). However, having catheterization alone, with
or without angioplasty, is associated with a low mortality
(222,293). Thus, the relatively favorable outcome of
angioplasty-treated patients may be, in part, due to a bias in
patient selection. Since the outcome of cardiogenic shock is
so unfavorable with contemporary medical therapy, angio-
plasty continues to be recommended as potential life-saving
therapy (222).
A randomized clinical trial has further clarified the role of
emergency revascularization in acute MI complicated by
cardiogenic shock (222). In this study, 302 patients with
acute MI and cardiogenic shock were randomly assigned to
emergency revascularization (ERV, n 5 152) by coronary
angioplasty or bypass surgery or to initial medical stabiliza-
tion (IMS, n 5 150). The 30-day mortality was significantly
lower (p # 0.01) for patients ,75 years old treated with
ERV (41.1% mortality) compared to IMS (56.8% mortali-
ty). By contrast, mortality among patients .75 years was
worse for those treated with ERV. The use of an IABP was
the same in both groups (86%). Among those receiving
ERV, 60% had PTCA and 40% received CABG with
30-day mortality rates of 45% and 42% respectively. For the
IMS group, 63% received thrombolytic agents and 25% had
delayed revascularization. This multicenter trial supports
the use of ERV with PCI in appropriate candidates for
patients ,75 years old with acute MI complicated by
cardiogenic shock (222). Hochman et al. (222) also dem-
onstrated that in patients with cardiogenic shock, emer-
gency revascularization did not significantly reduce overall
mortality at 30 days. However, after 6 months, there was
significant survival benefit to early revascularization. These
data strongly support the approach that patients ,75 years
with acute MI complicated by cardiogenic shock should
undergo emergency revascularization and support measures.
5. PCI Hours to Days After Thrombolysis. Patients who
achieve reperfusion and myocardial salvage following
thrombolytic therapy may experience reocclusion of the
infarct artery and recurrent MI. This concern has prompted
the routine use of catheterization and PCI prior to hospital
discharge to identify and dilate the culprit lesion. The value
of this approach was tested in two large, randomized clinical
trials. The SWIFT study (280) examined 800 patients with
acute MI randomly assigned to PCI within 2 to 7 days after
thrombolysis or to conservative management with interven-
tion for spontaneous or provocable ischemia. There were no
differences in the two treatment strategies regarding LV
function, incidence of reinfarction, in-hospital survival, or
1-year survival rate. Similarly in the TIMI-IIB trial (281),
3,262 patients randomized to angioplasty within 18 to 48 h
versus conservative management after acute infarct having
received t-PA were examined. The two groups had similar
mortality at 6 weeks (5.2% vs. 4.7%), incidence of nonfatal
reinfarction (6.4% vs. 5.8%), and LV ejection fraction (0.5%
vs. 0.5%). The 1- and 3-year survival rate, anginal class, and
frequency of bypass surgery were also similar between the
two groups (131,294). These data indicate that routine PCI
of the infarct-related artery in the absence of spontaneous or
provoked ischemia is not warranted.
A recent randomized trial comparing primary angioplasty
with a strategy of short-acting thrombolysis and immediate
planned rescue angioplasty in acute MI was performed by
the PACT (Plasminogen-activator Angioplasty Compati-
bility Trial) investigators by Ross et al. (295). This study
evaluated the safety and efficacy of reduced-dose fibrinolytic
therapy to promote early infarct patency coupled with PCI.
In 606 patients, 50 mg of rt-PA followed by immediate
angioplasty was performed to recanalize infarct-related ar-
teries. End points of time-to-artery patency and technical
results of angioplasty were reported. Patency in the cathe-
terization laboratory on arrival was 61% with rt-PA and
34% with placebo. Rescue and primary angioplasty restored
TIMI flow equally in both groups. There was no difference
in the incidence of stroke or bleeding. Left ventricular
Table 24. Contraindications and Cautions for Thrombolytic Use
in Myocardial Infarction*
Contraindications
c Previous hemorrhagic stroke at any time, other strokes or
cerebrovascular events within 1 year
c Known intracranial neoplasm
c Active internal bleeding (does not include menses)
c Suspected aortic dissection
Caution/relative contraindications
c Severe uncontrolled hypertension on presentation (blood pressure
.180/110 mm Hg)†
c History of prior cerebrovascular accident or known intracerebral
pathology not covered in contraindications
c Current use of anticoagulants in therapeutic doses (INR $2–3);
known bleeding diathesis
c Recent trauma (within 2–4 weeks) including head trauma or traumatic
or prolonged (.10 min) CPR or major surgery (3 weeks)
c Noncompressible vascular punctures
c Recent (within 2 to 4 weeks) internal bleeding
c For streptokinase/anistreplase; prior exposure (especially within 5 days–
2 years) or prior allergic reaction
c Pregnancy
c Active peptic ulcer
c History of chronic severe hypertension
*Viewed as advisory for clinical decision making and may not be all-inclusive or
definitive; †Could be an absolute contraindication in low-risk patients with myocar-
dial infarction.
Reproduced with permission from Ryan TJ, Antman EM, Brooks NH, et al.
ACC/AHA guidelines for the management of patients with acute myocardial
infarction: a report of the American College of Cardiology/American Heart Associ-
ation Task Force on Practice Guidelines (Committee on Management of Acute
Myocardial Infarction). J Am Coll Cardiol 1999;34:890–911 (193).
CPR 5 cardiopulmonary resuscitation; INR 5 International Normalized Ratio.
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function was highest in the patent infarct-related artery
group on arrival to the catheterization laboratory. In 88% of
angioplasty patients, the delay exceeded 1 h with a conva-
lescent ejection fraction of 57%. These findings indicated
that tailored thrombolytic regimes compatible with subse-
quent interventions lead to more frequent early recanaliza-
tion (i.e., before arrival in the catheterization laboratory)
which facilitates greater left ventricular preservation with no
augmentation of adverse events at follow-up.
Initial studies of late (.6 to 12 h) PCI in asymptomatic
survivors of MI, indicate that opening an occluded artery
does not appear to alter the process of LV dilation (296), the
incidence of spontaneous and inducible arrhythmias (297),
or prognosis (298). The TAMI-6 study (299) of angioplasty
of a persistently occluded infarct artery 7 to 48 h after
symptom onset demonstrated that the infarct-related artery
patency was similar in aggressive or conservatively treated
groups at 6-month follow-up. It was also noted at the end
of the same 6-month follow-up that there was a high
incidence of infarct-related artery patency in patients who
did not receive angioplasty as well as a high incidence of
reocclusion in those who did. LV ejection fraction, inci-
dence of reinfarction, hospital admission, and mortality
during follow-up were also similar between groups. In other
similar studies with small patient numbers, late angioplasty
of occluded infarct arteries improved LV performance, but
convincing outcome data are lacking to support late angio-
plasty in asymptomatic patients within 48 h of failed
thrombolysis (300).
The benefits of early reperfusion therapy, whether by
thrombolytic drugs or PCI, have been attributed to salvage
of severely ischemic myocardium, thereby limiting infarct
size and preserving LV function. However, there is increas-
ing evidence that achieving patency in the infarct-related
artery, even hours to days after the acute event, may
favorably influence the outcome by mechanisms other than
myocardial salvage (301–303). Late restoration of patency
appears to reduce infarct expansion (296) and ventricular
remodeling (304,305), and attenuate the risk for the devel-
opment of ventricular arrhythmias (297,306). These effects
could all contribute to improvements in survival indepen-
dent of the acute salvage of myocardium (298,307,308).
Although data supporting the argument to open occluded
infarct-related arteries are persuasive, at least for large
arteries subtending large areas of myocardium, there are few
randomized trials supporting this approach. It should be
noted that the overwhelming majority of trials were per-
formed prior to the widespread use of stents and platelet
IIb/IIIa receptor blockade and thus, the potential impact
and benefit of these newer therapies in this clinical setting
needs re-evaluation.
6. PCI After Thrombolysis in Selected Patient Sub-
groups. a. YOUNG AND ELDERLY POST-INFARCT PATIENTS.
Although not supported by randomized trials, routine
cardiac catheterization following thrombolytic therapy for
AMI has been a frequently performed strategy in all age
groups. Young (,50 years) patients often undergo cardiac
catheterization after thrombolytic therapy due to a “per-
ceived need” to define coronary anatomy and thus establish
psychological as well as clinical outcomes. In contrast, older
(.75 years) patients have higher in-hospital and long-term
mortality rates and enhanced clinical outcomes when treated
with primary PCI (309).
In a secondary analysis of the TIMI-IIB study comparing
angiographic findings and clinical outcomes among 841
young (,50 years) and 859 older (65 to 70 years) patients
randomly assigned to an invasive or conservative post-lytic
management strategy (310), the younger patients assigned
to the invasive strategy commonly had insignificant (i.e.,
,60% diameter stenosis) and single-vessel CAD. Severe
3-vessel or left main coronary disease findings were infre-
quent (3-vessel incidence, 4%; left main, 0%). Fatal and
nonfatal MI and death throughout the first year following
study entry was also infrequent. There were no differences in
the rates of in-hospital recurrent ischemia, reinfarction, or
death among patients assigned to the conservative strategy
of selective cardiac angiography and coronary revasculariza-
tion as compared to an invasive strategy, consisting of
routine post-lytic coronary angiography. Compared to
younger patients, older patients had a higher prevalence of
multivessel CAD (i.e., 44%) and high 42-day rates of
reinfarction and death.
In spite of these observations, there was no difference in
the 42-day rates of reinfarction or death among the older
patient subgroup, regardless of the post-lytic management
strategy. The TIMI-II data of younger and older infarct
patients are consistent with the overall results of other
randomized trials of thrombolysis/PTCA. Confirmatory
studies to determine quality-of-life aspects of care in
younger patients and to define the potential of other modes
of coronary revascularization in older patient groups are not
yet available. Based on the current data, with the exception
of patients presenting with cardiogenic shock, use of PCI
should be determined by clinical need without special
consideration of age.
b. PATIENTS WITH PRIOR MI. A prior MI is an independent
predictor of death, reinfarction, and need for urgent coro-
nary bypass surgery (311). In thrombolytic trials, 14 to 20%
of enrolled patients had a history of prior MI (254,281).
In the TIMI-II study, patients with a history of prior MI
had a higher 42-day mortality (8.8% vs. 4.3%; p , 0.001),
higher prevalence of multivessel CAD (60% vs. 28%; p ,
0.001), and a lower LV ejection fraction (42% vs. 48%; p ,
0.001) compared to patients with a first MI (312). Among
patients assigned to the conservative post-lytic strategy,
those with a prior MI had a significantly higher 42-day
mortality compared to patients with a first MI (11.5% vs.
3.5%; p , 0.001), whereas in the invasive strategy, the
mortality outcome was essentially the same in the two
patient groups. Mortality tended to be lower among patients
with a prior MI undergoing the invasive compared to the
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conservative strategy, a benefit which persisted up to 1 year
following study entry (294).
Based on the above findings and current practice, PCI
should be based on clinical need. The presence of prior MI
places the patient in a higher risk subset and should be
considered in the PCI decision.
Recommendations for Primary PCI for Acute
Transmural MI Patients as an Alternative to
Thrombolysis (Table 25)
Class I
1. As an alternative to thrombolytic therapy in pa-
tients with AMI and ST-segment elevation or new
or presumed new left bundle branch block who can
undergo angioplasty of the infarct artery <12 h
from the onset of ischemic symptoms or >12 h if
symptoms persist, if performed in a timely fashion*
by individuals skilled in the procedure† and sup-
ported by experienced personnel in an appropriate
laboratory environment.‡ (Level of Evidence: A)
2. In patients who are within 36 h of an acute ST
elevation/Q-wave or new left bundle branch block
MI who develop cardiogenic shock, are <75 years
of age, and revascularization can be performed
within 18 h of the onset of shock by individuals
skilled in the procedure† and supported by experi-
enced personnel in an appropriate laboratory envi-
ronment.‡ (Level of Evidence: A)
Class IIa
1. As a reperfusion strategy in candidates who have a
contraindication to thrombolytic therapy. (Level of
Evidence: C)
Class III
1. Elective PCI of a non–infarct-related artery at the
time of acute MI. (Level of Evidence: C)
2. In patients with acute MI who:
a. have received fibrinolytic therapy within
12 h and have no symptoms of myocardial
ischemia.
b. are eligible for thrombolytic therapy and
are undergoing primary angioplasty by an
inexperienced operator (individual who
performs <75 PCI procedures/year).
c. are beyond 12 h after onset of symptoms
and have no evidence of myocardial isch-
emia. (Level of Evidence: C)
Recommendations for PCI After Thrombolysis (Table
26)
Class I
1. Objective evidence for recurrent infarction or isch-
emia (rescue PCI) (194). (Level of Evidence: B)
Class IIa
1. Cardiogenic shock or hemodynamic instability.
(Level of Evidence: B)
Class IIb
1. Recurrent angina without objective evidence of
ischemia/infarction. (Level of Evidence: C)
2. Angioplasty of the infarct-related artery stenosis
within hours to days (48 h) following successful
*Performance standard: balloon inflation within 90 6 30 min of hospital admission;
†Individuals who perform $75 PCI procedures/year; ‡Centers that perform .200
PCI procedures/year and have cardiac surgical capability (193,194).
Table 25. Recommendations for Primary PCI in Acute Transmural MI Patients as an Alternative to Thrombolysis
Class I Class IIa Class III
As an alternative to thrombolytic therapy in patients
with AMI and ST-segment elevation or new or
presumed new left bundle branch block who can
undergo angioplasty of the infarct artery #12 h from
the onset of ischemic symptoms or .12 h if
symptoms persist, if performed in a timely fashion* by
individuals skilled in the procedure† and supported by
experienced personnel in an appropriate laboratory
environment.‡
(Level of Evidence: A)
In patients who are within 36 h of an acute ST
elevation/Q-wave or new left bundle branch block MI
who develop cardiogenic shock, are ,75 years of age
and revascularization can be performed within 18 h of
the onset of shock by individuals skilled in the
procedure† and supported by experienced personnel in
an appropriate laboratory experiment.‡
(Level of Evidence: A)
As a reperfusion strategy in
candidates who have a
contraindication to
thrombolytic therapy.
(Level of Evidence: C)
Elective PCI of a non–infarct-related artery at the
time of acute MI.
(Level of Evidence: C)
In patients with acute MI who:
c have received fibrinolytic therapy within 12 h
and have no symptoms of myocardial ischemia.
c are eligible for thrombolytic therapy and are
undergoing primary angioplasty by an
inexperienced operator.§
c care beyond 12 h after onset of symptoms and
have no evidence of myocardial ischemia.
(Level of Evidence: C)
*Performance standard: balloon inflation within 90 6 30 min of hospital admission; †Individuals who perform $75 PCI procedures per year; ‡Centers that perform .200 PCI
procedures per year and have cardiac surgical capability; §Individual who performs ,75 PCI procedures per year (193,194).
AMI 5 acute myocardial infarction; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention.
2239xxxiJACC Vol. 37, No. 8, 2001 Smith et al.
June 15, 2001:2239i–lxvi ACC/AHA Percutaneous Coronary Intervention Guidelines
thrombolytic therapy in asymptomatic patients
without clinical and/or inducible evidence of isch-
emia. (Level of Evidence: B)
Class III
1. Routine PCI within 48 h following failed throm-
bolysis. (Level of Evidence: B)
2. Routine PCI of the infarct-artery stenosis immedi-
ately after thrombolytic therapy. (Level of Evidence:
A)
Recommendations for PCI During Subsequent
Hospital Management After Acute Therapy for AMI
Including Primary PCI (Table 27)
Class I
1. Spontaneous or provocable myocardial ischemia
during recovery from infarction (194). (Level of
Evidence: C)
2. Persistent hemodynamic instability. (Level of Evi-
dence: C)
Class IIa
1. Patients with LV ejection fraction <0.4, CHF, or
serious ventricular arrhythmias. (Level of Evidence:
C)
Class IIb
1. Coronary angiography and angioplasty for an oc-
cluded infarct-related artery in an otherwise stable
patient to revascularize that artery (open artery
hypothesis). (Level of Evidence: C)
2. All patients after a non–Q-wave MI. (Level of
Evidence: C)
3. Clinical HF during the acute episode, but subse-
quent demonstration of preserved LV function (LV
ejection fraction >0.4). (Level of Evidence: C)
Class III
1. PCI of the infarct-related artery within 48 to 72 h
after thrombolytic therapy without evidence of
spontaneous or provocable ischemia. (Level of Ev-
idence: C)
D. Percutaneous Intervention in Patients With Prior
Coronary Bypass Surgery
Ischemic symptoms recur in 4 to 8% of patients/year
following CABG (313–316). Recurrence of symptoms can
be attributed to progression of native vessel coronary disease
(5%/year) and bypass conduit occlusion, particularly SVG
failure (7% in week 1; 15 to 20% in first year; 1 to 2%/year
during the first 5 to 6 years, and 3 to 5%/year in years 6 to
10 postoperatively) (313–315). At 10-years postoperatively,
Table 26. Recommendations for PCI After Thrombolysis
Class I Class IIa Class IIb Class III
Objective evidence for recurrent
infarction or ischemia (rescue
PCI) (194).
(Level of Evidence: B)
Cardiogenic shock or
hemodynamic instability.
(Level of Evidence: B)
Recurrent angina without objective
evidence of ischemia/infarction.
(Level of Evidence: C)
Routine PCI within 48 h
following failed thrombolysis.
(Level of Evidence: B)
Angioplasty of the infarct-related
artery stenosis within hours to
days (48 h) following successful
thrombolytic therapy in
asymptomatic patients without
clinical and/or inducible
evidence of ischemia.
(Level of Evidence: B)
Routine PCI of the infarct-artery
stenosis immediately after
thrombolytic therapy.
(Level of Evidence: A)
PCI 5 percutaneous coronary intervention.
Table 27. Recommendations for PCI During Subsequent Hospital Management After Acute Therapy for AMI Including Primary PCI
Class I Class IIa Class IIb Class III
Spontaneous or provocable myocardial
ischemia during recovery from
infarction (194).
(Level of Evidence: C)
Patients with LV ejection fraction
#0.4, congestive HF, or
serious ventricular arrhythmias.
(Level of Evidence: C)
Coronary angiography and angioplasty for
an occluded infarct-related artery in an
otherwise stable patient to revascularize
that artery (open artery hypothesis).
(Level of Evidence: C)
PCI of the infarct-related artery
within 48 to 72 h after
thrombolytic therapy without
evidence of spontaneous or
provocable ischemia.
(Level of Evidence: C)
Persistent hemodynamic instability.
(Level of Evidence: C)
All patients after a non–Q-wave MI
(Level of Evidence: C)
Clinical HF during the acute episode, but
subsequent demonstration of preserved
LV function (LV ejection fraction
.0.4).
(Level of Evidence: C)
AMI 5 acute myocardial infarction; HF 5 heart failure; LV 5 left ventricular; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention.
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approximately half of all SVG conduits are occluded and
only half of the remaining patent grafts are free of signifi-
cant disease (160,317–327). The requirement for repeat
revascularization procedures increases over time from the
initial revascularization, particularly in younger patients
(328). Although arterial conduits exhibit improved long-
term patency (157,329,330), stenosis or occlusion of these
grafts can occur. Thus, patients with recurrent ischemic
symptoms following CABG may require repeat revascular-
ization due to diverse anatomic problems.
Risk of repeat surgical revascularization is higher (hospi-
tal mortality 7 to 10%) than initial CABG (331–333) and
both long-term relief of angina and bypass graft patency are
lower than that of the first procedure (331,334,335). In
addition, patients with prior bypass surgery may have
limited graft conduits, impaired LV function, advanced age,
and coexisting medical conditions (cerebrovascular disease;
renal and pulmonary insufficiency) which may complicate
repeat surgical coronary revascularization and prompt con-
sideration for catheter-based intervention. Patients with
prior bypass surgery represent an increasing proportion of
patients being referred for percutaneous coronary revascu-
larization, and specific indications for therapy may be
influenced by both anatomic considerations and the timing
of recurrent ischemia postoperatively.
1. Early Ischemia After CABG. Recurrent ischemia early
(,30 days) postoperatively usually reflects graft failure,
often secondary to thrombosis (336–338), and may occur in
both saphenous vein and arterial graft conduits (339).
Incomplete revascularization and unbypassed native vessel
stenoses or stenoses distal to a bypass graft anastomosis may
also precipitate recurrent ischemia. Urgent coronary angiog-
raphy is indicated to define the anatomic cause of ischemia
and to determine the best course of therapy. Emergency
PCI of a focal graft stenosis (venous or arterial) or recana-
lization of an acute graft thrombosis may successfully relieve
ischemia in the majority of patients. Balloon dilation across
suture lines has been accomplished safely within days of
surgery (340–342). Intracoronary thrombolytic therapy
should be administered with caution during the first week
postoperatively (343–346) and if required, residual throm-
bus may be “targeted” in low doses through a local drug
delivery system. Conversely, mechanical thrombectomy
with newer catheter technologies may be effective without
the attendant risk of fibrinolysis (347). Adjunctive therapy
with abciximab for percutaneous intervention during the
first week following bypass surgery has been limited but
intuitively may pose less risk for hemorrhage than fibrino-
lysis. As flow in vein graft conduits is pressure dependent,
IABP support should be considered in the context of
systemic hypotension and/or severe LV dysfunction. If
feasible, PCI of both bypass graft and native vessel offending
stenoses should be attempted, particularly if intracoronary
stents can be successfully deployed.
When ischemia occurs 1 to 12 months following surgery,
the etiology is usually peri-anastomotic graft stenosis. Distal
anastomotic stenoses (both arterial and venous) respond
well to balloon dilation alone and have a more favorable
long-term prognosis than stenoses involving the mid-shaft
or proximal vein graft anastomosis (135,136,348–351).
Mid-shaft vein graft stenoses occurring during this time
frame are usually due to intimal hyperplasia. Restenosis may
be less frequent and event-free survival-enhanced following
angioplasty of SVGs dilated within 6 months of surgery
compared with grafts of older age. The immediate results of
PCI in mid-shaft ostial or distal anastomotic vein graft
stenoses may be enhanced by coronary stent deployment
(351,352). Ablative technologies such as directional
atherectomy or excimer laser coronary angioplasty may
facilitate angioplasty and stent deployment in patients with
aorto-ostial vein graft stenoses (353,354).
Stenoses in the mid-portion or origin of the internal
mammary artery graft are uncommon, but respond to
balloon dilation (355,356) with stent deployment as feasi-
ble. Long-term follow-up of patients after internal mam-
mary artery angioplasty has demonstrated sustained benefit
and relief of ischemia in the majority of patients (357,358).
Balloon angioplasty with or without stent deployment can
be successfully performed in patients with distal anasto-
motic stenoses involving the gastroepiploic artery bypass
graft and in patients with free radial artery bypass grafts as
well (359). Percutaneous intervention has also been effective
in relieving ischemia for patients with the stenosis of the
subclavian artery proximal to the origin of a patent left
internal mammary artery bypass graft (360,361).
2. Late Ischemia After CABG. Ischemia occurring more
than 1 year postoperatively usually reflects the development
of new stenoses in graft conduits and/or native vessels that
may be amenable to PCI (362). At 3 years or more
following SVG implantation, atherosclerotic plaque is fre-
quently evident and is often progressive. These lesions may
be friable and often have associated thrombus formation,
which may contribute to the occurrence of slow flow, distal
embolization, and periprocedural MI following attempted
percutaneous intervention (363). Slow flow occurs more
frequently in grafts having diffuse atherosclerotic involve-
ment, angiographically demonstrable thrombus, irregular or
ulcerative lesion surfaces, and with long lesions having large
plaque volume (364,365). Although a reduced incidence of
distal embolization has been reported following the use of
the extraction atherectomy catheter to recanalize stenoses in
older vein graft conduits (366–370), embolization may still
complicate adjunctive balloon dilation. Slow-flow with signs
and symptoms of myocardial ischemia may be ameliorated
by the intragraft administration of verapamil or diltiazem
(364,371). The adjunctive administration of abciximab dur-
ing vein graft intervention may reduce the incidence of
distal embolization and non–Q-wave MI (372), but contro-
versy remains regarding the benefit of prophylactic abcix-
imab therapy in patients with prior coronary bypass surgery
undergoing percutaneous intervention.
Although postprocedural minimum lumen diameter is
larger following directional coronary atherectomy
(140,373,374) or stent deployment (139,141,142,375–381)
2239xxxiiiJACC Vol. 37, No. 8, 2001 Smith et al.
June 15, 2001:2239i–lxvi ACC/AHA Percutaneous Coronary Intervention Guidelines
compared with balloon angioplasty of SVG stenoses, long-
term prognosis remains guarded, and late recurrent ischemic
events may be due to both restenosis of the target lesion and
diffuse vein graft disease (382–384). Final patency after
PTCA is greater for distal SVG lesions than for ostial or
mid-SVG lesions (349), and stenosis location appears to be
a better determinant of final patency than graft age or the
type of interventional device used.
Percutaneous intervention for chronic vein graft occlusion
has been problematic. Balloon angioplasty alone has been
associated with high complication rates and low rates of
sustained patency (385). Although prolonged intra-graft
infusion of fibrinolytic therapy was reported to successfully
recanalize 69% of a selected group of patients with chronic
SVG occlusion ,6 months duration, long-term patency
rates with or without adjunctive stent deployment were low
(386–388). In addition, prolonged fibrinolytic therapy has
been associated with thromboembolic MI (389–392), in-
tracranial (393) and intramyocardial hemorrhage (394), as
well as vascular access site complications. Favorable results
have been obtained with both local “targeted” and more
prolonged infusion of fibrinolytic agents for nonocclusive
intragraft thrombus (395,396). Thrombolytic catheter-
based systems appear to successfully treat SVG thrombosis
as well as or better than thrombolytic agents (397).
3. Early and Late Outcomes of Percutaneous Interven-
tion. Prior to the general availability of coronary stenting,
overall angioplasty procedural success rates exceeded 90%,
and adverse outcomes of emergency repeat coronary bypass
surgery (2.3%) and death (0.8%) were infrequent as reported
in combined series of over 2,000 patients with prior bypass
surgery undergoing percutaneous intervention (135,398–
410). These results are comparable to those achieved in
patients without prior bypass surgery, an observation con-
firmed by NHLBI registry data (6). The most common
complications observed in this population are NSTEMI and
atheroembolism, particularly following SVG intervention
(333,352).
Patients with prior bypass surgery who undergo successful
PCI have a long-term outcome that is dependent on patient
age, the degree of LV dysfunction, and the presence of
multivessel coronary atherosclerosis. The best long-term
results are observed after recanalization of distal anastomotic
stenoses occurring within 1 year of operation. Angioplasty
of distal anastomotic stenoses involving internal mammary
artery grafts have been associated with similar, favorable
long-term patency rates (357,358). Conversely, event-free
survival is less favorable following angioplasty of totally
occluded SVGs, ostial vein graft stenoses, or grafts with
diffuse or multicentric disease (382,383,385). Coexistent
multisystems disease, the presence of which may have
prompted the choice of a percutaneous revascularization
strategy, may also influence long-term outcomes in this
population.
4. Surgery Versus Percutaneous Reintervention. Aged,
diffuse, friable, and degenerative SVG disease in the absence
of a patent arterial conduit to the left anterior descending
artery represents a prime consideration for repeat surgical
revascularization. In contrast, the presence of a patent
arterial conduit to the left anterior descending artery may
militate for a percutaneous interventional approach (411).
The overall risk of repeat operation, especially the presence
of comorbidities such as concomitant cerebrovascular, renal,
or pulmonary disease and the potential for jeopardizing
patent, nondiseased bypass conduits must be carefully con-
sidered. Isolated, friable stenoses in vein grafts may be
approached with primary stenting or the combination of
extraction atherectomy and stenting in an attempt to reduce
the likelihood of distal embolization.
Another therapeutic option for patients with prior coro-
nary bypass surgery that has become available is grafting
using the internal mammary artery through a “minimally
invasive” surgical approach (158,412–416). This strategy,
which avoids both the risk of cardiopulmonary bypass
(stroke, coagulopathy) and repeat median sternotomy may
be particularly applicable to patients with chronic native
vessel left anterior descending coronary occlusion and friable
atherosclerotic disease involving a prior SVG to this vessel.
The role of combining a minimally invasive surgical ap-
proach with PCI requires further study (417,418).
In general, patients with multivessel disease, failure of
multiple SVGs, and moderately impaired LV function
derive the greatest benefit from the durability provided by
surgical revascularization with arterial conduits. Regardless
of repeat revascularization strategy, risk-factor modification
with cessation of smoking (419,420) and lipid lowering
therapy (421,422) should be implemented in patients with
prior CABG surgery. An aggressive lipid-lowering strategy
that targets a low-density lipoprotein level of ,90 mg/dl
can be effective in reducing recurrent ischemic events and
the need for subsequent revascularization procedures (422).
Recommendations for PCI With Prior CABG (Table
28)
Class I
1. Patients with early ischemia (usually within 30
days) after CABG (194). (Level of Evidence: B)
Class IIa
1. Patients with ischemia occurring 1 to 3 years post-
operatively and preserved LV function with discrete
lesions in graft conduits. (Level of Evidence: B)
2. Disabling angina secondary to new disease in a
native coronary circulation. (If angina is not typical,
the objective evidence of ischemia should be ob-
tained.) (Level of Evidence: B)
3. Patients with diseased vein grafts >3 years follow-
ing CABG. (Level of Evidence: B)
Class III
1. PCI to chronic total vein graft occlusions. (Level of
Evidence: B)
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2. Patients with multivessel disease, failure or multi-
ple SVGs, and impaired LV function. (Level of
Evidence: B)
E. Use of Adjunctive Technology (Intracoronary
Ultrasound Imaging, Flow Velocity, and Pressure)
The limitations of coronary angiography for diagnostic
and interventional procedures can be reduced by employing
adjunctive technology of intracoronary ultrasound imaging,
flow velocity, and pressure. Information obtained from the
adjunctive modalities of intravascular imaging and physiol-
ogy can improve PCI methods and outcomes.
1. IVUS. IVUS imaging provides a tomographic 360°
sagittal scan of the vessel from the lumen through the media
to the vessel wall. Intravascular ultrasound measurements of
arterial dimensions (minimal and maximal diameters, cross-
sectional area, and plaque area) complement and enhance
angiographic information. Intravascular ultrasound has been
used to refine device selection through plaque characteriza-
tion (e.g., calcified) and artery sizing. Intravascular ultra-
sound has contributed to the understanding of mechanisms
of coronary angioplasty and specifically, to the advancement
of coronary stenting without long-term anticoagulation
(423–428). In a large observational study, IVUS-guided
angioplasty resulted in a decreased final residual plaque area
from 51 to 34%, despite a final angiographic percent
stenosis of 0% (423). Intravascular ultrasound-facilitated
stent deployment was associated with a subacute thrombosis
rate of 0.3% without systemic anticoagulation, although
antiplatelet agents are still required for stenting (423). In the
placement of coronary stents, because radiographic contrast
material can be located between stent struts and the vascular
wall, an angiographic appearance of a large lumen may exist
when the stent has not been fully deployed. Intravascular
ultrasound documents full apposition of stent struts to the
vessel wall (423).
IVUS is not necessary for all stent procedures. The results
of the French Stent Registry study of 2,900 patients treated
without coumadin and without IVUS reported a subacute
closure rate of 1.8% (429). In the STARS trial (30), a
subacute closure rate of 0.6% in patients having optimal
stent implantation supports the approach that IVUS does
not appear to be required routinely in all stent implan-
tations. However, the use of IVUS for evaluating results
in high-risk procedures (i.e., those patients with multiple
stents, impaired TIMI grade flow or coronary flow
reserve, and marginal angiographic appearance) appears
warranted.
The long-term outcomes when adjunctive IVUS is used
are currently under study. In a trial of 161 patients (MUSIC
Trial) (430) evaluating optimal stent expansion (defined as
complete apposition of the stent over its length) with sym-
metrical expansion (defined as a luminal diameterminimum to
luminal diametermaximum .0.7) and minimal luminal area
(compared to .80% of the reference area), the subacute
closure rate was 1.3% with monotherapy of aspirin. The
angiographic restenosis was ,10% when stent cross-
sectional areas were .9.0 mm2.
Fitzgerald et al. report that the degree of stent expansion
as measured by IVUS directly correlates to the clinical
outcomes in the CRUISE study (431). This multicenter
study compared 270 patients with IVUS-guided stent im-
plantation to IVUS-documented, but not guided, stent
implantation in 229 patients. At 9-month follow-up, there
was no difference in death or MI rate, but the target lesion
revascularization rate was substantially lower in the IVUS-
guided group (8.5% vs. 15.3%; p 5 0.019). These data
suggest that ultrasound guidance of stent implantation may
result in more effective stent expansion compared with
angiographic guidance alone and subsequently reduced the
need for late target lesion revascularization.
In the context of published data and growing clinical
experience, the Writing Committee has modified prior
recommendations for the use of IVUS as follows.
Recommendations for Coronary Intravascular
Ultrasound (Table 29)
Class IIa
1. Assessment of the adequacy of deployment of cor-
onary stents, including the extent of stent apposi-
Table 28. Recommendations for PCI With Prior CABG
Class I Class IIa Class III
Patients with early ischemia (usually
within 30 days) after CABG
(194).
(Level of Evidence: B)
Patients with ischemia occurring 1 to 3 years postoperatively
and preserved LV function with discrete lesions in graft
conduits.
(Level of Evidence: B)
Disabling angina secondary to new disease in a native
coronary circulation. (If angina is not typical, then
objective evidence of ischemia should be obtained.)
(Level of Evidence: B)
Patients with diseased vein grafts .3 years following
CABG.
(Level of Evidence: B)
PCI to chronic total vein graft
occlusions.
(Level of Evidence: B)
Patients with multivessel disease, failure
of multiple SVGs, and impaired LV
function.
(Level of Evidence: B)
CABG 5 coronary artery bypass graft; LV 5 left ventricular; PCI 5 percutaneous coronary intervention; SVG 5 saphenous vein graft.
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tion and determination of the minimum luminal
diameter within the stent. (Level of Evidence: B)
2. Determination of the mechanism of stent restenosis
(inadequate expansion vs. neointimal proliferation)
and to enable selection of appropriate therapy
(plaque ablation vs. repeat balloon expansion).
(Level of Evidence: B)
3. Evaluation of coronary obstruction at a location
difficult to image by angiography in a patient with a
suspected flow-limiting stenosis. (Level of Evidence:
C)
4. Assessment of a suboptimal angiographic result
following PCI. (Level of Evidence: C)
5. Diagnosis and management of coronary disease
following cardiac transplantation. (Level of Evi-
dence: C)
6. Establish presence and distribution of coronary
calcium in patients for whom adjunctive rotational
atherectomy is contemplated. (Level of Evidence: C)
7. Determination of plaque location and circumferen-
tial distribution for guidance of directional coro-
nary atherectomy. (Level of Evidence: B)
Class IIb
1. Determine extent of atherosclerosis in patients with
characteristic anginal symptoms and a positive
functional study with no focal stenoses or mild
CAD on angiography. (Level of Evidence: C)
2. Preinterventional assessment of lesional character-
istics and vessel dimensions as a means to select an
optimal revascularization device. (Level of Evidence:
C)
Class III
1. When angiographic diagnosis is clear and no inter-
ventional treatment is planned. (Level of Evidence:
C)
2. Coronary Flow Velocity and Coronary Vasodilatory
Reserve. Coronary physiologic information has assumed
increasing importance in determining which coronary le-
sions may merit intervention and achieve an end point of
balloon angioplasty in consideration of provisional stenting.
Coronary flow velocity reserve (CVR), the ratio of hyper-
emic to basal flow, reflects flow resistance through the
epicardial artery and the corresponding myocardial bed.
Table 29. Recommendations for Coronary Intravascular Ultrasound (IVUS)
Class IIa Class IIb Class III
Assessment of the adequacy of deployment of coronary
stents, including the extent of stent apposition and
determination of the minimum luminal diameter
within the stent.
(Level of Evidence: B)
Determine extent of atherosclerosis in patients
with characteristic anginal symptoms and a
positive functional study with no focal
stenoses or mild CAD on angiography.
(Level of Evidence: C)
Preinterventional assessment of lesional
characteristics and vessel dimensions as a
means to select an optimal revascularization
device.
(Level of Evidence: C)
When angiographic diagnosis is
clear and no interventional
treatment is planned.
(Level of Evidence: C)
Determination of the mechanism of stent restenosis
(inadequate expansion vs. neointimal proliferation)
and to enable selection of appropriate therapy
(plaque ablation vs. repeat balloon expansion).
(Level of Evidence: B)
Evaluation of coronary obstruction at a location
difficult to image by angiography in a patient with a
suspected flow-limiting stenosis.
(Level of Evidence: C)
Assessment of a suboptimal angiographic result
following PCI.
(Level of Evidence: C)
Diagnosis and management of coronary disease
following cardiac transplantation.
(Level of Evidence: C)
Establish presence and distribution of coronary calcium
in patients for whom adjunctive rotational
atherectomy is contemplated.
(Level of Evidence: C)
Determination of plaque location and circumferential
distribution for guidance of coronary directional
atherectomy.
(Level of Evidence: B)
CAD 5 coronary artery disease; PCI 5 percutaneous coronary intervention.
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CVR ,2.0 is reproducibly and positively correlated to
abnormal stress perfusion imaging (432–434). In some
cases, the uncertainty as to whether the impaired flow
reserve is due to the target stenosis or to abnormal micro-
circulation may be reduced using a relative coronary flow
velocity reserve (rCVR; CVRtarget/CVRreference). From pre-
liminary studies, rCVR values .0.8 are similar in prognos-
tic value to negative stress testing (435). Recent confirma-
tion of the more lesion-specific nature of physiologic indices
resides in the correlation between rCVR and pressure-
derived fractional flow reserve (FFR) of the myocardium by
guidewire pressure measurements (vide infra) (435,436).
For lesion assessment, a normal CVR indicates a non-
physiologically significant stenosis. An abnormal CVR in-
dicates that the stenosis in the epicardial artery is significant
when the microcirculation is normal, confirmed by measur-
ing rCVR. Several studies report that deferring PCI of
non–flow-limiting lesions is safe, with ,10% rate of lesion
progression (437–439).
3. Coronary Artery Pressure and Fractional Flow Re-
serve. Historically, translesional pressure gradients were
used as end points for early interventional cardiology pro-
cedures. The use of a translesional pressure gradient mea-
sured at rest was abandoned because of weak correlations to
stress testing and difficult technique. Pijls et al. (440)
introduced the concept of the fractional flow reserve (FFR)
of the myocardium, the ratio of distal coronary pressure to
aortic pressure measured during maximal hyperemia, which
represents the fraction of normal blood flow through the
stenotic artery (436,441). The coronary pressure measuring
technique is relatively simple, especially using pressure
guidewires, a method superior to small catheters. The
normal FFR value for all vessels under all hemodynamic
conditions, regardless of the status of microcirculation is
1.0. FFR values ,0.75 are associated with abnormal stress
tests (438). Unlike CVR, the FFR is relatively independent
of hemodynamics and microcirculatory disturbances. FFR
does not use measurements in a reference vessel and is
thought to be epicardial lesion-specific. FFR provides no
information on the microcirculation nor on the absolute
magnitude of the change in coronary flow.
Reports indicate that a physiologic assessment can deter-
mine whether balloon angioplasty alone has achieved a
satisfactory result with 6-month outcome equivalent to that
reported with elective stenting. The DEBATE trial (442) in
224 patients found that when a final diameter stenosis
,35% and an excellent physiologic result (CVR .2.5) were
obtained after balloon angioplasty (44/224 patients), the
intermediate-term (6 months) target lesion revascularization
and angiographic restenosis rates were 16%. Similar data
have been reported for FFR (439). The application of
coronary physiologic adjunctive modalities can facilitate
decision-making for moderate lesions, the appropriateness
of balloon angioplasty, and the use of provisional stenting.
Recommendations for Intracoronary Physiologic
Measurements (Doppler Ultrasound, FFR) (Table 30)
Class IIa
1. Assessment of the physiological effects of interme-
diate coronary stenoses (30 to 70% luminal narrow-
ing) in patients with anginal symptoms. Coronary
pressure or Doppler velocimetry may also be useful
as an alternative to performing noninvasive func-
tional testing (e.g., when the functional study is
absent or ambiguous) to determine whether an
intervention is warranted. (Level of Evidence: B)
Class IIb
1. Evaluation of the success of percutaneous coronary
revascularization in restoring flow reserve and to
predict the risk of restenosis. (Level of Evidence: C)
2. Evaluation of patients with anginal symptoms with-
out an apparent angiographic culprit lesion. (Level
of Evidence: C)
Class III
1. Routine assessment of the severity of angiographic
disease in patients with a positive, unequivocal
noninvasive functional study. (Level of Evidence: C)
Table 30. Recommendations for Intracoronary Physiologic Measurements (Doppler Ultrasound, Fractional Flow Reserve)
Class IIa Class IIb Class III
Assessment of the physiological effects of
intermediate coronary stenoses (30 to
70% luminal narrowing) in patients
with anginal symptoms. Coronary
pressure or Doppler velocimetry may
also be useful as an alternative to
performing noninvasive functional
testing (e.g., when the functional study
is absent or ambiguous) to determine
whether an intervention is warranted.
(Level of Evidence: B)
Evaluation of the success of percutaneous
coronary revascularization in restoring
flow reserve and to predict the risk of
restenosis.
(Level of Evidence: C)
Evaluation of patients with anginal
symptoms without an apparent
angiographic culprit lesion.
(Level of Evidence: C)
Routine assessment of the severity of
angiographic disease in patients
with a positive, unequivocal
noninvasive functional study.
(Level of Evidence: C)
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VI. MANAGEMENT OF PATIENTS UNDERGOING PCI
A. Experience With New Technologies
The introduction of coronary stents and atherectomy
devices has broadened the scope of patients that can be
approached by PCI beyond those that could be safely
treated by PTCA alone. Directional coronary atherectomy
successfully treats eccentric, ostial and proximal left anterior
descending lesions or bifurcation lesions (443). Rotational
atherectomy successfully treats calcific and diffusely diseased
coronary vessels (444) and ostial stenoses (445,446). Exci-
mer laser can be used successfully to treat diffuse diseases
and fibrotic coronary stenoses (447). All atherectomy de-
vices successfully remove or “debulk” plaque, allowing for
improved acute angiographic results when followed by
balloon angioplasty or stenting (448). Whether debulking
before stenting reduces restenosis is currently under inves-
tigation.
Stenting has been successful in the initial treatment of
SVGs previously not suitable for balloon angioplasty (139).
For total occlusions, excimer laser has not been shown to be
significantly better than balloon angioplasty in terms of
acute success or late outcomes (449).
1. Acute Results. Historically, one of the important limi-
tations of balloon angioplasty has been its high rate of
abrupt closure (4 to 7%) and less than optimal acute
angiographic result (30% residual diameter stenosis with
frequent evidence of dissections). Significant reduction in
the acute complication rate for PTCA has resulted from the
adjunctive use of glycoprotein receptor IIb/IIIa blockers,
which have been shown to reduce abrupt closure and
periprocedural MI rates compared to placebo. Improved
acute outcomes (in terms of abrupt closure rates and reduced
target lesion residual diameter stenosis) have also been seen
with the use of coronary stents, DCA, and adjunctive
rotational atherectomy (31,32,34,450).
2. Late-Term Results. PCI devices offer the possibility of
lower restenosis compared to PTCA in the native coronary
circulation. Lower restenosis rates have been demonstrated
for balloon-expandable slotted tubular stents in large
($3 mm) native coronary arteries (31,32) but are variable
depending on lesion length for SVG lesions (139). Initial
trials of DCA showed no benefit compared to balloon
angioplasty for elective single lesion treatment (58,59).
However, a trial using DCA in a more aggressive fashion to
produce larger acute coronary lumens was associated with a
lower angiographic restenosis rate, but did not show any
significant improvement in clinical outcomes (34).
Despite the improvement in acute results seen for rota-
tional atherectomy and excimer laser, there is no evidence
that these devices improve the late outcomes in lesions than
can be feasibly treated by balloon angioplasty or stenting
alone (450–452).
B. Antiplatelet and Antithrombotic Therapies and
Coronary Angioplasty (Table 31)
1. Aspirin, Ticlopidine, Clopidogrel. Aspirin reduces the
frequency of ischemic complications after coronary angio-
plasty. Although the minimum effective aspirin dosage in
the setting of coronary angioplasty has not been established,
an empiric dose of aspirin, 80 to 325 mg, given at least 2 h
before the PCI procedure is generally recommended (453).
While other antiplatelet agents have similar antiplatelet
effects to aspirin (454), only the thienopyridine derivatives
(455) ticlopidine and clopidogrel have been routinely used
as alternative antiplatelet agents in aspirin-sensitive patients
during coronary angioplasty. In elective settings, ideally
ticlopidine and clopidogrel should be given for at least 72 h
prior to the procedure in order to achieve maximum platelet
inhibition (456,457).
Prior to the advent of potent combination antiplatelet
therapy in recent years, enthusiasm for stenting during acute
MI or unstable angina use was tempered by the sudden, and
Table 31. Recommendations for Pharmacologic Management of Patients Undergoing PCI
Clinical Status
Drugs
Class I
Angina
Class II–IV,
Angina Unstable,
Angina NSTEMI
Transmural MI
Acute
Phase MI
After
Thrombolysis
Hospital
Management Phase
Aspirin I* I I I I
Ticlopidine, clopidogrel† I‡ I I I I§
Warfarin\ III \ III III II I¶
GP blockers# II I II I III
c Abciximab
c Tirofiban
c Eptifibatide
UF heparin** I I I II III††
*Roman numerals indicate ACC/AHA class indication I, II, III; †in conjunction with stenting; ‡to be given 24 to 48 h before
planned stenting, if possible; §2 to 4 weeks post-stent placement; \patients without atrial fibrillation or other pre-existing clinical
indications; ¶patients with anterior myocardial wall motion abnormalities or LV thrombus; #every indication may not apply to
all individual agents; **low molecular weight heparin (LMWH) under investigation to replace unfractionated (UF) heparin;
††other noncoronary thrombotic complications (e.g., thrombophlebitis).
ACC/AHA 5 American College of Cardiology/American Heart Association; LV 5 left ventricular; MI 5 myocardial
infarction; NSTEMI 5 non–ST-segment elevation myocardial infarction; PCI 5 percutaneous coronary intervention.
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often unpredictable, occurrence of subacute stent thrombo-
sis, which developed in 3.5 to 8.6% of stent-treated patients
(25,31,32,458). Anatomic factors (e.g., underdilation of the
stent, proximal and distal dissections, poor inflow or outflow
obstruction, ,3 mm vessel diameter) were felt to predispose
to the occurrence of subacute stent thrombosis in some
patients (423,459,460).
Several randomized trials have evaluated the efficacy of
combination antiplatelet therapy in patients undergoing
urgent and elective stent implantation. In the ISAR trial of
517 patients treated with Palmaz-Schatz (PS) stents for
acute MI, suboptimal angioplasty, or other “high-risk”
clinical and anatomic features, patients were randomly
assigned to treatment with aspirin 1 ticlopidine or aspirin,
intravenous heparin, and phenprocoumon after successful
stent placement (461). The primary end point of cardiac
death, MI, coronary bypass surgery, or repeat angioplasty
occurred in 1.5% of patients assigned to antiplatelet therapy
and 6.2% of those assigned to anticoagulant therapy (rela-
tive risk, 0.25; 95% confidence interval, 0.06 to 0.77) (461).
In another randomized trial of antiplatelet (aspirin 1
ticlopidine) versus anticoagulant (aspirin 1 warfarin) ther-
apy in high-risk patients (suboptimal or multiple stent
deployment), antiplatelet therapy was again associated with
a reduction in the composite occurrence of death, MI, and
urgent repeat revascularization (5.6% vs. 11%; p 5 0.07) and
in major bleeding or vascular complications (1.7% vs. 6.9%)
compared with anticoagulation therapy respectively (462).
In the STARS trial (30), the efficacy of aspirin (325 mg
daily), the combination of aspirin (325 mg daily) 1 ticlo-
pidine (500 mg daily for 1 month), and aspirin (325 mg
daily) 1 warfarin on ischemic end points at 30 days in 1,653
“low-risk” patients after “optimal” PS stent placement dem-
onstrated more adverse events in patients not receiving
ticlopidine as part of the therapeutic regimen. The primary
30-day composite end point of death, target lesion revascu-
larization, subacute thrombosis, or MI was 3.6% in patients
only assigned to aspirin, 2.7% assigned to aspirin 1 warfa-
rin, compared to 0.5% in those assigned to aspirin 1
ticlopidine (aspirin 1 ticlopidine vs. aspirin alone; p ,
0.001; aspirin 1 ticlopidine vs. aspirin 1 warfarin; p 5
0.014) (30). Pretreatment with ticlopidine for more than
24 h may allow more effective inhibition of platelet activa-
tion than shorter durations of therapy (456,463).
Ticlopidine has a number of important side effects,
including gastrointestinal distress (20%) (464), cutaneous
rashes (4.8 to 15%) (464), and abnormal liver function tests
(464). The most severe side effect is severe neutropenia,
occurring in approximately 1% of patients (464,465).
Ticlopidine-induced neutropenia is generally reversible after
its discontinuation (466), although infrequent episodes of
sepsis and death have been reported. Rare (,1:1,000), but
fatal, episodes of thrombotic thrombocytopenic purpura
have also been reported (467–469), and patients receiving
ticlopidine should be monitored for the occurrence of this
untoward sequelae. Shorter durations (10 to 14 days) of
ticlopidine therapy may reduce untoward side effects of
therapy while maintaining therapeutic efficacy (470,471).
Clopidogrel, 300 mg loading dose followed by 75 mg
daily, may be used as an alternative to ticlopidine in patients
undergoing stent placement. A number of nonrandomized
trials (472–474) and a randomized trial (475) have failed to
show a difference in the clinical outcomes among patients
treated with ticlopidine and clopidogrel after stent place-
ment. A small number of cases of thrombocytopenia pur-
pura have been reported in patients treated with clopidogrel;
therefore, patients should be monitored during treatment
for occurrence of this untoward effect (469).
The routine use of warfarin is no longer recommended
after stent implantation, unless there are other indications
for its use, such as a poor LV function, atrial fibrillation, or
mechanical heart valves.
2. Glycoprotein IIb/IIIa Inhibitors. Aspirin is only a
partial inhibitor of platelet aggregation (476,477), as it
affects only cycloxygenase, thereby preventing the formation
of thromboxane A2. Functionally active glycoprotein (GP
IIb/IIIa) receptors aggregate platelets through fibrin bound
at the receptor sites. These receptors are activated by a
variety of agonists, including thromboxane A2, serotonin,
ADP, and collagen, among others. The binding of fibrin-
ogen and other adhesive proteins to adjacent platelets by
means of the GP IIb/IIIa receptor serves as the “final
common pathway” of platelet-thrombus formation and can
be effectively attenuated by GP IIb/IIIa antagonists. These
agents have reduced the frequency of ischemic complica-
tions after coronary angioplasty.
a. ABCIXIMAB. The clinical safety and efficacy of abciximab
was evaluated in the Evaluation of 7E3 for the Prevention of
Ischemic Complications (EPIC) Trial, which included
2,099 patients with acute MI, refractory unstable angina, or
“high-risk” clinical or anatomic features (478). Patients were
randomly assigned to treatment with aspirin and fixed-dose
heparin alone, aspirin, fixed-dose heparin, and a bolus of
abciximab (0.25 mg/kg), or aspirin, fixed dose heparin, and
a bolus of abciximab (0.25 mg/kg) 1 a 12-h abciximab
infusion (10 mg/min). A 35% reduction in the frequency of
the primary composite end point of death, nonfatal MI,
repeat revascularization, and procedural failure resulting in
stent or IABPplacement was found in the patients given
both the bolus 1 infusion abciximab compared with
placebo-treated patients; (8.3% vs. 12.8%, p 5 0.008) (478).
The bolus of abciximab alone did not produce a significant
reduction in ischemic events. The major effect of abciximab
was a reduction in nonfatal MI (5.2% vs. 8.6% in placebo-
treated patients; p 5 0.013) and in the need for repeat
coronary angioplasty (0.8% vs. 4.5% in placebo-treated
patients; p , 0.001); these benefits were maintained for at
least 3 years following the procedure (479). It should be
noted that the reduction in ischemic complications in EPIC
was offset by a doubling of the bleeding complication rate
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associated with non–weight-adjusted heparin use (14% vs.
7% in placebo-treated patients; p 5 0.001), likely due to the
fixed-dose heparin regimen used for the procedure.
The value of abciximab in patients undergoing primary
angioplasty for acute MI was prospectively evaluated in a
trial of 483 patients who were randomly assigned to therapy
with abciximab or placebo (480). The 30-day composite end
point of death, reinfarction, or urgent revascularization was
reduced in patients treated with abciximab (5.8% vs. 11.2%
in placebo-treated patients; p 5 0.03), mostly due to a
reduction in the need for urgent revascularization in patients
treated with abciximab (1.8% vs. 5.6% in placebo-treated
patients; p 5 0.03) (480). There was also a reduction in the
need for a “bailout” stent with abciximab (11.9% vs. 20.4%
in placebo-treated patients; p 5 0.031) (480).
The strategy of low-dose heparin and early sheath re-
moval in conjunction with abciximab therapy in relatively
“low-risk” patients undergoing coronary angioplasty was
evaluated in the EPILOG Trial (27). In this study, 2,792
patients were randomly assigned to therapy with aspirin plus
standard-dose weight-adjusted heparin and abciximab, or
aspirin plus low-dose weight-adjusted heparin and abcix-
imab, or aspirin plus standard-dose weight-adjusted heparin
alone (27). The 30-day major event rate was 11.7% in the
placebo with standard-dose heparin group; 5.2% in the
abciximab with low-dose heparin group (hazard ratio, 0.43;
p , 0.001); and 5.4% in the abciximab with standard-dose
heparin group (hazard ratio, 0.45; p , 0.001) (27). The
need for unplanned coronary stent use was also reduced in
patients treated with abciximab (480,481). In EPILOG,
there were no differences in major bleeding rates among the
three groups although minor bleeding was more frequent
among patients receiving abciximab with standard-dose
heparin (27).
To assess the role of GP IIb/IIIa blockade in the setting
of elective stenting, the Evaluation of Platelet IIb/IIIa
Inhibition in STENTing (EPISTENT) trial evaluated the
effect of abciximab therapy among patients undergoing
stenting or balloon angioplasty relative to the strategy of
stenting alone. A total of 2,399 patients were randomized to
stenting plus placebo, balloon angioplasty plus abciximab, or
the combination of stenting and abciximab. Stenting was
performed using contemporary high-pressure implantation
techniques, with ticlopidine administered for 4 weeks after
the procedure. The primary end point of death, MI, or
urgent repeat revascularization at 30 days was 10.8% in the
stented plus placebo group, 6.9% in the angioplasty plus
abciximab group (p 5 0.007), and 5.1% in the stent plus
abciximab group (p , 0.001) (28). By 6 months, rates of
repeat target-vessel revascularization were 10.6% in the
stent plus placebo, 8.7% in the stent plus abciximab group
(p 5 0.22), and 15.4% in the angioplasty plus abciximab
group (p 5 0.005) (89). In the predefined subgroup of
patients with diabetes mellitus undergoing stenting, treat-
ment with abciximab diminished rates of repeat target-
vessel revascularization by 51% compared with placebo
(8.1% vs. 16.6%, p 5 0.021). Angiographic results among
diabetics enrolled in an angiographic substudy were concor-
dant with the clinical outcome: minimal luminal diameters
(MLDs) and net gain at 6-months follow-up were im-
proved by abciximab with stenting compared with stenting
alone. EPISTENT 1-year follow-up demonstrated a sur-
vival advantage in favor of abciximab in stented patients.
Mortality at 1 year was 2.4% in stent and placebo patients
and 1.0% in stent and abciximab patients (p 5 0.037) (482).
Heeschen et al. (483), for the CAPTURE investigators,
demonstrated that troponin-T but not C-reactive protein,
was predictive of cardiac risk during the initial 72-h period
when treating unstable angina patients with standard ther-
apy or with abciximab. C-reactive protein was an indepen-
dent predictor of both cardiac risk and repeated coronary
revascularization during the 6-month follow-up. In a similar
study, Hamm et al. (484), for the CAPTURE investigators,
also reported that among the 1,265 patients with unstable
angina enrolled in the CAPTURE trial, troponin-T and
CK-MB from 890 patients correlated with subsequent
6-month adverse cardiac risk. In patients without elevated
troponin-T levels, there was no benefit of treatment with
respect to the relative risk of death or MI at 6 months (odds
ratio 1.26, CI 95%, 0.74 to 2.31; p 5 0.47). This study
indicated that serum troponin-T level, which is considered
to be a surrogate marker for thrombus formation, identified
a high-risk subgroup of patients with refractory unstable
angina suitable for coronary intervention who would partic-
ularly benefit from antiplatelet treatment with abciximab.
Patients requiring unplanned or “bailout” coronary stent
deployment appear to be at especially high risk for the
development of ischemic events early following stent de-
ployment. In patients who required unplanned stent deploy-
ment in the EPILOG trial, the prophylactic administration
of abciximab was associated with a reduction in the com-
posite end point of death, MI, or urgent revascularization at
30 days (p , 0.001) and 6 months (p , 0.001) (481). A
subsequent analysis of 529 patients having unplanned cor-
onary stent deployment in the EPILOG, EPIC, and CAP-
TURE trials demonstrated a reduction in mortality at 30
days (p 5 0.04) (481) in addition to reduction in the
composite end point of death, MI, or urgent intervention at
30 days (p , 0.001) at 6 months (p 5 0.002), in patients
who had received prophylactic therapy with abciximab.
These data suggest that prophylactic adjunctive platelet GP
IIb/IIIa blockade improves the clinical outcomes of patients
who require unplanned coronary stent deployment.
One putative limitation of abciximab is the potential for
immune-mediated hypersensitivity reactions following sub-
sequent readministration. With the first administration,
human antichimeric antibodies (HACA) form in approxi-
mately 6% of patients (478). The implications of HACA,
however, are unclear. Among 500 patients enrolled in the
ReoPro Readministration Registry (R3), there were no cases
of anaphylaxis or other allergic manifestations whether or
not HACA was present, and HACA was not predictive of
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any other measure of complication or success. From the R3
Study, HACA has been shown to be an IgG (not IgE)
immunoglobulin that does not neutralize abciximab. The
more worrisome clinical phenomenon associated with read-
ministration is the potential for increased rates of throm-
bocytopenia. In the 500-patient Registry, a 4.4% incidence
in thrombocytopenia (to a platelet count of ,100 3 109/L)
was observed, with half of the patients developing acute
profound thrombocytopenia (to a platelet count of ,20 3
109/L). This potential complication should always be mon-
itored when treating a patient with abciximab (485–488).
b. EPTIFIBATIDE. The clinical utility of eptifibatide, a
short-acting cyclic heptapeptide that also inhibits the GP
IIb/IIIa receptor, was evaluated in the Integrilin to Manage
Platelet Aggregation to prevent Coronary Thrombosis-II
(IMPACT-II) trial, a double-blind, randomized, placebo-
controlled multicenter trial that enrolled 4,010 patients
undergoing coronary angioplasty (489). Patients were as-
signed to treatment with aspirin, heparin and placebo,
aspirin, heparin and eptifibatide bolus (135 mg/kg) followed
by a low-dose eptifibatide infusion (0.5 mg/kg per min for
20 to 24 h), or aspirin, heparin, and eptifibatide bolus
(135 mg/kg) and higher dose infusion (0.75 mg/kg per min
for 20 to 24 h) (489). The 30-day composite primary end
point of death, MI, unplanned surgical or repeat percuta-
neous revascularization, or coronary stent implantation for
abrupt closure occurred in 11.4% of placebo-treated patients
compared with 9.2% in the 135/0.5 eptifibatide group (p 5
0.063) and 9.9% in the 135/0.75 eptifibatide group (p 5
0.22) (489). The frequency of major bleeding events and
transfusions was similar among the three groups.
A higher bolus and infusion of eptifibatide was evaluated
in 10,948 patients with unstable angina who were assigned
to treatment with placebo or 1 of 2 doses of eptifibatide: 180
mg/kg bolus 1 1.3 mg/kg per min infusion (180/1.3) or 180
mg/kg bolus 1 2.0 mg/kg per min infusion (180/2.0) (490).
Compared with placebo, patients receiving 180/2.0 eptifi-
batide had a lower frequency of 30-day death or MI (15.7%
vs. 14.2%; p 5 0.042). In patients undergoing early (,72 h)
coronary intervention, 30-day composite events occurred
less often in patients receiving 180/2.0 eptifibatide (11.6%
and 16.7% in placebo-treated patients; p 5 0.01) (491,492).
The ESPRIT (Enhanced Suppression of the Platelet
IIb/IIIa Receptor with Integrilin Therapy) Trial evaluated
the efficacy and safety of eptifibatide treatment as adjunctive
therapy during nonemergency coronary stent implantation.
A total of 2,064 patients were enrolled from June 1999 to
February 2000 in this multicenter, randomized, double-
blind, parallel-group, placebo-controlled (crossover-
permitted) clinical trial. A double-bolus regimen of eptifi-
batide (180 mg/kg bolus followed by a 2.0 mg/kg-min
infusion, with a second 180 mg/kg bolus given 10 min after
the first bolus) was compared to placebo treatment. The
48-h primary composite end point of death, MI, urgent
target-vessel revascularization, or bailout treatment with
open-label GP IIb/IIIa inhibitor therapy was reduced 37%
from 10.5 to 6.6% (p 5 0.0015). There was a consistent
treatment benefit across all components of the end point as
well as across all subgroups of patients. At 30 days, the key
secondary composite end point of death, MI, and urgent
large-vessel revascularization was also improved 35% from
10.4 to 6.8% (p 5 0.0034) (491,492).
c. TIROFIBAN. Tirofiban is a nonpeptidyl tyrosine derivative
that produces a dose-dependent inhibition of GP IIb/IIIa
mediated platelet aggregation (493). The clinical effect of
tirofiban during coronary angioplasty was evaluated in the
Randomized Efficacy Study of Tirofiban for Outcomes and
Restenosis (RESTORE) Trial, a double-blind, placebo-
controlled trial of 2,139 patients with unstable angina
pectoris or acute MI (494). Patients were randomly assigned
to aspirin, heparin and a tirofiban bolus (10 mg/kg over
3 min) 1 infusion (0.15 mg/kg per min), or to aspirin,
heparin, and a placebo bolus 1 infusion for 36 h. The
primary end point of the trial was the occurrence of major
30-day events, including death from any cause, MI, coro-
nary bypass surgery due to angioplasty failure or recurrent
ischemia, repeat target-vessel angioplasty for recurrent isch-
emia, or insertion of a stent due to threatened abrupt closure
(494). The primary 30-day end point was reduced from
12.2% in the placebo group to 10.3% in the tirofiban group
(p 5 0.160). Patients treated with tirofiban had a 38%
relative reduction in the composite end point at 48 h (p ,
0.005), and a 27% relative reduction at 7 days (p 5 0.022).
The incidence of major bleeding was similar in the two
groups using the Thrombolysis In Myocardial Infarction
(TIMI) criteria (2.4% in tirofiban-treated patients and 2.1%
in the placebo-treated patients; p 5 0.662) (494), although
major bleeding tended to be higher in tirofiban-treated
patients (5.3% vs. 3.7% in the placebo-treated patients; p 5
0.096), Thrombocytopenia was similar in both groups (0.9%
for the placebo group vs. 1.1% for the tirofiban group; p 5
0.709) (494). A larger clinical benefit with tirofiban was
seen in patients with unstable angina undergoing coronary
angioplasty in the PRISM-PLUS Study, a randomized trial
of 1,570 patients with unstable angina or non–Q-wave MI
assigned to 48 to 108-h treatment with heparin 1 tirofiban
or heparin alone (495). Coronary angioplasty was performed
in 30.5% of patients between 49 to 96 h after randomization
(495). The composite end point of death, MI, or refractory
ischemia was significantly reduced in the heparin 1 tirofi-
ban group or compared to the heparin alone group (10.0%
vs. 15.7%; p , 0.01) (495).
Based on the numerous trials to date (Fig. 4), intravenous
GP IIb/IIIa receptor inhibitors should be considered in
patients undergoing coronary angioplasty, particularly in
those with unstable angina or with other clinical character-
istics of high-risk. There is no consistent evidence that the
GP IIb/IIIa inhibitors reduce the frequency of late resten-
osis in the non-diabetic patient. In EPISTENT (as noted
previously), diabetic patients who received abciximab ther-
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apy in conjunction with stent deployment had a 51%
reduction in target-vessel revascularization at 6 months
(133,496). This trial is the only one that has shown a
reduction in target-vessel revascularization in the diabetic
group. It will be important to determine if supporting
evidence is found from other trials using this agent and
other GP IIb/IIIa antagonists.
3. Heparin. Intravenous unfractionated heparin prevents
clot formation at the site of arterial injury (498) and on
coronary guidewires and catheters used for coronary angio-
plasty (499). While the intensity of anticoagulation with
unfractionated heparin is generally determined using acti-
vated partial thromoboplastin times (aPTTs), these values
are less useful for monitoring anticoagulation during coro-
nary angioplasty because higher levels of anticoagulation are
needed than can be discriminated with the aPTT alone.
Instead, the activated clotting time (ACT) has been more
useful to follow heparin therapy during coronary angioplasty
(500). The Hemochron and HemoTec devices are com-
monly used to measure ACT values during coronary angio-
plasty (500–502). The Hemochron ACT generally exceeds
the HemoTec ACT by 30 to 50 s, although considerable
measurement variability exists.
Empiric recommendations regarding heparin dosage dur-
ing coronary angioplasty have been proposed (503,504), but
ACT levels after a fixed dose of unfractionated heparin may
vary substantially due to differences in body size (505),
concomitant use of other medications, including intrave-
nous nitroglycerin (506,507), and in the presence of acute
coronary syndromes that increase heparin resistance.
The relationship between the level of the ACT and
development of ischemic complications during coronary
angioplasty has been controversial. Whereas some studies
have identified an inverse relationship between the initial
ACT and the risk of ischemic events (508,509), others
found either no relationship or a direct relationship between
the degree of anticoagulation and occurrence of complica-
tions (510). It is generally felt that very high levels (ACTs
.400 to 600 s) of periprocedural anticoagulation are asso-
ciated with an increased risk for bleeding complications
(511).
The safety of low-dose heparin during coronary angio-
plasty has also been shown in a recent study. Fatal compli-
cations (0.3%), emergency bypass surgery (1.7%), MI
(3.3%), or repeat angioplasty within 48 h (0.7%) were
uncommon after an empiric bolus of heparin 5,000 U at the
beginning of the procedure (512). In a smaller randomized
study of 400 patients assigned to fixed-dose heparin (15,000
IU) or weight-adjusted heparin (100 IU/kg), there were no
differences in procedural success or bleeding complications
between the two groups (513), although use of the weight-
adjusted heparin resulted in earlier sheath removal and more
rapid transfer to a stepdown unit (513). Another advantage
of weight-adjusted heparin dosing is that “overshooting” the
ACT value can be avoided.
The results of these limited studies suggests that heparin
is an important component for PCI, despite dosing uncer-
tainties and an unpredictable therapeutic response with the
unfractionated preparation. Higher levels of anticoagulation
with heparin are roughly correlated with therapeutic efficacy
in the reduction of complications during coronary angio-
plasty, albeit at the expense of bleeding complications at
very high levels of heparin dosing. It appears that weight-
adjusted heparin dosing may provide a clinically superior
anticoagulation method over fixed heparin dosing, although
definitive studies are lacking.
Routine use of unfractionated heparin after an uncom-
plicated coronary angioplasty is no longer recommended
Figure 4. Death or nonfatal myocardial infarction outcomes at 30 days in 10 randomized, placebo-controlled trials of GP IIb/IIIa blockers. CI 5 confidence
interval; GP 5 glycoprotein; MI 5 myocardial infarction; OR 5 odds ratio. Reproduced with permission from Topol EJ, et al. Lancet 1999;353:227–31
(497). Data and acronyms from references 30–39 (These numbers coincide with references in the original article). Risk ratio with 95% CI, size of RR box
being proportional to total sample size. Frequency of death or nonfatal myocardial infarction in columns 4 and 5. Overall (all 10 trials) benefit of GP IIb/IIIa
blockade highly significant (RR 5 0.79 [95% CI 0.73–0.85]; p , 1029).
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(53,514–517), and may be associated with more frequent
bleeding events (53,514), particularly when platelet GP
IIb/IIIa inhibitors are used (53,514). Subcutaneous admin-
istration of unfractionated heparin (515) may provide a safer
and less costly means of extending antithrombin therapy
than intravenous unfractionated heparin, if there are clinical
reasons to continue anticoagulation, such as residual throm-
bus or significant residual dissections.
Some patients with unstable angina are treated with
low-molecular-weight heparin (LMWH) prior to coronary
angioplasty (518). Anticoagulation monitoring is not rou-
tinely possible with LMWH, and conventional dosages of
unfractionated heparin are currently recommended. Con-
ventional ACT monitoring methods may underestimate the
true degree of periprocedural anticoagulation with LMWH.
Use of LMWH as the sole anticoagulant during PCI is not
supported at this time in the absence of absolute or relative
contraindications to unfractionated heparin, although data
from clinical trials of these agents administered alone or in
conjunction with GP IIb/IIIa blockade are forthcoming.
a. HEPARIN DOSING GUIDELINES. In those patients who do
not receive GP IIb/IIIa inhibitors, sufficient unfractionated
heparin should be given during coronary angioplasty to
achieve an ACT of 250 to 300 s with the HemoTec device
and 300 to 350 s (491,492) with the Hemochron device.
Weight-adjusted bolus heparin (70 to 100 IU/kg) can be
used to avoid excess anticoagulation. If the target values for
ACT are not achieved after a bolus of heparin, additional
heparin boluses (2,000 to 5,000 IU) can be given. Early
sheath removal should be performed when the ACT falls to
,150 to 180 s.
The unfractionated heparin bolus should be reduced to 50
to 70 IU/kg when GP IIb/IIIa inhibitors are given in order
to achieve a target ACT of 200 s using either the HemoTec
or Hemochron device. Currently recommended Target
ACT for eptifibatide and tirofiban is ,300 s during
coronary angioplasty. Postprocedural heparin infusions are
not recommended during GP IIb/IIIa therapy (519–521).
C. Post-PCI Management
Following PCI, in-hospital care should focus on moni-
toring the patient for recurrent myocardial ischemia, achiev-
ing hemostasis at the catheter insertion site, and detecting
and preventing contrast-induced renal failure. Attention
should also be directed toward implementing appropriate
secondary atherosclerosis prevention programs. The patient
should understand and adhere to recommended medical
therapies and behavior modifications known to reduce
subsequent morbidity and mortality from coronary heart
disease.
Most patients can be safely discharged from the hospital
within 24 h after an uncomplicated elective PCI. Special
skilled nursing units have been developed by many institu-
tions to facilitate post-PCI management. Specific protocols
for sheath removal, continuation of anticoagulation or
antiplatelet therapies, and observation for recurrent myocar-
dial ischemia/infarction and contrast-induced renal failure
are of particular assistance in ensuring appropriate outcomes
during this period. Pilot studies suggest that selected pa-
tients may be discharged on the same day after PCI
(522,523) especially when the procedure is performed by the
percutaneous radial or brachial approach. However, confir-
mation by larger studies is necessary prior to widespread
endorsement of this strategy.
In the prior setting of aggressive systemic anticoagulation,
vascular complications may occur in as many as 14% of
patients after PCI, but those requiring surgical repair occur
in $3.5% (511) of patients, although lower rates of vascular
complications can now be expected with reduced anticoag-
ulation and smaller sheath sizes (524–529). Major factors
associated with vascular complications include use of throm-
bolytic or platelet inhibitor therapy, coexisting peripheral
vascular disease, female gender, prolonged heparin use with
delayed sheath removal, and older age (511,525,527–531).
Although most bleeding complications at the vascular access
site are obvious and readily managed, physicians and nurses
should remain alert for retroperitoneal hematoma, the signs
and symptoms of which may include hypotension, marked
suprainguinal tenderness, and severe back or lower quadrant
abdominal pain (532). Post-PCI hematocrit should be
monitored for a decrease .5 to 6%. Computed tomography
can confirm the diagnosis of retroperitoneal hematoma, and
.80% of patients can be treated conservatively using trans-
fusions without surgery (531). Pseudoaneurysms may be
treated effectively with ultrasound-directed compression in
the majority of patients who are not bleeding and do not
require continued anticoagulation (530,533,534). Arterio-
venous fistulas, generally occurring late after a procedure,
are detected by a continuous murmur over the puncture site
and, in rare cases, may be associated with high output
failure. Both pseudoaneurysm and arteriovenous fistula can
occur secondary to cannulation of the superficial rather than
the common femoral artery (535). Newer arterial compres-
sion systems and percutaneous vascular closure devices hold
promise to reduce the incidence of vascular complications.
However, the degree to which these technologies reduce
length of hospital stay, and cost remains to be determined
(531,536–538).
1. Post-Procedure Evaluation of Ischemia. After PCI,
chest pain may occur in as many as 50% of patients. ECG
evidence of ischemia identifies those with significant risk for
acute vessel closure (5,93,96,97,539–541). When angina
pectoris or ischemic ECG changes occur after PCI, the
decision to proceed with further interventional procedures,
CABG surgery, or medical therapy should be individualized
based on factors such as hemodynamic stability, amount of
myocardium at risk and the likelihood that the treatment
will be successful.
A 12-lead ECG should be obtained before and immedi-
ately after PCI, and again if symptoms should occur.
Angina-like symptoms with ECG changes will assist in
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deciding upon the need for repeat angiography and for
additional therapy.
As discussed elsewhere in this document, coronary stents
and platelet glycoprotein receptor inhibitors have signifi-
cantly reduced the incidence of acute closure. Factors that
correlate with a poor outcome after acute coronary closure
include age $70 years, large ischemic burden, presentation
with ACS, and LV ejection fraction #30% (539–541).
Elevated levels of CK or the MB subfraction (CK-MB),
or ECG abnormalities are reported to occur in 5 to 30% of
patients after PCI (20). The mechanisms associated with
CK release include side branch occlusion, distal emboliza-
tion, intimal dissection, and coronary spasm (542). A more
frequent requirement for revascularization procedures and a
higher risk of death or subsequent MI are associated with
elevated cardiac enzymes, increasing as a continuous func-
tion with no obvious threshold effect. Both acute and
chronic complications are higher among patients with
elevated enzymes. Even in patients with low-level elevations
of CK-MB where the in-hospital risk is low, the
intermediate- and long-term risks are also increased. Post-
procedural increases in CK and CK-MB are not specific for
a particular technique and have been reported after balloon
angioplasty, directional and rotablator atherectomy, excimer
laser angioplasty, and stent placement. Kong et al. (543)
found increased levels of CK are a significant independent
predictor of cardiac mortality and subsequent MI (363).
Cardiac mortality after elective PCI was significantly higher
for patients with high (.3.0 times normal) and intermedi-
ate CK (1.5 to 3.0 times normal) compared with low CK
(.1.0 to ,1.5 times normal) elevations and control patients
(p 5 0.007).
CK and CK-MB should be obtained in patients with
suspected ischemia (prolonged chest pain, side branch
occlusion, recurrent ischemia, hemodynamic instability)
during PCI. Ideally, the ESC/ACC recommends that small
infarcts may and should be detected by serial blood sampling
and analysis before and after the procedure (6 to 8 h and
24 h, respectively) (544). In patients in whom a clinically
driven CK-MB determination is made, a CK-MB index
increase of .3 times the upper limit of normal should be
treated as having a MI and be recommended for further
observation. The results of CK-MB should be considered
for the discharge management strategies for these patients.
The troponin isoforms TnI and TnT have a high level of
sensitivity and specificity for the diagnosis of acute MI.
However, the clinical significance of elevated TnT or TnI
after PCI procedures has not been widely investigated, and
further studies are necessary to establish the clinical utility of
these MI markers.
Patients with renal dysfunction and diabetes should be
monitored for contrast-induced nephropathy. In addition,
those patients receiving higher contrast loads or a second
contrast load within 72 h should have renal function
assessed. Whenever possible, nephrotoxic drugs (certain
antibiotics, nonsteroidal anti-inflammatory agents, and cy-
closporine) and metformin (especially in those with pre-
existing renal dysfunction) should be withheld for 24 to 48 h
prior to performing PCI and for 48 h afterwards (545).
2. Risk Factor Modifications. All patients should be
instructed about necessary behavior and risk factor modifi-
cation and the appropriate medical therapies for the sec-
ondary prevention of atherosclerosis prior to leaving the
hospital. The interventional cardiologist should emphasize
the importance of these measures directly to the patient as
failure to do so may suggest that secondary prevention
therapies are not necessary. The interventional cardiologist
should interact with the primary care physician to assure
that necessary secondary prevention therapies are initiated
and maintained. Secondary prevention measures are an
essential part of long-term therapy because they can reduce
future morbidity and mortality associated with the athero-
sclerotic process.
Depending on the risk factors and contraindications
present, advice should include aspirin therapy, hypertensive
control, diabetic management, aggressive control of serum
lipids to a target LDL goal ,100 mgm/dl following AHA
guidelines, abstinence from tobacco use, weight control,
regular exercise, and ACE Inhibitor therapy for those with
LV dysfunction (LVEF ,0.40) as recommended in the
AHA/ACC consensus statement on secondary prevention
(Fig. 5). Given the nature and natural history of CAD
among patients undergoing PCI, with the exception of
those patients intolerant to the agents, the clinically indi-
cated secondary prevention measures which usually include
ASA, statin therapy, and ACE inhibitors, should be con-
tinued indefinitely (546–548). Patients should receive in-
structions on the timing of return to full activities and be
informed to contact their physician or seek immediate
medical attention if symptoms recur.
3. Exercise Testing After PCI. The published ACC/
AHA practice guidelines for exercise testing (549) provide
an excellent summary of the available information on exercise
testing after PTCA. Although restenosis remains the major
limitation of PCI, symptom status is an unreliable index to
development of restenosis with 25% of asymptomatic patients
documented as having ischemia on exercise testing (550).
To identify restenosis rather than predict the probability
of its occurrence, patients may be tested later (3 to 6 months
after PCI). Table 32 reviews the predictive value of exercise
testing for restenosis (551–558). Variability is attributed
predominantly to differences in the populations studied and
criteria for restenosis.
Because myocardial ischemia, whether painful or silent,
worsens prognosis (559), some authorities have advocated
routine testing. However, the ACC/AHA practice guide-
lines for exercise testing favor selective evaluation in patients
considered to be at particularly high risk (e.g., patients with
decreased LV function, multivessel CAD, proximal left
anterior descending disease, previous sudden death, diabetes
mellitus, hazardous occupations, and suboptimal PCI re-
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sults). The exercise ECG is an insensitive predictor of
restenosis, with sensitivities ranging from 40 to 55%, sig-
nificantly less than those obtainable with SPECT (560,561)
or exercise echocardiography (562,563). This lower sensi-
tivity of the exercise ECG and its inability to localize disease
limits its usefulness in patient management both before and
after PCI (552,564,565). For those reasons, stress imaging
is preferred to evaluate symptomatic patients after PCI. If
the patient’s exertional capacity is significantly limited,
coronary angiography may be more expeditious to evaluate
symptoms of typical angina. Exercise testing after discharge
is helpful for activity counseling and/or exercise training as
part of cardiac rehabilitation. Neither exercise testing nor
radionuclide imaging is indicated for the routine, periodic
monitoring of asymptomatic patients after PCI without
specific indications.
VII. SPECIAL CONSIDERATIONS
A. Ad-Hoc Angioplasty–PCI at the Time of Initial
Cardiac Catheterization
Ad-hoc coronary intervention is PCI performed at the
same time as diagnostic cardiac catheterization. Since the
last revision of these Guidelines there has been an increase
in ad-hoc interventions with reported incidence ranging
from 52 to 83% (566–568). During the past several years, in
Figure 5. AHA guide to comprehensive risk reduction for patients with coronary and other vascular disease. ACE 5 angiotensin-converting enzyme;
AHA 5 American Heart Association; CHF 5 congestive heart failure; HDL 5, high density lipoprotein; LDL 5 low density lipoprotein; LV 5 left
ventricular; MI 5 myocardial infarction; TG 5 triglycerides. Adapted with permission from Smith SC, Blair SN, Criqui MH, et al. Preventing heart attack
and death in patients with coronary disease. Circulation 1995;92:2–4. June 1999 Update.
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an effort to reduce hospital length of stay and potentially
reduce costs, PCI is increasingly being performed immedi-
ately following the diagnostic coronary angiographic proce-
dure (569). The indications for diagnostic catheterization
are discussed in the ACC/SCA&I Expert Consensus Doc-
ument on Catheterization Laboratory Standards (184) (Ta-
ble 33).
Ad-hoc angioplasty has several inherent advantages. It
expedites patient care, avoids a second invasive procedure
with its associated risks and recognized morbidity, reduces
total X-ray exposure and, therefore, cost. However, ad-hoc
intervention is associated with a higher procedural contrast
use and may preclude adequate pretreatment with aspirin or
other oral antiplatelet agents.
In contrast to ad-hoc angioplasty, a staged approach also
has several advantages. It allows ample time to review the
angiogram and plan the procedural strategy, discuss the
risks, benefits, and alternatives with the patient and family,
and obtain consultation from cardiothoracic surgical col-
leagues. It is far more difficult to adequately inform the
patient of risks, benefits, and alternatives without the
knowledge of the anatomy and the extent of coronary
disease. A staged approach also allows for optimal hydration
and pretreatment with oral antiplatelet agents. Explicit and
clear informed consent especially for ad-hoc PCI should be
discussed with the patient and family.
Studies evaluating the outcome of patients undergoing
ad-hoc coronary intervention have reported that informed
patients with suitable anatomy have a shorter hospital stay,
less radiation exposure, and lower costs without an increase
in procedural complications in comparison to patients un-
dergoing a staged approach (566,570,571). In a multicenter
cohort study of 35,700 patients undergoing elective coro-
nary angioplasty between 1992 and 1995, the risk of a major
complication (MI, emergency coronary artery bypass sur-
gery, or death) from combined (ad-hoc) versus staged
procedures was 2% and 1.6%, respectively. After adjusting
for clinical and angiographic differences between groups, the
risk from combined procedures was not significantly differ-
ent. However, patients with multivessel disease, women,
patients .65 years, and patients undergoing multilesion
coronary angioplasty were at increased risk of an adverse
Table 32. Predictive Value of Exercise Electrocardiographic Testing for Identification of Restenosis After PTCA
Author Year Reference N Clinical
Post-PCI,
Month
Restenosis,
%
PV 1,
%
PV 2,
% Definition of Restenosis
Kadel 1989 551 398 Consecutive Up to 6 33 66 75 .70% luminal diameter stenosis
Honan 1989 553 144 Post-MI 6 40 57 64 .75% luminal diameter stenosis
Schroeder 1989 552 111 Asymptomatic 6 12 53 63 .70% luminal diameter stenosis
Laarman 1990 554 141 Asymptomatic 1 to 6 12 15 87 .50% luminal diameter stenosis
el-Tamimi 1990 555 31 Consecutive 6 45 100 94 Loss of .50% initial gain of lumen diameter
Bengtson 1990 550 200 Asymptomatic
(n 5 127)
6 44 46 63 .75% luminal diameter stenosis
200 Symptomatic
(n 5 66)
6 59 76 47 .75% luminal diameter stenosis
Roth 1994 556 78 1-vessel CAD 6 28 37 77 .50% luminal diameter stenosis
Desmet 1995 557 191 Asymptomatic 6 33 52 70 .50% luminal diameter stenosis
CAD 5 coronary artery disease; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention; PTCA 5 percutaneous transluminal coronary angioplasty; PV 5
predictive value.
Table 33. Exclusion Criteria for Invasive Cardiac Procedures in Settings Without Full-Support Services
Location
Type of
Patient Diagnostic Procedures Therapeutic Procedures
Hospitals Adult Age .75 yrs
NYHA Class III or IV heart failure
Acute, intermediate or high-risk ischemic syndromes
Recent myocardial infarction with post-infarction ischemia
Pulmonary edema felt to be caused by ischemia
Markedly abnormal noninvasive test indicating a high
likelihood of left main or severe multivessel coronary disease
Known left main coronary artery disease
Severe valvular dysfunction especially in the setting of
depressed LV performance
All valvuloplasty procedures, complex adult congenital
heart disease diagnostic or therapeutic procedures
Diagnostic pericardiocentesis when the effusion is
small or moderate in size and there is no
tamponade
Elective coronary interventions
Pediatric No procedures approved No procedures approved
Freestanding
Laboratories
Adult All of the above plus high-risk patients by virtue of comorbid
conditions including need for anticoagulation, poorly
controlled hypertension or diabetes, contrast allergy, or renal
insufficiency
Pediatric No procedures approved No procedures approved
LV 5 left ventricular; NYHA 5 New York Heart Association.
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outcome (572). Therefore, performing PCI following diag-
nostic catheterization is safe in selected patients.
Ad-hoc coronary intervention is particularly suitable for
patients with clinical evidence of restenosis 6 to 12 months
following the initial procedure (573), patients undergoing
primary angioplasty for MI, and patients with refractory
unstable angina in need of urgent revascularization (574).
Prior to the procedure, these patients should be treated with
aspirin and clopidogrel (575) and should give appropriate
informed consent for anticipated PCI. Ad-hoc PCI should
be performed only in a well-informed patient, particularly in
the setting of single-vessel disease without morphologic
features predictive of an adverse outcome, when it is clear
that this treatment strategy is the best alternative. However,
ad-hoc percutaneous revascularization should not be per-
formed in patients in whom the angiographic findings are
unanticipated or the indication, suitability, or preference for
percutaneous revascularization is unclear (269). Patient
safety should be the paramount consideration when con-
templating ad-hoc intervention is being considered. This
Committee endorses the recommendations from the
SCA&I that ad-hoc PCI be individualized and not be a
standard or required strategy for all patients (269).
B. PCI in Cardiac Transplant Patients
Allograft atherosclerosis and vasculopathy is the main
cause of death in cardiac transplant recipients. Because no
medical therapy is known to prevent graft atherosclerosis
and retransplantation is associated with decreased survival,
palliative therapy with PCI has been proposed and per-
formed. No single medical center has performed PCI in
many patients and, thus, the responses and outcomes of a
large cohort are unavailable for review. However, pooled
information from 11 medical centers retrospectively analyz-
ing results of coronary angioplasty in cardiac transplant
patients has been reported (576).
These investigators concluded that although high proce-
dural success can be achieved and PCI may be applied in a
selected cardiac transplant population with comparable
success and complication rates to the routine patient pop-
ulation, it remains unknown whether PCI prolongs allograft
survival.
Coronary stenting in cardiac allograft vascular disease has
been performed in small numbers of patients with favorable
results. Heublein et al. (577) compared angioplasty and
stenting in 27 patients who received 48 stents, 5.7 6 2.9
years after heart transplantation. Coronary angioplasty re-
sulted in minimal increase in luminal dimensions as com-
pared to stenting (for angioplasty 2.04 6 0.36 vs. 2.53 6
0.38 mm for stenting). There were no stent thrombosis or
bleeding complications. At a mean follow-up period of 8 6
5 months (range 2 weeks to 23 months), all patients were
clinically event-free. Six of 24 stented vessels in 16 patients
had restenosis .50% by ultrasound or angiography 6
months after the procedure. Long-term survival effects
remain under examination (Table 34).
C. Management of Clinical Restenosis
1. Background. Angiographic restenosis after balloon an-
gioplasty occurs in 32 to 40% of patients within 6 months
after the procedure (32,34). Initial procedural success rates
after balloon angioplasty of restenotic lesions appear similar
to those after balloon angioplasty for de novo lesions. The
risk for repeat angiographic restenosis after repeat balloon
PTCA for a single episode of restenosis also appears similar
to the restenosis risk for de novo lesions (582,583). The risk
of recurrent symptoms progressively increases with the
number of restenosis episodes, approaching 50 to 53% for
patients undergoing a fourth PTCA for a third episode of
restenosis (584,585).
2. Clinical and Angiographic Factors. A number of fac-
tors are associated with lesion recurrence for patients un-
dergoing a second balloon angioplasty attempt for resteno-
sis. These factors include an interval ,60 to 90 days
between the initial angioplasty and the treatment of resten-
osis (582–586), left anterior descending lesion location
(585), multi- versus single-redilations (586), the presence of
diabetes mellitus (582,586), hypertension (582), unstable
angina (582), need for higher ($7 atmosphere) balloon
inflation pressures (583), and multiple ($3) balloon infla-
tions (583,584). Of these, the most important factor is the
time between the initial and subsequent PTCA (587). In a
series of 423 patients, restenosis was more common in those
having repeat angioplasty ,3 months after a first angio-
plasty than patients undergoing later redilation (56% vs.
37%, p 5 0.007) (587).
Some studies have suggested that lesions become longer
and more severe after repeat balloon angioplasty of rest-
enotic lesions (588,589). In a serial angiographic study, the
mean stenosis length before the initial angioplasty was
7.0 mm but increased to 8.7 mm at the time of the repeat
procedure (.1.7 mm, 95% confidence interval 0.6 to
2.8 mm, p , 0.01) (589). A history of restenosis may also
predict the risk for subsequent restenosis after PTCA of a
Table 34. Summarizes Coronary Angioplasty Studies in Heart Transplant Patients
Author Year Reference N Proc. Lesions
Time Post-Tx
(months) Success
Major
Complex
Minor
Complex
Restenosis
>6 Month
1-Year
Event-Free
>6 Month Late
Death, re-Tx
Halle 1992 576 35 51 95 46 6 5 93% 3 3 — 60% 7
Pande 1996 578 8 — 11 — 91% 1 1 — 50% 3
Sandhu 1992 579 8 11 13 43 6 19 85% — 1 — 38% 4
von Scheidt 1995 580 14 38 62 41 6 25 97% 1 — 61% 60% 5
Swan 1993 581 13 31 — — — — — 100% — —
Proc. 5 procedure; Tx 5 treatment.
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new lesion (76). Multivariate analysis identified that prior
restenosis (p , 0.02, odds ratio (OR) 5 3.4), left anterior
descending artery location of stenosis (p , 0.04, OR 5 3.0),
and severity of stenosis before PTCA (p , 0.02, OR 5 1.8)
were independently associated with restenosis after PTCA
(76).
3. Management Strategies. Long-term patency of the
initial target lesion may be achieved with repeated balloon
dilations. In a series of 1,455 de novo lesions treated with
balloon angioplasty, angiographic restenosis requiring re-
peat balloon angioplasty developed in 32% (590). Late
patency was achieved in 93% of lesions with up to 3 balloon
angioplasty procedures. Only 23 (1.6%) lesions required 4 or
more procedures (590).
Although atheroablation devices have been developed in
an attempt to lower the second restenosis risk in patients,
none has shown an incremental benefit over PTCA. In a
study of 1,569 patients who underwent excimer laser coro-
nary angioplasty for restenotic (n 5 620 patients) or de novo
(n 5 949) lesions (591), procedural success was higher in
restenotic patients (92% vs. 88% in de novo patients; p ,
0.001), although clinical recurrence was high in both groups
(49% in restenotic patients and 44% in de novo patients;
p 5 NS) (591).
Stent placement is superior to balloon angioplasty for the
treatment of restenotic lesions. In the REstenosis STent
(REST) Study (592), a randomized clinical trial, late clinical
and angiographic outcomes were compared in 351 patients
undergoing either balloon angioplasty or PS stent placement
for restenotic lesions. Stent-treated patients had lower rates
of target lesion revascularization (10% vs. 32% in balloon-
treated patients) and restenosis (18% vs. 32% in balloon-
treated patients; p 5 0.03) (592).
Based on these findings, it is recommended that patients
who develop restenosis following an initially successful
PTCA be considered for repeat PCI with stent placement.
Factors that may influence this decision include the techni-
cal difficulty of the initial procedure, the potential for the
lesion to be treated successfully with a stent, and the severity
and extent of the restenotic process. If restenosis presents as
a much longer lesion than was originally present, additional
procedures may aggravate rather than relieve coronary nar-
rowing. If repeat intervention is performed, treatment with
a stent appears to be preferred. Each time restenosis recurs,
consideration should be given to alternate methods of
revascularization, particularly CABG surgery, as well as
continued medical therapy. Patients who have angiographic
evidence of restenosis but no symptoms or evidence for
ischemia can usually continue with medical therapy alone.
Late angiographic follow-up suggests that these lesions can
improve further with time (593). It is recommended that
patients who develop a first episode of restenosis after
balloon or new device PTCA are candidates for repeat
coronary intervention using balloon angioplasty or intra-
coronary stents. The procedure success rates after PTCA are
high (.93%) with a risk of restenosis that is comparable to
de novo lesions.
Patients who develop a second episode of restenosis after
balloon angioplasty or new device PCI may also be candi-
dates for at least 1 attempt at repeat balloon angioplasty or
stent implantation. It is less certain that patients who
develop restenosis after a third episode will benefit with an
additional PCI procedure, due to a recurrence rate that may
approach 50%. These patients may be candidates for alter-
native methods of revascularization or coronary bypass
surgery. Patients who have no signs or symptoms of isch-
emia but have intermediate (50%) stenoses at the time of
clinical follow-up should not undergo routine PCI, but
should be followed for evidence of ischemia due to the good
clinical outcome reported in these patients (592).
D. Restenosis After Stent Implantation (In-Stent Restenosis)
1. Background. Although coronary stents have been
shown to reduce the frequency of restenosis compared with
conventional balloon angioplasty, lumen renarrowing due to
intimal hyperplasia within the stent may develop in 17 to
32% of patients (31,32,594). A number of factors have been
associated with the propensity to develop stent restenosis,
including small vessel size (595), smaller post-procedure
minimum lumen diameter (596), higher residual percent
diameter stenosis (597), lesions located in the left anterior
descending (31) stent length, and the presence of diabetes
mellitus (589,590,592,595–598).
Stent restenosis may occur within the stent, due to
intimal hyperplasia, or at the stent margins, due to both
intimal hyperplasia and/or arterial remodelling (599). A
serial IVUS study performed in 115 lesions treated with the
PS stent demonstrated that tissue growth was uniformly
distributed throughout the stent at follow-up study, with a
slightly higher tendency for neointimal tissue accumulation
at the central articulation (599). The stent lumen tended to
be smallest at the articulation site, presumably due to tissue
prolapse between the stent struts. For multiple stents there
was no difference in the post-intervention or follow-up
lumen when overlapped stents were compared with non-
overlapped stents (599). In another series of patients treated
with the PS stent, 77 (26%) of 301 stent margins were
restenotic at follow-up (.50% late lumen loss) (600). The
dominant periprocedural predictor of stent margin resteno-
sis was the plaque burden of the contiguous reference
segment (600).
Balloon angioplasty has been used frequently to treat
patients with stent restenosis (601–603). The mechanism of
lumen improvement after balloon angioplasty for stent
restenosis relates to further stent expansion (601) and
extrusion of the tissue through the stent struts (601,604). In
an IVUS study of 64 restenotic PS stents, 56 6 28% of the
lumen enlargement was the result of additional stent expan-
sion and 44 6 28% was the result of a decrease in
neointimal tissue (601). Despite the use of high-pressure
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balloon dilation, a relatively high residual stenosis (18 6
12%) remained after treatment with balloon angioplasty.
The outcome after balloon angioplasty has been variable,
depending, in part, on the size of the stented segment and
length of the stent restenosis (605). In a consecutive series of
124 patients presenting with stent restenosis successfully
treated with repeat percutaneous intervention, clinical
follow-up was obtained at 27.4 6 14.7 months (605).
Recurrent clinical events occurred in 25 patients (20%),
including death (2%), MI in 1 (1%), and target-vessel
revascularization (11%) (605). Cumulative event-free sur-
vival at 12 and 24 months was 86.2% and 80.7%, respec-
tively (605).
A number of factors have been related to the frequency of
clinical recurrence after balloon angioplasty for stent resten-
osis (605), which include repeat intervention in SVGs,
multivessel disease, low ejection fraction and a #3-month
interval between stent implantation and repeat intervention.
1 Preliminary report has shown target lesion revasculariza-
tion was related to the length of the stent restenosis, ranging
from 10% for focal stent stenosis, 25% for intrastent
restenosis, 50% for diffuse stent restenosis, and 80% for
stent total occlusions (606).
New coronary devices, including directional (607,608),
rotational (609,610), extraction (611–615), and pullback
(616) atherectomy, a cutting balloon and excimer laser-
assisted angioplasty, have also been used for stent restenosis
prior to balloon dilation. Although some comparative reg-
istry series have suggested an improved angiographic out-
come associated with the use of these ablative devices, no
long-term studies demonstrating advanced benefit have
been completed.
When a significant residual stenosis exists after conven-
tional PTCA or stent restenosis fails to achieve an optimal
lumen diameter, additional stents have been used to im-
prove the initial angiographic result (617–619). Preliminary
results of clinical trials fail to demonstrate a benefit of
routine, additional stent placement for the treatment of
stent restenosis (80).
Acute platelet inhibition with abciximab does not reduce
in-stent restenosis as demonstrated in the ERASER study
(165). In a study of 225 patients randomly allocated to
placebo or abciximab before intervention, 215 patients
received a stent and the study drug. Of the 191 patients who
returned for follow-up more than 4 months after evaluation,
there was no difference between tissue volume as measured
by IVUS between the placebo and treatment group. Lack of
abciximab benefit was confirmed by quantitative angiogra-
phy. The investigators concluded that potent platelet inhi-
bition with abciximab as administered in the ERASER
study did not reduce in-stent restenosis.
2. Radiation for Restenosis. Initial studies suggest that
radiation may reduce the incidence of recurrent stent re-
stenosis (81). In a small randomized study, 55 patients were
randomly assigned to treatment with 192Iridium (n 5 26) or
to placebo (n 5 29) (81). At follow-up 6.7 6 2.2 months
later, the mean MLD was larger in the 192Iridium group
than in the placebo group (2.43 6 0.78 mm vs. 1.85 6
0.89 mm; p 5 0.02) (81). Late luminal loss was significantly
lower in the 192Iridium group than in the placebo group
(0.38 6 1.06 mm vs. 1.03 6 0.97 mm; p 5 0.03) (81).
Binary restenosis ($50% follow-up diameter stenosis) oc-
curred in 17% of the 192Iridium-treated patients compared
with 54% in placebo-treated patients (p 5 0.01) (81). Other
studies evaluating the effect of vascular radiation for in-stent
restenosis are ongoing (80,620).
Intracoronary vascular radiation for in-stent restenosis
with either gamma or beta-radiation is the most promising
therapy for in-stent restenosis at this time, reducing the
chance for repeat restenosis by other methods from 50 to
60% to 25 to 35%. In the absence of vascular radiation for
in-stent restenosis, there appears to be little difference in
outcome between angioplasty alone as compared to combi-
nation with ablative techniques.
A cautionary note regarding the use of intracoronary
vascular radiation for in-stent restenosis should be raised.
Waksman et al. describe late total occlusion after intracoro-
nary vascular radiation for patients with in-stent restenosis.
Of 473 patients who presented with in-stent restenosis
enrolled in various radiation protocols, 165 placebo-treated
patients were compared to 388 patients irradiated with both
beta and gamma emitters. Late total occlusion (mean time
5 6 3 months) was documented in 9.1% of the irradiated
group versus 1.2% of the placebo group (p , 0.001). The
late total occlusion rates were similar across studies and
emitters. In the irradiated group, late total occlusion pre-
sented as acute myocardial infraction in 12 patients, unsta-
ble angina in 14 patients, and as an asymptomatic occlusion
in 2 patients. The main predictor of late total occlusion was
intracoronary radiation, suggesting that prolonged anti-
platelet therapy, up to 6 months, may be strongly considered
for these patients (620). The largest randomized study of
in-stent restenosis (START) utilized a strategy of avoiding
new stenting within the old stent and extension of the
clopidogrel and aspirin therapy to three months duration.
Several ongoing trials have extended this treatment until 6
months. It is important to note that in the preliminary
presentation of the START trial, no late thrombotic events
were identified (Popma JJ, oral presentation, American
College of Cardiology Scientific Session, Orlando, March
2001). Intravascular ultrasound should be considered at the
time of in-stent restenosis evaluation to ensure that stent
expansion is optimal. Also, IVUS may demonstrate exces-
sive tissue prolapse and justify the use of an additional stent.
Routine use of a stent-in-a-stent is not advised (82).
E. Cost-Effectiveness Analysis for PCI
Among all diseases worldwide, ischemic heart disease
currently ranks fifth in disability burden, and is projected to
rank first by the year 2020 (621). As healthcare delivery
systems in countries with established economic markets
continue to incorporate new and expensive technologies, the
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costs of medical care have seemingly escalated beyond the
revenue historically allotted to health care. Given limited
healthcare resources, a cost-effectiveness analysis (CEA) is
appropriate to evaluate percutaneous coronary revasculariza-
tion strategies (622). The results of CEAs for any compa-
rable treatment are reported in terms of the incremental cost
per unit of health gained, such as 1 year of life adjusted to
perfect health (quality-adjusted life year, QALY) compared
to the standard of care (623). By modeling different treat-
ments, different patient subsets and different levels of
disease, a series of cost-effectiveness ratios may be con-
structed to show the tradeoffs associated with choosing
among competing interventions.
While there is no established cost-effectiveness ratio
threshold, cost-effectiveness ratios of ,$20,000 per QALY
(such as seen in the treatment of severe diastolic hyperten-
sion or cholesterol lowering in patients with ischemic heart
disease) are considered highly favorable and consistent with
well accepted therapies. Incremental cost-effectiveness ratios
that range between $20,000 and $60,000 per QALY may be
viewed as reasonably acceptable cost-effective in most eco-
nomic market countries, whereas ratios .$60,000 to
$80,000 may be considered to be too expensive for most
healthcare systems. The Committee defines useful and
efficacious treatments, in terms of cost-effectiveness, as
treatments with acceptable or favorable cost-effectiveness
ratios. CEA is not by itself sufficient to incorporate all
factors necessary for medical decision making on an indi-
vidual patient basis, nor is it sufficient enough to dictate the
broad allocation of societal resources for health care. Rather,
CEA aims to serve mainly as an aid to medical decision
making on the basis of comparison with other evaluated
therapies.
The results of CEA in the field of percutaneous revascu-
larization for ischemic heart disease have been derived from
decision models that incorporate literature-based
procedure-related morbidity and mortality, coronary disease
related mortality, and estimates of the benefit of selected
revascularization procedures. When available, results from
randomized trials, (Levels of Evidence A and B), are used to
estimate the outcomes of each decision tree branch within
the decision-analytical model, for example, using data esti-
mating the restenosis rate following uncomplicated coronary
stenting of a single, simple, lesion. CEAs have been used to
compare medical therapy with PTCA with coronary bypass
surgery (624), balloon angioplasty with coronary stenting
(625,626), and routine coronary angiography following
acute MI with symptom-driven coronary angiography
(627).
In patients with severe angina, normal LV function, and
single-vessel disease of the left anterior descending artery,
the cost-effectiveness ratio for PTCA, directional coronary
atherectomy, or coronary stenting that can be expected to
provide .90% success rate with ,3% major acute compli-
cation rate is very favorable (,$20,000 per QALY) com-
pared to medical therapy (624). The rating also applies to
patients with symptomatic angina or documented ischemia
and 2-vessel coronary disease in which percutaneous coro-
nary revascularization can be expected to provide .90%
success rate with ,3% major acute complication rate. In
patients with 3-vessel coronary disease who have comor-
bidities that increase operative risk for CABG surgery, PCI
that is felt to be safe and feasible is reasonably acceptable
($20,000 to $60,000 per QALY). In patients in the post-MI
setting, a strategy of routine, nonsymptom-driven, coronary
angiography and PCI performed for critical (.70% diam-
eter stenosis) culprit coronary lesions amenable to balloon
angioplasty or stenting has been proposed to be reasonably
cost-effective in many subgroups (627).
In patients with symptomatic angina or documented
ischemia and 3-vessel coronary disease, for which bypass
surgery can be expected to provide full revascularization and
an acute complication rate of ,5%, the cost-effectiveness of
PCI is not well established. Although PTCA for 2- and
3-vessel coronary disease appears to be as safe, but initially
less expensive, than CABG surgery, the costs of PTCA
converge towards the higher costs of bypass surgery after 3
to 5 years (628,629). Thus, while PTCA or CABG surgery
has been shown to be cost-effective when compared to
medical therapy, there is no evidence for incremental
cost-effectiveness of PTCA over bypass surgery for 2- or
3-vessel coronary disease in patients who are considered
good candidates for both procedures. For patients with 1- or
2-vessel coronary disease who are asymptomatic or have
only mild angina, without documented left main disease,
the estimated cost-effectiveness ratios for PCI are .$80,000
per QALY compared with medical therapy, and are thus
considered less favorable.
The initial mean cost of angioplasty was 65% that of
surgery, but need for repeat interventions increased medical
expenses so that after 5 years the total medical cost of
PTCA was 95% that of surgery ($56,225 vs. $58,889), a
significant difference of $2,664 (p 5 0.047). Compared to
CABG, PTCA appeared less costly for patients with
2-vessel disease, but not for patients with 3-vessel disease.
Because CEA research is new in the field of percutaneous
coronary intervention, CEA results are limited. The Com-
mittee underscores the need for cost containment and
careful decision making regarding the use of PCI strategies.
VIII. FUTURE DIRECTIONS
The field of coronary intervention has expanded dramati-
cally over the past decade and will continue to evolve over
the next several years. New directions will focus on the
strategies that will further improve procedural safety, reduce
the recurrence rate after PCI, and expand the procedure to
more complex anatomic subsets. Clinical acceptance of
these technologies will be based on demonstration of safety
and efficacy over conventional therapies in randomized
clinical studies. A few of these novel strategies are reviewed.
An exciting arena of active investigation relates to meth-
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ods of distal protection of the coronary vascular bed during
PCI. It is now recognized that distal embolization is an
important contributor to complications in patients under-
going SVG intervention. Distal embolization is often due to
dislodgement of large, macroparticles from the friable graft,
rather than release of platelet-mediated aggregates. This
complication can be prevented by the use of distal occlusion
balloons, such as the PercuSurge Guardwire, or with the use
of distal filters that trap the debris and remove it from the
distal circulation. A number of filter devices are currently
undergoing clinical evaluation, particularly in saphenous
vein graft disease and during carotid intervention.
Restenosis has also remained a vexing problem, despite
the benefits achieved with stent implantation. Novel ther-
apies have been developed, such as the application of
therapeutic ultrasound, photodynamic therapy, and systemic
administration of the anti-inflammatory agent tranilast. An
area of active investigation involves the use of balloon-
expandable stents coated with rapamycin, paclitaxol, or its
derivative. The local delivery of these agents has shown
promise in early clinical trials, and longer-term studies are
currently underway.
New therapies have also been tried in patients with
lesions poorly suitable for coronary intervention. Chronic
total occlusions are also still a major clinical challenge and
represent a major cause of procedural failure in patients
undergoing PCI. New therapies currently being evaluated
for use in recanalizing chronic total coronary occlusion
include an excimer laser guidewire, a low-frequency ultra-
sound catheter, and spectroscopically-guided vessel meth-
ods, may be useful, but more information is needed. It is not
certain whether laser revascularization methods for patients
without options using either surgical or percutaneous ap-
proaches provide an advantage of intensive medical ap-
proaches, and randomized trials with careful blinding of
patients and physicians to the type of therapy delivered are
needed prior to their full acceptance into clinical practice.
Similar trials are needed in the angiogenesis arena.
Rigorous scientific evaluation of these new therapies is
critical to assure that these innovative therapies are safe,
effective, and provide overall clinical utility to patients with
CAD. Physician practice should be based on sound
evidence-based data provided by careful clinical studies.
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